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S u m m a r y
G-proteins are central mediators of the signal transduction process, 
conveying information from agonist activated receptor to intracellular effector. 
However, it is unclear whether G-proteins function in a specific manner, or are 
promiscuous and able to interact with a wide variety of transmembrane receptors 
and effectors.
In an attempt to analyse G-protein specificity, the interaction of receptors 
with G-proteins in the neuroblastoma x glioma NG108-15 cell line was examined.
As a means of identifying individual members of the G-protein famiiy, a series of 
antipeptide antisera were generated against synthetic peptides corresponding to the 
C-terminal region of the various G-protein a-subunits. These antisera were 
demonstrated to be specific in their ability to recognise individual members of the 
G-protein family and thus allowed the identification of the pertussis toxin sensitive 
G-proteins; Gi2, Gi3, and Go in the NG108-15 cell line. In addition, two forms of the 
cholera toxin sensitive G-protein, Gs were expressed. However it was not possible to 
detect expression of G il. NG108-15 cells express 6-opioid receptors which function 
to inhibit adenylyl cyclase in a manner attenuated by prior treatment with pertussis 
toxin, and a poorly defined growth factor receptor which does not functionally 
interact with adenylyl cyclase. In membranes derived from NG108-15 cells, agonist 
activation of the both the 6-opioid receptors and growth factor receptors by DADLE 
and foetal calf serum respectively, stimulated GTPase activity through activation of 
separate species of pertussis toxin sensitive G-protein, as assessed by additivity 
experiments. This demonstrated that tight regulation of receptor-G-protein coupling 
occurs in membrane systems.
In an attempt to determine which pertussis toxin sensitive G-protein(s) is 
activated by the 6-opioid receptor, and thus ascertain which G-protein functions to 
inhibit adenylyl cyclase, a variety of approaches were adopted.
XII I
Firstly, although 'Gi' is classically a substrate for pertussis toxin, it is 
possible to catalyse the ADP-ribosylation of 'Gi' with cholera toxin, when suitable 
conditions are employed, namely the absence of added guanine nucleotide. In NG108- 
15 cell membranes, cholera toxin catalysed ADP-ribosylation of 'Gi' was stimulated 
in a dose-dependent manner by the addition of the 6-opioid agonist, DADLE, thus 
providing a means of identifying the G-protein which interacts with the 6-opioid 
receptor.
Secondly, the C-terminal region of the G-protein a-subunit is postulated to 
be the domain of interaction with receptor. In an attempt to block interaction of the 
6-opioid receptor with the G-protein with which the receptor interacts, NG108-15 
cell membranes were preincubated with IgG fractions isolated from the various G- 
protein specific antisera. Functional uncoupling of the 6-opioid receptor from both 
GTPase stimulation and Inhibition of adenylyl cyclase was achieved by preincubation 
with an IgG fraction isolated from antiserum AS7, an antiserum which specifically 
recognizes Gi2 in this celi line. Preincubation with IgG fractions isolated from either 
Gi3, Go or Gs specific antisera were ineffective. Preincubation with an IgG fraction 
isolated from preimmune serum was also ineffective.
Thirdly, pertussis toxin catalysed ADP-ribosylation of Gi attenuates 
productive coupling between receptor and Gi, leaving the receptor in a state with 
lowered affinity for agonist. Preincubation of NG108-15 cell membranes with an 
IgG fraction isolated from antiserum AS7 produced the same functional consequence 
as pertussis toxin pretreatment. As before, preincubation with IgG fractions derived 
from antisera specific for Gi3, Go, Gs or preimmune serum were ineffective.
These data demonstrate that in cell membranes, receptors are specific in 
their ability to activate G-proteins, the 6-opioid receptor functions through 
activation of Gi2, and that GI2 must therefore be the G-protein which mediates 
inhibition of adenylyl cyclase in NG108-15 cell membranes.
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Chapter 1
In t ro d u c t io n .
1 ■ 1 Historical  perspectives
The control of cellular activity is dependent upon the concerted action of a 
variety of hormones, neurotransmitters and growth factors which bind to specific 
receptors traversing the plasma membrane. The mechanism by which the binding 
of a suitable ligand to a transmembrane receptor exerts an intracellular effect is 
currently unclear and is the subject of much endeavour. Pioneering work by 
Sutherland and Rail on the effects of glucagon and adrenaline in liver homogenates, 
demonstrated that in the presence of hormone, a heat stable factor was produced 
which was abie to activate phosphorylase in the supernatant fraction, whilst 
glucagon and adrenaline were without effect (Rail et al., 1957). The heat stable 
factor was identified as being an adenine ribonucleotide and was designated 3,5 AMP 
(Sutherland and Rail, 1957). Further research identified 3,5 AMP as a cyclic 
monophosphate which is now termed 3',5' cyclic AMP (cAMP). The enzyme 
catalysing the production of 3,5 AMP from ATP was known as adenylyl cyclase.
This data allowed the formulation of the second messenger hypothesis, whereby 
binding of hormone (primary messenger) to specific receptors on the plasma 
membrane elicited the production of a secondary messenger, (cAMP) which was 
functionally active and able to regulate intracellular events.
An insight into the transduction mechanism of hormonal binding to control of 
adenylyl cyclase came in 1971, when Rodbell and colleagues demonstrated that 
hormonal regulation of adenylyl cyclase in hepatocytes required guanoslne 
triphosphate (GTP) (Rodbell et al., 1971a). This requirement had not been 
previously noted, due to heavy contamination of available preparations of ATP with 
GTP. The difference in activation of adenylyl cyclase produced by the addition of 
GTP and poorly hydrolysed analogues of GTP such as Gpp(NH)p and GTPyS, 
suggested the involvement of a guanylnucieotide binding site (Schramm and 
Rodbell,. 1975). Both GTPyS and Gpp(NH)p were able to promote the persistent 
activation of adenylyl cyclase, which was in contrast to the effect of GTP, which 
produced a transient activation. This allowed speculation that the guanylnucieotide
1
binding site involved in the regulation of adenylyl cyclase activity was capable of 
binding and hydrolysing GTP. In 1976, this theory was corroborated by Cassel and 
Seiinger, who demonstrated that hormonal stimulation of adenylyl cyclase in the 
turkey erythrocyte membrane system produced a concomitant increase in the rate 
of high affinity GTPase activity. The elucidation of a technique to measure high- 
affinity GTPase activity in membrane preparations (Cassel and Seiinger, 1976) 
allowed the proposal of a mechanism for control of adenylyl cyclase whereby the 
coupling of a stimulatory hormone to receptor caused the exchange of GDP for GTP 
on a regulatory protein. The hydrolysis of GTP on the regulatory protein resulted 
in the termination of activation of adenylyl cyclase (Casse! and Seiinger, 1977). 
The isolation of a GTP-binding protein from pigeon erythrocytes by Pfeuffer 
supported the earlier work and led to the concept that the transduction of 
information from receptor to effector required a GTP-binding protein (G-protein) 
(Pfeuffer, 1977). Such proteins are capable of binding and hydrolysing GTP.
In addition to receptor-mediated stimulation of adenylyl cyclase, the 
possibility of hormonal inhibition of adenylyl cyclase, which had been suggested by 
earlier studies (Murad et al., 1962), was clarified by Rodbell and colleagues, who 
demonstrated in adipocyte preparations that GTP exerts a biphasic effect on 
adenylyi cyclase activity, (Rodbell, 1975). In the absence of stimulatory 
hormone, guanine nucleotides such as GTP, elicited an inhibition of adenylyl 
cyclase, it was therefore suggested that adenylyl cyclase activity may be regulated 
by both stimulatory and inhibitory G-proteins (Rodbell, 1980)
1 .2  The identification of the stimulatory and inhibitory G- 
proteins: G_s and Gi.
The identification of the stimulatory and inhibitory G-proteins termed Gs and 
Gi respectively, was aided by the isolation of certain exotoxins isolated from 
cultures of both Vibrio cholerae and Bordetella pertussis. Gill and Meren 
demonstrated that the cholera toxin activation of adenylyl cyclase in pigeon
erythrocytes correlated with the radiolabelling of a 42kDa polypeptide, in the 
presence of [^^P] NAD+ (Gili and Meren, 1978). The presumed reaction was an 
ADP-ribosylation, similar to that already detailed for the action of diptheria toxin 
on a protein component required for protein synthesis (Collier, 1975). The effect 
of cholera toxin was similar to that obtained by non-hydroiysable anaiogues of 
GTP, thus allowing the identification of Gs as both a substrate for cholera toxin 
catalysed ADP-ribosylation and a protein capable of binding and hydrolysing 
guanine nucleotides.
In a similar manner, pertussis toxin, which is also termed Islet activating 
protein (lAP), isolated from Bordetella pertussis, was shown to produce 
alterations in receptor mediated control of cyclic AMP production (Katada and Ui, 
1979, 1981). Initial experiments with this toxin In rat 06 glioma cells 
demonstrated an enhancement of GTP activation of adenylyl cyclase, concomitant 
with the transfer of ADP-ribose from NAD+ to a 41kDa membrane associated 
polypeptide (Katada and Ui, 1982). The release of tonic inhibition of adenylyl 
cyclase activity paralleled by the modification of the 41kDa protein thus identified 
this polypeptide as the putatively proposed, but previously unidentified inhibitory 
G-protein of the adenylyl cyclase cascade (Gi). lAP functions in a similar manner 
to cholera toxin in that it is an ADP-ribosyl transferase, catalysing the transfer of 
ADP-ribose from NAD+ onto the G-protein a-subunit. In contrast to pertussis 
toxin, cholera toxin requires the presence of a protein co-factor termed ADP- 
ribosylation factor (ARF) which is itself able to bind GTP (Kahn and Gilman, 
1984a), in order to catalyse the ADP-ribosylation of Gs. The functional effect of 
cholera toxin catalysed ADP-ribosylation of Gsa is to attenuate the ability of Gsa to 
hydrolyse GTP, thus producing an irreversibly activated Gs a-subunit (Cassel and 
Seiinger, 1977; Birnbaumer et al., 1980). After treatment with cholera toxin, 
adenylyl cyclase becomes maximally activated and is no longer responsive to 
hormonal stimulation. In contrast, the functional effect of pertussis toxin catalysed 
ADP-ribosylation of Gia is to prevent productive coupling between receptor and 
G-protein, thus receptor mediated inhibition of adenylyl cyclase is attenuated after 
pretreatment with pertussis toxin (Katada and Ui, 1979; Burns et al., 1983).
This observation led to the prevalent hypothesis that any event which is attenuated 
by prior treatment with pertussis toxin, was Indicative of a role for Gi in 
mediating the response, however this has been demonstrated to be too simplistic, as 
will be described later.
1 .3  G-prote in  puri f icat ion
Initial attempts to purify Gs using GTP affinity chromatography were 
designed to resolve Gs from adenylyl cyclase, thus proving Gs to be a separate 
protein, as opposed to a guanine nucleotide binding site on the catalytic moiety of 
adenylyl cyclase (Pfeuffer and Helmreich, 1975; Spiegel et al., 1979). Studies of 
mutants of the 849 murine lymphoma cell line provided further evidence that 
receptor, Gs and adenylyl cyclase were separate entities. This cell line was 
particularly useful as a model system to dissect the adenylyl cyclase system since 
an increase in intracellular cyclic AMP is cytocidal, a characteristic enabling the 
isolation of mutants which were defective in their ability to produce cAMP. 
Tomkins and co-workers isolated a clone of S49 which lacked the ability to 
synthesise cyclic AMP (Bourne et al., 1975). Initially designated AC-, later eye-, 
the clone was later shown to be deficient in Gs, and thus provided a powerful 
functional assay for the purification of Gs. This was exploited by Ross and Gilman 
who were able to reconstitute adenylyl cyclase activity into eye- membranes using 
a detergent extract of wild type membranes in which adenylyi cyclase had been 
inactivated (Ross and Gilman, 1977).
Purified Gs was shown initially to be composed of cx subunits of either 52 or 
45kDa and a 35kDa p-subunit (Northup et al., 1980), The a -subun its  
corresponded to the guanine nucleotide binding site, as well as the substrate for 
cholera toxin catalysed ADP-ribosylation (Cassel and Pfeuffer, 1978). 
Subsequently a low molecular weight 7-subunit (8kDa) was found to be associated 
with Gs and other G-proteins, Its presence had been 'missed’ before, due to its poor
ability to be stained with conventional protein stains (Hildebrandt et aL, 1984)
Parallel work on the mechanism of visual transduction in retinal 
photoreceptor rod cells led to the purification of a heterotrimeric G-protein 
termed transducin, which serves to couple the light receptor rhodopsin to cyclic 
GMP phosphodiesterases (Baehr et al., 1982). The ease of preparation of rod outer 
segment membranes and the comparative abundance of transducin, which may 
represent over 5% of the total membrane protein in rod outer segment membranes 
(Fung, 1985) allowed the purification of quantities large enough to.allow 
biochemical studies (Fung, 1983), generation of specific antisera, and amino-acid 
sequencing of the three G-protein subunits (Hurley et al., 1984a; Sugimoto et al., 
1985; Fong et al., 1986).
Initial attempts at purification of Gi employed methods which were 
essentially identical to those employed for purification of Gs, since Gi comigrated 
with Gs during the initial chromatographic steps (Bokoch et al., 1983). Pertussis 
toxin catalysed ADP-ribosylation was used as a specific means of identifying 
purified Gi. Using tissues such as rabbit liver (Bokoch et al., 1983), and human 
erythrocytes (Godina et al., 1983) it was possible to resolve an apparently single 
polypeptide, although of apparently dissimilar molecular weight (41kDa and 
39kDa respectively). The purified rabbit liver Gi was demonstrated to be 
functionally able to inhibit adenylyl cyclase, when reconstituted into S49 eye- cell 
membranes, which suggested that the 41kDa polypeptide was indeed the G-protein 
involved in the inhibitory regulation of adenylyl cyclase (Katada et al., 1984a,b,c)
1 . 4  G-prote in heterogeneity
Initial demonstrations that more than a single pertussis toxin sensitive G- 
protein existed came from attempts to purify 'Gi' from brain. Three groups of 
workers noted that purified preparations of pertussis toxin substrates from brain 
contained either two (Sternweis and Robishaw, 1984; Milligan and Klee, 1985) or
three (Neer et al., 1984) polypeptides in the 39-41 kDa range along with p,7 
subunits.
Subsequently, several additional heterotrimeric G-proteins have been 
identified and purified. Measurement of high-affinity specific guanine nucleotide 
binding in brain suggested (hat brain might be a rich source of GTP-binding 
proteins (Sternweis and Robishaw,1984). This was confirmed by the purification 
of a novel G-protein, Go, which comprised approximately 1 to 2% of total brain 
membrane protein (Sternweis and Robishaw, 1984; Neer et al., 1984; Milligan 
and Klee, 1985). In addition to these studies, immunochemical analysis of 
neutrophil plasma membranes, using antisera derived from injecting rabbits with 
purified transducin, suggested the existence of novel forms of pertussis toxin 
sensitive G-proteins (Gierschik et al., 1986a). It was thus becoming apparent that 
the G-protein family was not restricted to Gs, Gi and transducin, and that additional 
heterogeneity was evident. The fact that Go co-purified with Gi from brain, 
suggested that the increasing variety of G-proteins might share structural 
similarities (Miiiigan and Klee, 1985).
1 .5  Mechanism of action of G-protelns
Using the available data on the effects of cholera toxin and non-hydroiysable 
GTP analogues on Gs, together with the ability to measure hormonal stimulation of 
high-affinity GTPase activity, Cassel and Seliinger were able to propose a model to 
account for G-protein function which Is still applicable (Cassel and Seiinger, 
1978). The 'classical' G-proteins are thought to have a mechanism of action which 
is intrinsically similar; the binding of ligand to its receptor causes the a -subun it 
of the specific G protein to lose its bound GDP and bind GTP (Brandt and Ross, 
1986). This results in the dissociation of Ga from its p,7 subunits in a Mg%+- 
dependent process (Iyengar and Birnbaumer, 1982). The binding of GTP reduces 
the affinity of the receptor for agonist, resulting in dissociation of the ternary 
complex (see later). This permits one receptor to re-cycle and activate many G-
proteins (Pedersen and Ross, 1982) The Ga-GTP is now in an activated state and 
may interact with a specific effector protein. After this interaction, GTP is 
hydrolysed by the a-subunit’s intrinsic GTPase activity to GDP (Rodbeil, 1980). 
Ga-GDP is now in an inactive form and can re-associate with its p.y subunits. This 
system is cyclical and dependent on the presence and binding of ligand, GTP and 
Mg2+ (Bourne, 1986) (Figure 1.1).
The dissociation which follows binding of GTP, means that the activation 
process is essentially irreversible (Fung, 1985), however it has not yet proved 
.possible to demonstrate the dissociation of the a-subunit from the p,y subunits 
either in a membrane system, or in response to the G-protein's physiological 
ligand, GTP. In the absence of an agonist-receptor complex, the rate of dissociation 
of GDP limits the GTPase cycle, since the catalytic rate (kcat) is approximately 
ten-fold higher than the GDP-dissociation rate (Ferguson et al., 1986). The 
purified a-subunit of Gs, has a kcat of approximately 10 min*' (at 30°C), thus 
an activated a-subunit has a lifespan of many seconds, a facet which may allow 
interaction and activation of a number of effector moieties, and hence amplification 
of the signal relayed by the binding of hormone to receptor.
G-proteins can be activated by the use of non-hydroiysable analogues of GTP, 
such as Gpp(NH)p and GTP7S in a reaction which is no longer dependent on agonist 
occupancy of receptor, but still requires magnesium (Godina et al., 1983). In 
addition, aluminium fluoride (AIF4") Is able to activate G-proteins by mimicking 
the terminal phosphate of GTP when GDP is in the G-protein guanine nucleotide 
binding site, thus removing the requirement for GDP-dissociation for G-protein 
activation (Bigay et al., 1985).
Fig. 1.1 The role of GTP binding and hvdrolvsis in the 
activation and deactivation of a G-proteJn.
The function of the G-proteins is to couple agonist activated receptors to 
intracellular effector systems. As this process is of limited duration, then the G- 
protein is required to undergo a cyclical pattern of activation followed by a 
deactivation. Figure 1.1 is a diagramatic representation of the mechanism of G- 
protein action, as described in section 1.5, and is reproduced from Milligan,
(1 9 8 8 ).
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1 .6  The identification of a receptor which functions
through G-protein act ivation
G-proleins have been either identified or implicated in mediating a wide 
variety of transmembrane signals. This has led to an accepted rationale for 
determining whether a receptor of interest functions through G-protein activation. 
In addition to showing an absolute requirement for GTP (Rodbell et al., 1971; 
Litosch, 1987), together with the attenuation of a receptor-mediated response by 
pretreatment with either pertussis or cholera toxin, the remaining methods 
currently available for detecting G-protein involvement in mediating a receptors' 
response are ; a) ligand binding assays and, b) GTPase assays.
1.6fh Liaand binding assays
The effect of guanine nucleotides on ligand binding to receptor was firstly 
noted by Rodbell et al. (1971b) , with the demonstration that the affinity of 
glucagon binding to the plasma membrane of rat liver, was decreased by the 
presence of guanine nucleotides. Maguire et al. (1976) were later able to 
demonstrate that in rat C6G1A glioma cell membranes, the binding of p-adrenergic 
agonists, but not antagonists was reduced by the presence of the GTP analogue 
Gpp(NH)p, Further studies on p-adrenergic receptors revealed that whilst 
competition curves for antagonist versus radiolabelled antagonist are steep with 
pseudo Hill coefficients close to 1, competition curves for agonist versus 
radiolabelled antagonist are shallower with pseudo Hill coefficients less than 1 (De 
Lean, et al., 1980). This data suggested the existence of two affinity states for 
agonist, but only one affinity state for antagonist. In the presence of guanine 
nucleotides a low affinity state of receptor for agonist was adopted, wheras in the 
absence of guanine nucleotides the receptor demonstrated a higher affinity for 
agonist. In an attempt to account for the body of data emerging on guanine nucleotide
effects on ligand binding, De Lean et al. (1980) proposed a model involving a 
ternary complex. In the unstimulated state, the inactive G-protein a-subunit (G- 
inact) may interact with receptor (R), leading to the agonist (H) promoted 
formation of a high affinity ternary complex (H.R.G-inact). In the presence of 
guanine nucleotides which activate Ga, the ternary complex is destabilised and both 
agonist and G-protein can dissociate from receptor.
Although the ternary complex model was originally proposed to account for 
the effect of guanine nucleotides on agonist binding to receptors linked to 
stimulation of adenylyl cyclase, ligand binding experiments performed on receptor 
signalling systems linked to the inhibition of adenylyl cyclase yielded similar 
results (U'Prichard et al., 1978, Koski et al., 1981) and led to the general 
conclusion that if a receptors' affinity for agonist is altered by the presence of 
guanine nucleotides, then that receptor functions through activation of a G-protein,
1.6fin Receptor st imulated GTPase activi ty
The steady state of GTP hydrolysis by the G-protein a-subunit is In the range 
of 0.2 to 0.5 min-1 (Gilman, 1987). When G-protein a-subunits are depleted of 
GDP, which is tightly bound under physiological conditions, and GTPase activity 
assessed, the rate of GTP hydrolysis Is markedly Increased. In kinetic experiments, 
the rate of association of GTPyS closely mirrors the rate of dissociation of GDP. 
These observation led to the hypothesis that the rate limiting step for G-protein 
activation is the dissociation of bound GDP (Ferguson et al.. 1986). The role of the 
receptor is to accelerate the rate of guanine nucleotide exchange.
Apart from the visual transduction systems, receptor regulation of G-protein 
GTPase activity has mainly been characterised for receptors mediating the 
inhibition of adenylyl cyclase (Aktories et al., 1984). For many receptors known 
to function through G-protein activation, it has not been possible to assay GTPase 
activity. This is particularly true for receptors which function to stimulate the
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rate of hydrolysis of inositol containing phospholipids in a pertussis toxin 
insensitive manner, and also for receptors which stimulate adenylyl cyclase 
activity through activation of Gs (Jakobs et aL, 1984). Indeed, although GTPase 
activity was firstly identified as Gs mediated, it is only possible to measure 
receptor stimulated high-affinity GTPase activity by Gs in a very limited number 
of model systems studied, namely the turkey erythrocyte (Cassel and Sellinger, 
1978) and the platelet (Houslay et al., 1986a). In contrast, stimulation of GTPase 
activity by receptors which interact with pertussis toxin sensitive G-proteins has 
been reported for a wide variety of membrane systems. The reason for this 
discrepancy may lie in the relative proportion of G-proteins which are present and 
able to interact with the receptor which is under scrutiny. In most signal 
transduction model systems, the expression of Gs is lower than that of Gi. (Ransnas 
and Insel, 1988). In addition the intrinsic GTPase activity of purified Gs is lower 
than that of purified Gi (Gilman, 1987). It is also conceivable that receptor 
number is a limiting factor since data exists to suggest that the greater the number 
of receptors present, the greater the GTPase stimulation obtained (see later). As 
such, receptor mediated stimulation of GTPase activity may indeed occur for all 
receptors which function through G-protein activation, but the proportion of 
substrate which is hydrolysed is too low for detection using current techniques of 
GTPase measurement.
Application of the above considerations has led to the identification of a wide 
variety of signalling pathways which are G-protein mediated. These include; the 
receptor mediated stimulation and inhibition of adenylyl cyclase, (Krupinski et al., 
1989; Levitzki, 1986), the stimulation of cyclic GMP phosphodiesterases 
(Stryer, 1988) the stimulation of phosphoinositidase C (Litosch, 1987), the 
stimulation of phospholipase A2 (Burch et al., 1986), the inhibition of voltage 
operated Ca channels (Yatani el al., 1987b; Rosenthal et al., 1988), and the 
stimulation of certain voltage operated K'*' channels (Brown and Birnbaumer, 
1988). In addition, less well characterised events such as secretion and exocytosis 
(Fernandez et al., 1984), olfactory transduction (Lancet and Pace,, 1987), 
glucose transport (Schurmann et al., 1989) and Na+ channel activity (Cantiello et 
al., 1989) have been demonstrated to involve G-protein activation.
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1 . 7  The mechanism of G-protein interaction with effector
The G-protein dissociation model was originally developed under the 
assumption that the G-protein a-subunit is the site of functional interaction with 
both receptor and intracellular effector. This implies that the intrinsic function of 
each G-protein is encoded by the a-subunit, with the subunits having a more 
passive role, being required to recognise the GDP-bound form of the a-subunit and 
to anchor the a-subunit to the plasma membrane (Sternweis, 1986). However, 
there is evidence to suggest that the (3,y complex is a requirement for interaction of 
Ga with receptor, since guanine nucleotide exchange is diminished in the absence of 
p,Y subunits (Cerione et al., 1985) and a receptor G-protein complex will not 
form in the absence of subunits (Fung, 1983). In the last few years it has 
become apparent that the P,y subunits may fulfill a more complex role in the 
control of transmembrane signalling, (see below).
Although it has been appreciated that the function of Gi in transmembrane 
signalling is the transduction of agonist binding to inhibition of adenylyl cyclase 
(Klee et al., 1985). The mechanism by which this occurs remains an open 
question, with two main mechanisms of action being proposed. In the first of these 
proposals, the (3,y complex is thought to be primarily responsible for mediating the 
inhibition of adenylyl cyclase activity. Herein, Gi activation and dissociation would 
leave an increased concentration of free p,y.in the membrane millieu. By mass- 
action, this increase in free (3,y would potentiate reassociation of any free Gsa w ith 
(3,y, effectively attenuating stimulation of adenylyl cyclase (Katada et al., 
1984a,b,c). This hypothesis is supported by work on S49 wild type membranes, 
where the addition of purified (3,y complex results in a dose dependent inhibition of 
Gsa stimulated adenylyl cyclase activity. In addition, for this theory to be correct, 
one would expect to find Gi present in larger amounts than Gs. As such, activation of 
Gi would release a proportionately large amount of free p,y complex which could 
de-activate Gsa. This has been shown to be the case (Gilman et al., 1987). 
Interestingly, the addition of purified unliganded Gia can actually activate adenylyl
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cyclase activity in both platelet and S49 ceil membranes, presumably by binding 
to subunits and shifting the equilibrium to release free Gsa (Katada et al., 
1984a,b,c).
Secondly, it is possible that the Gia subunit inhibits cAMP production 
directly by acting at a specific regulatory site on adenylyl cyclase (Hildebrand! et 
al., 1983). Evidence for the latter has been obtained from work on 849 eye cells 
where Gsa is not.expressed but inhibition of adenylyl cyclase can occur through an 
inhibitory agonist, somatostatin (Ross and Gilman, 1977). This inhibition cannot 
be explained by a p,7 deactivation of Gsa. Interestingly, kinetic experiments have 
shown Gi to inhibit Gs stimulated adenylyl cyclase activity .in a non-competitive 
manner, suggesting that if Gia is indeed able to directly Inhibit adenylyl cyclase, it 
acts at a different site on adenylyl cyclase to that of Gsa (Hildebrandt et al.,
1983). It is possible to reconcile both theories by suggesting that in wild type 
cells which express functional Gs, inhibition of adenylyl cyclase by Gi is a 
consequence of both direct a-subunit inhibition and p,7 subunit inhibition, thus 
implying a specific role for both Gia and the p,7 subunits in signal transduction.
The role of the p,y subunits in the control of signal transduction has been the 
subject of several recent reports. Katada et al. (1987) have reported an 
Interaction of the p,y subunits with the calcium binding protein, calmodulin, which 
has previously been noted to stimulate specific forms of adenylyl cyclase. It is not 
known whether the interaction between the p,y subunits and calmodulin is 
physiologically relevant, or if It may simply be explained by a hydrophobic 
interaction between the proteins. However, in the presence of Ca^+, purified p,y 
subunits were able to Inhibit Ca^+Zcalmodulin stimulation of adenylyl cyclase, but 
not Gs or forskolin stimulation, suggesting a broader role for p,y subunits in the 
control of adenylyl cyclase activity.
In rod outer segment membranes, photon activation of phospholipase A2 
activity has been shown to occur by a transducin-dependent mechanism, requiring 
dissociation of the heterotrimer. The addition of purified p,y subunits to
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îransducin-depleîed rod outer segments produced a stimulation of phospholipase A2 
activity which was attenuated by addition of purified transducin a -subun its , 
suggesting a dual role for transducin in the stimulation of both cyclic GMP 
phosphodiesterases and phospholipase A2 (Jelsema and Axelrod, 1987).
A role for p,y subunits as direct activators of certain K+ channels has been 
proposed by Neer and co-workers, (Logothetis et al., 1987), Chick embryonic 
atrial cells contain muscarinic acetylcholine receptors which „are involved in the 
opening of an inwardly rectifying potassium channel. The addition of poorly 
hydroiysable GTP analogues has been demonstrated to open the K+ channel in the 
absence of receptor agonist. Pretreatment with lAP abolished agonist-induced 
channel opening which suggested the involvement of an lAP substrate such as Gi 
(Pfaffinger et al., 1985). Perfusion of embryonic chick atrial cells with purified 
Gia, Goa and p,y subunits, unexpectedly showed that addition of p,y subunits alone 
was enough to produce opening of the K+ inflow channel, and that purified a- 
subunits from either erythrocytes (40kDa polypeptide), or brain (39kDa 
polypeptide), were also able to promote opening of the K+ channel, but were less 
efficacious than purifed p,y subunits from brain (Logothetis et al., 1987). The 
situation has been complicated by the work of Birnbaumer and colleagues, who have 
purified a G-protein from human red blood cells which is capable of opening a 
subset of potassium channels present in guinea pig atrial cells (Yatani et al.,
1987a; Yatani et al., 1988a,b). Although originally termed Gk, the G-protein ' 
responsible has been identified as GI3 (Codina et al., 1988), and when activated 
with GTPyS, opens K+ channels in an essentially Irreversible manner. Most 
experiments conducted In patch clamp systems have Involved the addition of 
purified G-proteins to reconstitute receptor-mediated effects on the channel under 
study. However, many 'pure' G-protein samples may contain a heterogeneous 
population of a-subunits which cannot be resolved under standard SDS- 
polyacrytamide gel electrophoresis and may therefore be significantly impure. To 
circumvent this problem, Birnbaumer and colleagues have expressed recombinant- 
Ga fusion polypeptides with an additional nine N-terminal amino-acids in 
Escherichia coli. The recombinants may comprise up to 10% of total cellular 
protein, enabling easy purification. Surprisingly, when either recombinant Gia
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1,2 or 3 were activated with GTPyS and applied to atrial membrane patches, ail 
three subunits were equally capable of opening K+ channels (Yatani et al., 1988c). 
Controversy has continued subsequent to two reports which identify arachidonic 
acid metabolites produced by stimulation of phospholipase A2 (Kim et al.,
1989), as being able to open K+ channels in atrial cells (Kurachi et al., 1989), 
thus the identification of the G-protein which can Interact with K+ channels in 
atrial cells, together with the elucidation of the respective subunit which mediates 
the effect, remains to be resolved.
1 .8  G-protein cloning and sequence homoloav
With Improved G-protein purification protocols, sequence data quickly 
emerged, allowing the cloning of complementary DNA's encoding putative G-protein 
a-subunits The heterogeneity of the G-proteins thus identified structurally was 
rapidly becoming apparent, and to date there are at least 30 amino-acid sequences 
corresponding to at least 9 different classes of a-subunits (Table 1.1).
Amongst the best characterised G-proteins are; Gs, transducin and Gi. Two 
forms of transducin (Td) occur, Tdl and Td2, which are encoded by separate 
mRNA's, are found in rod and cone cells respectively (Lerea et al, 1986) and serve 
to couple rod and opsins to cyclic GMP phosphodiesterases. The two forms of 
transducin show a very limited distribution and it has been suggested that one 
transducin variant Is involved In mediating colour vision, whilst the other 
mediates mono-chromatic vision. (Stryer, 1988). Gs and Gi are thought to be 
ubiquitously expressed and function to couple various receptors to the stimulation 
and Inhibition of adenylyl cyclase respectively. At least four forms of Gsa, exist 
which are obtained from alternate splicing of a transcript produced from a single 
gene (Bray et al., 1986). These have been grouped into two subtypes which are 
termed long and short Gsa. The cDNA's that encode two of the forms of Gsa have 
been isolated from a bovine adrenal cDNA library and are identical except for a
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Table 1.1 The form and function of the a-subunits of the 
Ic i.a^,.sI g a l l . .. G --P lp..1 e
The 'classical' G-proteins can be defined according to their sensitivity to 
either pertussis toxin or cholera toxin {section 1,2), their function (section 1.6ii) 
and their distribution (section 1.8). Table 1.1 provides a summary of the form and 
function of the 'classical' G-proteins, and is taken from Milligan, (1989).
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Table 1.1 The structure and function of the a subunits of the 
'c lassical '  G-proteins,
G*Protein
Sensitivity .to 
ADP-ribosylation 
by bacterial toxins
Function D istribution
Gs Yes, cholera toxin stimulation of adenylyl cyclase, 
activation of dihydropyridine- 
sensitive Ca2+ channels.
universal
Golf Yes, cholera toxin stimulation of adenylyl cyclase olfactory sensory
neurones
G il Yes, pertussis toxin undefined limited; high 
levels in brain
GI2 Yes, pertussis toxin inhibition of adenylyl cyclase universal
stimulation of phospholipase C?
Gi3 Yes, pertussis toxin regulation of K+ channels undefined; 
universal ?
Go
Gz
Yes, pertussis toxin regulation of Ca2-i- channels
No undefined, stimulation 
of phospholipase C ?
lim ited
Undefined but 
restricted
TD1 Yes, cholera and 
pertussis toxins
activation of cGMP 
phosphodiesterase
rod outer 
segments
TD2 Yes, cholera and 
pertussis toxins
activation of cGMP 
phosphodiesterase
cone outer 
segments
sequence of 46 nucleotides in wtiich the shorter forms of Gsa contains alterations 
in 4 nucleotides and a deletion of 42 others (Robishaw et al., 1986). Where<^sat 
least two forms of Gs are expressed In most tissues, their relative amounts can 
vary (Mumby et al., 1986). Functional differences between the two forms of Gs 
have been difficult to assess since current protein purification protocols fail to 
fully resolve long and short Gsa, however a recent report suggests that the shorter 
42kDa form of Gsa may have greater functional activity than the larger 52kba 
form (Walseth et al., 1989). To circumvent the poor resolution of the various 
forms of Gsa by current purification techniques, cDNÀ's which encode both long 
and short forms of Gsa have been expressed in Escherichia coli. When partially 
purified, both forms of Gsa can reconstitute, albeit with low intrinsic activity, 
receptor, AIF4" and guanine nucleotide stimulation of adenylyl cyclase activity in 
S49 eye cells with equal efficacy, suggesting that there is no functional difference 
between the long and short forms of Gsa (Graziano et al., 1987). The failure to 
produce more active Gsa in Escherichia coli may be due to the lack of a co- or 
post-translational modification of the protein which .is a requirement for 
interaction with the effector, adenylyl cyclase (Graziano et al., 1989). A 
hypothesis supported by the ability of rabbit reticulocyte lysates to synthesise Gsa 
which is fully active but which migrates anomalously upon SDS-Page (Oiate et al., 
1988). Although Gs was originally identified as the G-protein required for 
receptor mediated stimulation of adenylyl cyclase, the protein has a more recently 
defined role as an activator of dihydropyridine-sensitive Ca^+ channels (Yatani et 
al., 1987b).
Initial attempts to isolate cDNA's corresponding to Gi were performed by a . 
number of groups, who employed a variety of different tissues such as bovine brain 
(Nukada et al., 1986), bovine pituitary (Michel et al., 1986), human monocyte 
(Didsbury et al., 1987), mouse macrophage (Sullivan et al, 1986) and rat C6 
glioma cells (ttoh et al., 1986). The cDNA's isolated were termed Gi cDNA's either 
on the basis of identity in amino-acid sequence with a known 41kDa pertussis toxin 
substrate from brain, or on the basis of a potential site for pertussis toxin 
modification (Kim et al., 1988). Comparison of two different cDNA clones obtained 
from a human brain cDNA library (X g tll)  suggested that two types of Gi existed
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(Bray et at., 1987). The first type, isolated from bovine brain libraries, was 
found to correspond exactly to the 41kDa pertussis toxin substrate from brain 
(Michel et al., 1986; Nukada et al., 1986) and has been termed Gi-1 (Bray et al., 
1987; Jones and Reed, 1987). The most commonly found sequence Is that reported 
by Itoh et al. (1986), which has been designated Gi-2 by Jones and Reed (1987). 
Sequences which are essentially identical to this Gi-2 have been found in a mouse 
monocyte library (Sullivan et al., 1986), a bovine pitiutary library (Michel et 
al., 1986) and a human monocyte library (Didsbury et al., 1987). More recently, 
a sequence corresponding to a third form of Gi has been Isolated and termed Gi-3 
(Jones and Reed, 1987; Suki et al., 1987; Itoh et al., 1988; Kim et al., 1988). 
Although the name Gi is derived from an initial association with adenylyl cyclase 
inhibition (Katada et al., 1986; Katada et al., 1987), the protein products of the 
genes which encode G il, Gi2 and Gi3 seem to play a role in the opening of K+ 
channels (Yatani et al., 1987a) and possibly in the activation of phosphoinositidase 
C (PLC) (Ohta et al., 1985) and phospholipase A2 (Bokoch and Gilman, 1984), 
Less well characterised G-proteins include Go, (o for other) which is abundant in 
neural tissue such as brain (Sternweis and Robishaw, 1984). At present, only one 
sequence corresponding to Go has been Identified in mammals (Itoh et al., 1986; 
Jones and Reed, 1987), however two separate mRNA's which hybridize to a Go 
specific probe have been identified (Jones and Reed, 1987), suggesting that 
heterogeneity In the forms of Go which may be expressed Is possible. This Is borne 
out by purification data which demonstrate the occurence of more than one form of 
G-protein immunologically corresponding to Go (Goldsmith et al., 1988;
Kobayashi et al., 1989). The function of Go remains unresolved, however evidence 
is accumulating to suggest that the G-protein may be involved in the regulation of 
receptor-mediated inhibtion of voltage operated Ca "^** channels (Hescheler et al., 
1987; Harris-Warrick et al., 1988; Ewald et al., 1988). More recently, a 
sequence for a G-protein termed Gx (also Gz, Fong et al., 1988) has been isolated 
from a human retinal cDNA library. This sequence lacks an apparent ADP- 
ribosyiation site for pertussis toxin and when translated, would be similar in size 
to the pertussis toxin sensitive G-proteins (Matsuoka et ai., 1988). Although a 
particular function has yet to be ascribed to Gz (Gx), it has been suggested that this
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G-protein may mediate signal transduction in signalling systems which are not 
blocked by pertussis toxin, such as the control of the pertussis toxin insensitive 
forms of linkage to phosphoinositidase C. However this remains to be 
experimentally assessed (Fong et al., 1988). A subtype of Gs, termed Gpif has been 
cloned from olfactory epithelia (Jones and Reed, 1989). It has been suggested that 
Golf may function in a manner analogous to that of Gs, but in contrast to Gs, which 
appears to be expressed ubiquitously, G^jf shows a different pattern of 
distribution, being located solely in olfactory epithelia, (Jones and Reed, 1989).
The above G-protein sequences do not represent the entire family of G- 
proteins which may be expressed. Simon and colleagues have recently made use of 
polymerase chain reaction technology to detect additional gene products in mouse 
brain. The group failed to detect two of the known Gi sequences and as such the G- 
p rote in sequences detected do not represent a comprehensive screen of a -subun it 
sequences in mouse, however four previously undetected sequences were observed, 
suggesting that an even greater number of unique G-protein a-subunits may be 
expressed and involved in transmembrane signalling (Strathmann et at., 1989).
When the predicted protein sequences of Go, G il, 2, 3, Tdl and Td2 (rat) are 
aligned (Figure 1.2), the G-protein a-subunits show impressive amino-acid 
sequence homology (Jones and Reed, 1987). Gsa is the most divergent, containing 
several insertions that the others lack, and is approximately 40 % identical to any 
of the other six a-subunits. The three Gi's and Go share greater homology, with Go 
73% identical to G il, 68% with GI2 and 70% with GI3. Gi2 shares 88% identity 
to G il and 85% identity with Gi3. G il and 3 are most homologous, with 94% 
identity. Gz (Gx) shows strongest homology to G il, GI2 and Gi3 (66-67%) whilst 
being 60% homologous to Go and only 41% homologous to Gs. Between species, 
amino-acid homology is even more startling, with at least 98% identity of Gi2, 
Gi3, Gx and Go from rat, bovine and human sources.
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Fig. 1.2 Primary sequences of the a-subunits of the
currently identified pertussis toxin sensitive G- 
proteins expressed in rat.
Areas of identity are shaded. In cases in which identity at particular residues 
does not extend across all the polypeptides, then the closest homology to the 'Gi-like' 
subfamily is indicated. Where each of Gi1, Gi2 and Gi3 is represented by a different 
amino-acid at one position then no further homology to Go, Tdl or Td2 is noted. The 
sequences for Go, G il, Gi2 and Gi3 are taken from Jones and Reed (1987), that for 
Tdl from Tanabe et al. (1985), and that for Td2 from Lochrie et al. (1985). Figure
1.2 is reproduced from Milligan (1988).
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It thus appears that according to amino-acid homology the G-proteins may be 
grouped Into several categories, the Gi-like G-proteins, which are G il, 2 , 3 and 
Go, the Gs-like G-proteins, Gs and Golf. The transducins Td-j and Td2, and Gz (Gx), 
which is as divergent from the Gi group as are the transducins and is therefore best 
categorized as a separate class of G-protein (Fong et al., 1988).
In contrast to the diversity in the number of a-subunits, a similar degree of 
diversity in (3-subunits has not been observed. Purification of G-proteins from a 
variety of sources had previously demonstrated that at least two forms of the p- 
subunit existed (Sternweis et al., 1981 ; Sternweis and Robishaw, 1984) which 
were immunologically distinct (Evans et al., 1987), and had molecular masses of 
35 and 36kDa. In visual transduction systems, expression of p-subunits is limited 
to the 36kDa form, however both forms may be expressed in other tissues. To date 
the sequences of three cDNA clones corresponding to p i,  p2 and p3 have been 
determined (Sugimoto et al., 1985; Fong et al., 1987; Gao et al., 1987; Levine et 
al., 1990). All three p-subunits are highly homologous at the primary sequence 
level however p1,(35kDa) and p2 (36kDa) are 10% divergent In amino acid 
sequence. The functional significance of these differences is unknown.
At present, one 7-subunit sequence is available (Ovchinnikov et al., 1985; 
Hurley et al., 1984a). The cloned transducin 7 subunit cDNA encodes a peptide with 
a calculated molecular weight of 8400. Data exists to suggest that there are other 
7-subunits to be characterised. Antisera raised against purified transducin a,p,7, ■ 
are capable of recognising the p-subunit in purified preparations of Gi or Gs, but 
do not recognise the 7 subunit of Gi or Gs, implying that the p-subunits of 
transducin, Gs and Gi may be homologous, but the 7 subunits of transducin are not 
(Gierschik et al., 1986b). In addition, both Immunological studies on the p,7 
complex purified from human placenta (Evans et al,, 1987) and peptide mapping 
of purified 7-subunlts (Hildebrandt et al., 1985), suggest that there is more than 
one non transducin 7-subunit, and therefore at least three 7-subunlts exist. Under 
normal physiological conditions the p,7 subunits which are tightly, though not 
covalently bound, do not dissociate, and may be thought of as a single entity.
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The G-protein a-subunits have molecular masses of between 39 to 46 kDa, 
as calculated from primary sequence data. However, a variety of other proteins 
exist which are capable of specifically binding and hydrolysing guanine nucleotides. 
Initiation and elongation factors required for protein synthesis, such as Ef-Tu, 
utilise GTP hydrolysis as part of their activity. This has proved extremely 
beneficial to current understanding of G-protein structure, since Ef-Tu was the 
first GTP-binding protein to be crystallised in its GDP bound form (Jurnak,
1985; La Cour et al., 1985). Proteins involved in maintaining cellular structure 
such as the tubulins, are capable of the binding and hydrolysis of GTP, however 
these proteins do not appear to function in an analogous manner to the G-proteins 
which have been characterised to date (Seckier et al., 1990).
1 .9  Small moJecular __welght G-proteins
A range of smaller molecular weight G-proteins exists, with molecular 
masses of between 21-27kDa (Chardin, 1988). The 21 kDa protein products of the 
ras oncogene may also be designated as belonging to the G-protein family since 
these proteins have the ability to bind and hydrolyse GTP. Overexpression of this 
oncogene results in stimulation of inositol phospholipid hydrolysis and 
uncontrolled cell growth, which led to the suggestion that ras may be involved in 
signal transduction (Wakelam et al., 1986). However it has recently been 
demonstrated that the uncontrolled cell growth elicited by expression of mutated 
forms of ras, cannot be explained by constitutive activation of inositol lipid 
breakdown, so the exact site of ras action remains elusive (Seuwen et al., 1988). 
Although a specific role for small molecular weight G-proteins has yet to be 
defined, the high degree of evolutionary conservation of amino-acid sequence 
suggests that they have a definite role in cellular function. Several members of this 
family have been purified including ARF, a protein cofactor required for cholera 
toxin catalysed ADP-ribosylation of Gs, (Kahn and Gilman, 1984a), and Gp, not to 
be confused with the G-protein mediating stimulation of phosphoinositidase C, has
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been purified from human placenta (Evans et al., 1986). Gp was reported to co- 
purify with subunits Indistinguishable to those present in heterotrimeric G- 
protein complexes. This remains the only example of a small molecular weight G- 
protein being able to interact with (3,7 subunits. Brain tissue has proved to be a 
rich source of low molecular weight G-proteins, with a report claiming as many as 
six distinct polypeptides (Kikuchi et al., 1988). In contrast to the 'classical' G- 
proteins, little is known about the mechanism of action of these smaller G- 
proteins. However, as well as the obvious difference in size they are not 
susceptible to either cholera or pertussis toxin mediated modifications. In 
contrast, several low molecular weight G-proteins including the rho gene 
product, serve as substrates for ADP-ribosylation catalysed by certain botulinum 
toxins (Yamamoto et al., 1988; Bokoch et al., 1988). Although small molecular 
weight G-proteins are capable of binding and hydrolysing GTP, a putative 
nucleotide exchange reaction is lacking, which Is perhaps related to the striking 
difference shown by the kinetics of guanine nucleotide binding to ras. When 
compared to Its larger counterparts, the rate of GTP hydrolysis by ras in vitro is 
at least ten fold lower (McCormick, 1989). However the rate of GTP hydrolysis by 
ras in vivo has been demonstrated to occur very much faster than in vitro. This 
is due to the presence of a GTPase-activating protein, GAP, which has been found in 
the cytoplasm of all vertebrate cells (Trahey and McCormick, 1987). GAP has 
been purified and cloned and demonstrated to have a molecular mass of 116kDa. 
From in vitro experiments, the protein appears to function enzymatically by 
converting the GTP bound form of ras to the GDP bound form (Gibbs et al., 1988).
1 . 1 0  G-proteins in veast and invertebrate transmembrane  
s ignal l ing  systems.
Much of the biochemical characterisation of G-proteins has been centred on 
vertebrate signal transduction systems, however several recent studies have 
focussed on the mating pheromone response pathway of the yeast saccharomyces 
cerevisiae, which contains components sharing strong structural similarities to
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the mammalian G-protein signalling pathway. Haploid yeast cells of the MATa and 
MATa designation express cell-type specific pheromone receptors encoded by the 
STE2 and STE3 genes (Burkholder and Hartwell, 1985; Nakayama et al., 1985, 
Hagen et al., 1986; Dietzel and Kurjan, 1987). These receptors, although not 
homologous to each other, have seven hydrophobic, potential membrane spanning, 
domains as well as a serine/threonine rich C -terminal domain and as such are 
homologous to mammalian G-protein linked receptors. Mutations in the STE2 and 
STE3 genes leads to a loss of responsiveness to pheromones and a sterile phenotype. 
Yeast has also been shown to encode a gene termed either SCG1 (Dietzel and Kurjan,
1987) or GPA1 (Nakafuku et al., 1987) which encodes a 54kDa polypeptide 
homologous to the a-subunits of Gs, Go, and Td, and is thought to be involved in the 
mating pheromone response pathway. Disruption of the SCG1 gene Is lethal to 
haploid cells due to constitutive activation of the pheromone respone pathway along 
with cell cycle arrest, interestingly, expression of rat Gsa in yeast can suppress 
growth arrestment, suggesting that SCG1 functions in a manner analogous to 
mammalian Gs. The products of several other STE genes are required for 
pheromone response. Two such genes, STE4 and STE18, have been cloned and 
sequenced and shown to be homologous to the p i and p2 subunits of bovine and 
human Td (STE4) and to the y-subunit of bovine Td (STE18). Mutations in either 
gene supress the lethality conferred by mutation in the SCG1 gene. This data has led 
to a model whereby binding of pheromone to receptor (STE2 and STE3 gene 
products) promotes dissociation of the a-subunit (SCG1 gene product) from p,y 
(STE4 and STE18 gene products), with the free p,y subunits interacting with 
effector. Although speculative, this model suggests a definite role for the p,y 
subunits in transmembrane signalling.
In addition to the data obtained from studies on yeast, it is apparent that 
invertebrates employ G-proteins in cellular signalling. Non-hydrotysable guanine 
nucelotides have produced phototransduction effects in limulus (Fain, 1986), 
squid (Tsuda et al., 1986) and house flies (Blumenfield et al., 1985). In addition, 
a 39-40kDa pertussis toxin substrate has been observed in nervous tissue of a 
variety of invertebrates (Hopkins et al., 1988). This protein cross-reacts with
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polyclonal antibodies generated to vertebrate Goa (Homburger et al., 1987), and 
may be involved in mediating a dopamine -induced decrease in neuronal calcium 
currents in snails (Harris-Warrick et al., 1988). Perhaps one of the most widely 
studied invertebrates is the fruit fly. Drosophila melanogaster, the nervous 
system of which has been shown to express ion channels (Salkoff et al., 1987), 
visual pigments (Zuker et at., 1985) as well as adenylyl cyclase (Chen et al
1986). More importantly, a range of G-proteins have been identified in 
Drosophila,the nomenclature of which is based on the respective homology to 
mammalian G-protein sequences. Thus, G-proteins which have been termed; G ila , 
Gi2a, Gsa, andGoa, have been described (Provost et al., 1988; Quan et al., 1989; 
deSousa et al., 1989; Thambi et al., 1989). In addition a putative p-subunit has 
been isolated (Yarfitz et al., 1988). As yet the function of these mammalian G- 
protein homologues in Drosophila remains to be determined.
When deprived of nutrients, Dictyostelium discoideum amoebae cease growth 
and initiate a developmental program to form a multicellular organism (Gerisch,
1987). The ceils move in a chemotactic manner in response to extracellular cyclic 
AMP, which activates two signal transduction pathways by binding to 
transmembrane receptors. The primary structure of the cyclic AMP receptor(s) 
displays seven putative transmembrane domains, homologous to mammalian G- 
protein linked receptors (Klein et al., 1988). Biochemical studies indicate that the 
cAMP activated signal transduction pathways involve G-proteins, and indeed the 
cDNA for two such G-proteins has been isolated and designated Gal and Ga2. Both 
proteins are homologous to rat Gil a.
As yet, the respective function of invertebrate G-protein homologues remains 
to be ascertained, however the high degree of amino-acid sequence conservation 
over the long evolutionary distance between yeast, insects and mammals suggests 
that function may also be conserved. The ability to produce mutants, together with 
the well characterised genetics in invertebrate signal transduction systems, 
suggest that such systems are likely to provide an increasingly powerful tool in the 
analysis of mammalian G-protein function.
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1 . 1 1  Structural  and functional G-protein characterist ics
In addition to sharing extensive amino-acid homology (Figure 1.2), the G- 
proteins which have been most widely studied are thought to share similar 
functional characteristics, these include;
(i) the ability to bind and hydrolyse GTP
(ii) interaction with p,7 subunits
(iii) interaction with receptor
(iv) functional interaction with effector
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If the amino-acid sequence of the a-subunits of each of Gi 1,2 and 3, Go, Gs 
(long form) from rat, human Gz and bovine rod and cone transducin are aligned, 
then some 82 invariant amino acids can be identified (Figure 1.2). A majority of 
the most highly conserved sequences are near regions predicted to be involved in 
the binding of guanine nucleotides. The basis for these predictions comes from 
studies of genetic mutations in ras which affect guanine nucleotide interactions, 
and from biophysical data obtained from the crystal structures of the GDP-bound 
form of Ef-Tu (Jurnak, 1985; LaCour et al., 1985), It has been possible to 
identify four concensus sequence elements which have been termed A, C, E, and G, 
using the Halliday classification (Halliday, 1983), which are sequentially 
arranged along the primary protein structure from the amino to carboxy terminal. 
The A concensus sequence is Gly-X-X-X-X-Gly-Lys. In EF-Tu this region is near 
the a-phosphate of GDP. Mutations in an analogous region of ras, for example 
replacement of glycine at position 12 with a variety of amino-acids, reduces GTP 
binding and GTPase activity (Der et al., 1986) as well as increasing transforming 
ability (Seeburg et al., 1984). The C-region concensus sequence is Asp-X-X-Gly. 
A mutation of Asp-X-Ala-Gly to Asp-X-Thr-Gly in ras results in auto- 
phosphorylation of threonine if GTP is used as substrate. The E region is 
hydrophobic and often contains an alanine residue which is 26 amino-acids
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removed from the aspartic acid residue in the C-region. In ras, mutation of the 
analogous alanine to threonine results in a 30-fold reduction in GTP-affinity (Feig 
et al., 1986). The G-region has the concensus sequence Asn-Lys-X-Asp and 
confers nucleotide binding specificity. A mutation of the aspartic acid in the G- 
region of EF-Tu to asparagine alters the nucleotide specificity to xanthine 
diphosphate over guanosine diphosphate (Hwang and Miller, 1987). Mutations in 
this region in ras reduce, alter or abolish nucleotide, binding (Feig et al., 1986; 
Sigal et al., 1986; Walter et al., 1986).
Several recent reports have taken advantage of the above described 
predictions of regions of the G-protein a-subunit required for GTP binding and 
hydrolysis to produce a variety of G-protein mutants which have been expressed in 
either 849 eye- cells or in Escherichia coli. Expression of Gsa in 849 eye- cells 
in which leucine replaces glutamine 227 (designated Q227L, and corresponding to 
glutamine 61 in ras) results in the constitutive activation of adenylyl cyclase and 
reduction of GTPase activity of Gs. In another mutant in which valine replaces 
glycine 49 (designated G49V and corresponding to glycine 12 in ras), there is also 
a reduction in GTPase activity, however the G-protein cannot stimulate adenylyl 
cyclase due to an inability to adopt an active confirmation (Masters et al., 1989). 
When the same mutated Gsa-subunits are expressed in Escherichia coli, purified 
and reconstituted Into 849 eye- cells, similar results are obtained (Graziano and 
Gilman, 1989). This confirms the inferences drawn from similarities in the 
primary structure of both EF-Tu and ras with the G-protein a-subunit, in that 
the amino-acid residues surrounding glycine 49 and glutamine 227 of Gsa are 
involved in guanine nucleotide binding and hydrolysis.
Amino-acid sequences outside of the Halliday regions are thought to be 
neces5o.ry for a-subunit specific interactions such as interaction with p,7 
subunits, interaction with receptor and interaction with effector.
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fût Interaction with p.-v subunits
There is some evidence to suggest that the N-terminus .is important for 
interaction with the p,Y subunits. The a-subunit of many G-proteins contains a site 
sensitive to trypsin, which'is close to the N-terminus (Hurley.et a!., 1984b; 
Winslow et al., 1987) In the presence of GTP7S, trypsin cleaves a 2kDa peptide 
from the amino terminus of G ila  and Goa, the remaining 39 and 37kDa proteins 
being resistant to further proteolysis. G il and Go are virtually identical in this 
region, and the tryptic site has been demonstrated to be after residue 21 in Go, a 
site present in both a-subunits. After tryptic cleavage at the N-terminal region, 
the a-subunits of G il and Go are no longer able to interact with the {3,7 subunits, 
since both subunits are no longer substrates for pertussis toxin (Neer et al.,
1988). Limited proteolysis of transducin a, Involving the removal of a 1-2kDa 
fragment from the N-terminus, results in the diminuition of a number of reactions 
which are thought to require a,p,7 Interaction, such as ADP-ribosylation by 
pertussis toxin, rhodopsin binding, Gpp(NH)p binding (Fung and Nash, 1983), and 
immunoprécipitation of Td a,{3,7 by a monoclonal antibody which identifies Td a 
(Navon and Fung, 1987).
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The C-terminus of Ga has been implicated in the interaction with receptor. 
The main evidence for this statement lies In the role of pertussis toxin to ADP- 
ribosylate Gi. This covalent modification, at a residue close to the extreme C- 
terminus of Gi, attenuates productive couplng between receptor and G-protein, 
with no impairment of the ability of Gi to dissociate in response to activating 
guanine nucleotides (Katada et al., 1986). In addition, a mutant ofthe S49 murine 
lymphoma exists which has been termed une (uncoupled) (Haga et al., 1977). In 
this cell line, it is possible to obtain stimulation of adenylyl cyclase using agents 
which are able to directly activate Gs, such as ALF^" and non-hydrolysable 
analogues of GTP. However, it is not possible to demonstrate receptor mediated 
stimulation of adenylyl cyclase by either p-adrenergic receptor agonists, or PGE1.
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In addition, the sensitivity of p-adrenergic agonist binding to guanine nucleotides 
is no longer apparent (Haga et al., 1977). Two-dimensional electrophoretic 
analysis has demonstrated that in the une mutant, Gsoc migrates as a more acidic 
species than Gsa from wild type S49 cells, by approximately one charge, 
suggesting that the impairment in signal transduction lies in the a-subunit of Gs 
(Schleifer et al., 1980). The subsequent sequencing of complementary DNAs 
encoding Gsa in both une and wild type S49 cells showed that In the une mutant, a 
point mutation in Gsa results in the replacement of an arginine residue by a 
proline residue, at a position six amino-acids from the C-terminus. The functional 
-consequence of this mutation is the inability of the G-protein to interact with 
receptor. (Sullivan et al., 1987; Rail and Harris,, 1987).
(iv) Interaction with effector
The mechanism by which a G-protein may interact with an effector is 
probably the least well understood aspect of G-protein function. Sequences thought 
to be involved in the interaction with effector lie between the Halliday regions A 
and 0 where there is most variability between the G-protein a-subunits. The 
analogous region in Ef-Tu binds aminoacyl-tRNA in a GTP-dependent reaction, and 
mutations in ras in this region disrupt its biological activity without Interfering 
with either nucleotide or membrane interaction (Stein et al., 1986). A mutant of 
Gs termed H21 a is able to interact with receptor and bind guanine nucleotides, but 
is unable to interact with adenylyl cyclase, suggesting that the mutation is In the 
domain of interaction of Gsa with effector, however it has since been demonstrated 
that the mutation, which involves the replacement of a glycine with an alanine at 
position 226, prevents Gsa adopting an active conformation (Miller et al., 1988). 
Thus the domain of G-protein interaction with effector remains unresolved.
A conserved restriction endonuclease site, present in almost all mammalian 
a-subunit cDNA's, separates the putative domains Involved in receptor and effector 
interaction (Masters et al., .1986). This allows the production of chimeric cDNA's 
in which a hybrid G-protein a-subunit derived from two different a-subunits is 
encoded by a single reading frame. In this manner it has been possible to produce a
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Gs/Gi2 hybrid, which is derived from the amino-terminal 212 amino-acids of Gi2 
and the C-terminal 160 amino-acids of Gs. The C-terminal region of Gs is thought 
to be the domain of interaction with receptor, wheras the 212 N-terminal amino- 
acids encoded by the Gi2 section of the chimera is thought to contain the domain of 
interaction with effector. It was thus theorised that the chimeric G-protein would 
be capable of interaction with receptors which stimulate adenylyl cyclase, and 
couple to the inhibition of adenylyl cyclase. When the chimeric G-protein was 
expressed in S49 eye- cells, a polypeptide of approximately 46kDa which is 
immunologically identifiable as both Gs and Gi, is prevalent (Masters et al.,
1988). Surprisingly, the Gia/Gsa chimera was shown to mediate p-adrenergic 
receptor stimulation of adenylyl cyclase activity to a similar extent as wild type 
Gs, and be Incapable of mediating inhibition of adenylyl cyclase activity by either 
stimulatory or Inhibitory receptors.
A similar chimeric construct in which the 356-amino-terminal amino acid 
residues are contributed by Gsa and the 36 residues at the carboxy terminus are 
derived from Gi2a has been produced. Expression of this chimera in mamrnalian 
cos cells resulted in a constitutive elevation of intracellular cyclic AMP, 
presumably as a result of increased stimulation of adenylyl cyclase. Kinetic studies 
suggest that the increased ability of the chimeric G-protein to interact with 
adenylyl cyclase may be due to an enhanced rate of GDP-dissociation. This implies 
that in addition to interacting with receptor, the C-terminal region of the G- 
protein a-subunit may also play a role in the regulation of guanine nucleotide 
exchange (Woon et al., 1989).
1 . 1 2  Covalent modificat ions of G-proteins.
G-protein heterotrimers are known to be associated with the cytoplasmic 
surface of the plasma membrane, and with the exception of transducin, can only be 
extracted from membranes using detergents. This is in keeping with their known
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functions, to modulate the level of activity of intracellular effectors at the plasma 
membrane. However the exact basis for membrane association has not been 
rigorously defined. Purified a-subunits do not readily associate with phospholipid 
vesicles unless. subunits are present, suggesting that the subunits 
functionally serve to anchor the G-protein to the plasma membrane (Sternweis,
1986). Recent reports have indicated that G-protein a-subunits need not be 
continuously associated with the plasma membrane, since long term incubation of 
membrane preparations with non-hydrolysable GTP analogues promotes the 
release of the a-subunits of Gs, Gi2 and Go into a supernatant fraction (Milligan 
and Unson, 1989; Milligan et al., 19.88; McArdle et al., 1988). Further, in S49 
celts, agonist occupation of p-adrenergic receptors promotes a redistribution of 
Gsa from the plasma membrane into the cytosol (Ransnas et al., 1989). These 
observations suggest that dissociation of the G-protein a-subunit from the 
subunit attenuates the ability of the a-subunit to remain at the plasma membrane, 
and that the p,y subunits must therefore play a role in G-protein membrane 
attachment. However this leaves the question of the method of attachment of the p,y 
complex to the plasma membrane. The possibility of either of these subunits being 
transmembrane spanning proteins is unlikely, since, in common with the a- 
subunits, a suitable hydrophobic stretch of amino-acids is not immediately 
apparent (Chabre, 1988).
The a-subunits of both Gi and Go have recently been shown to be 
myristoylaled (Buss et al., 1987; Schultz et al., 1987). This is a covalent. 
modification which Is thought to occur co-translationally and results in the 
attachment of the 14-carbon fatty acid, myristate to the N-terminal glycine 
residue of the a-subunit (Sefton and Buss, 1987). This covalent modification has 
been described for other proteins, many of which are membrane attached, such as 
the src oncogene (Garber et at., 1985) and is thought to be a requirement for 
protein function. Indeed, mutations which remove the N-terminal glycine from 
src result in a protein which is no longer myristoylated, can no longer associate 
with the plasma membrane, and is incapable of promoting cellular transformation 
(Kamps et al., 1985). Studies with purified N-methyltransferases on synthetic 
peptides have revealed the concensus sequence required for myrlstoylation to be;
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Met, Gly, X, X, X, Ser. The methionine is not present in the mature polypeptide, 
having been removed presumably by an aminopeptidase. All G-protein subunits 
which have been cloned to date, share the above concensus sequence, with the 
exception of Gsa, p35, p 36 or the 7 subunits. Gsa has the prerequisite N-terminal 
glycine, but has an asparagine residue at position 6, this difference could reduce 
the Km of Gsa for N-methyltransferase by several thousand fold (Towler et al.,
1988). If the amino-terminal glycine of G il is modified by site directed mutation 
to an alanine residue, Gi1 can no longer be myristoylated, and can be detected 
predominately in the cytoplasmic region of cells in which it is expressed. (Jones et 
al., 1990). This may be regarded as strong evidence for myrlstoylation as the 
mechanism of G-protein attachment to the plasma membrane, however, since It has 
not been possible to detect a similar covalent modification of either Gsa, p35, p3 6 
or 7 subunits which are undoubtedly localised at the plasma membrane, it may be 
suggested that myrlstoylation is not the only mechanism of membrane attachment 
employed by G-proteins (Buss et al., 1987).
Ras proteins are acytated with various lipids, primarily palmitate, which 
was originally thought to be present on a cysteine residue, (cys186), four amino- 
acids from the C-terminus (Grand et al, 1987). Mutational analysis has revealed, 
that cys186 is essential for membrane localisation (Wiliumsen et al., 1984). 
Examination of a number of proteins which are thought to be paimitoylated at this 
position has led to the identification of a concensus sequence; Cys-Al-AI-X, where 
A1 represents an aliphatic amino-acid and X represents any amino-acid. Goa,
G il ,2,3a, T d ia , Td2a and Tdyall possess this so-called CAAX box and as such may 
be subject to other lipid.modifications. Recent reports have noted that instead of 
being paimitoylated, the cysteine present in the CAAX box of p21ras is both 
farnesylated and methylated, with palmitate present on a cysteine residue which is 
several residues further upstream. The remaining three amino-acids are cleaved 
by a m H^'peptidase (Hancock et al., 1989). It has recently been reported that 
the 7-subunit of transducin is methylated on the carboxyl group of a G-terminal 
cysteine residue (Fung et at., 1990). This modification is likely to be associated 
with both proteolytic removal of the three C-terminal amino-acids in the CAAX
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sequence and lipidation of the methylated cysteine (Fung et al., 1990). üpidation 
at the cysteine would serve to anchor the complex and assist in the anchorage of 
the G-protein a-subunit to the plasma membrane. It is therefore possible that G- 
proteins may be substrates for a range of lipid modifications which may be 
required for anchorage to the plasma membrane.
1 . 1 3  P h o s p h o ry la t io n
The activity state of a large number of cellular enzymes is controlled by 
phosphorylation/dephosphorylation events. Regulation of receptor function 
through phosphorylation has been well documented (Sibley et al., 1987). As 
central mediators of transmembrane signalling, it might well be hypothesised that 
G-protein function may also be regulated by kinase and phosphatase activity. The 
phosphorylation of Gia and transducin-a has been demonstrated in vitro by 
protein kinase C (Katada et al., 1985; Zick et al., 1986), the preferred substrate 
being the GDP-liganded a-subunit. Phosphoamino analysis revealed incorporation 
to be on serine residues. The exact residue(s) involved were not determined, but 
Ser at position 12 is a likely candidate (Zick et al., 1986), being conserved in all 
G-protein a-subunits except Gsa. As previously described, the N-terminal region 
of the G-protein a-subunit has been postulated to be the site of interaction with 
the p,Y subunits, as such it is of interest to note that the phosphorylation of Gia by 
protein kinase C was inhibited by addition of the complex (Katada et al., 1985). 
In addition to these in vitro studies, it has recently been demonstrated that the a- 
subunit of Gi can be phosphorylated In intact hepatocyles, (Pyne et al., 1989; 
Büshfield et al., 1990), platelets (Crouch and Lapetina, 1988) and U937 cells 
(Issakani et al., 1989). This may be presumed to be mediated through activation of 
protein kinase 0 , since the effect was obtained when cells were treated with agents 
which activate protein kinase 0  either directly, or through the stimulation of 
inositol phospholipid metabolism. In both hepalocytes and U937 cells, GI2 seems to 
be the G-protein modified, wher@%in platelets both GI2 and Gz(x) may be
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phosphorylated (Carlson et al., 1989). The functional effect of G-protein 
phosphorylation has yet to be rigo rously defined, however it is likely that G- 
protein activation is attenuated.
1 . 1 4  The Interaction of receptors with G-proteins
The first step in the conveyance of information from the outside to the inside 
of a cell is the binding of a hormone neurotransmitter or growth factor to a 
transmembrane receptor which is present on the plasma membrane of the cell. Cell 
surface receptors may be functionally classified into several categories, according 
to the specific signal transduction pathways that they stimulate. These classes 
include; a) growth factor receptors which have an intrinsic tyrosine kinase 
activity (for example, receptors for insulin, PDGF and EGF)(Hunter and Cooper, 
1985), b) multisubunit receptors which are ion channels (the nicotinic 
acetylcholine, 7-amino butryic acid and glycine receptors)(Changeux et al.,
1987), c) receptors which function as carrier proteins (transferrin 
receptor)(Go!dstein et al., 1985), and (d) receptors which activate G-proteins 
(Strader et al., 1989; Dohlman et al., 1987). Based on this functional 
classification, the largest class of receptors are those which interact with and 
activate G-proteins, and as such, these receptors have been the subject of much 
research in recent years (Weiss et al., 1988).
Recent reports have suggested that this delineation of receptor-G-protein 
linked signalling pathways may not be absolute, since the EGF receptor, which is a 
tyrosine kinase, has been shown to stimulate adenylyl cyclase activity in perfused 
rat hearts (Nair et al., 1989), and by the demonstration that EGF is able to 
stimulate phospholipase A2 activity in rat inner medullary collecting tubule cells, 
in a manner stimulated by GTP7S and inhibited by pertussis toxin pretreatment 
(Teitelbaum, 1990). However, it is still generally accepted that receptors which 
function through an intrinsic tyrosine kinase activity do not directly interact with 
G-proteins.
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Although the G-protein linked signal transduction systems are diverse in 
nature, the cloning and sequencing of several G-protein linked receptors has 
demonstrated strong structural homology, and a number of key features have 
emerged. The predicted membrane topography of the human Ç>2 adrenergic receptor 
is shown (Figure 1.3.). Hydropathy analysis of G-protein linked receptors has 
revealed the existence of seven hydrophobic stretches of between 20 to 25 aniino 
acids. Each of these stretches is proposed to form an alpha-helical membrane 
spanning domain. The intervening hydrophilic sections are exposed extra and 
intracellularly (alternately). This results in the localisation of the N-terminus 
extracellularly, with the C-termlnus being intracellular (Strader et al., 1989). 
All G-protein linked receptors which have been sequenced, are known have between 
one to three concensus sites for N-linked glycosylation at the amino-terminal 
region of the protein (Dohlman et al., 1987). The functional significance of these 
glycosylation sites is currently unknown, although they may be required for 
localisation of the receptor to the plasma membrane. One of the most interesting 
questions regarding G-protein linked receptors, lies in the identification of the 
domains responsible for both ligand binding and G-protein interaction. Current 
data suggests that ligand binds to receptor within the plane of the lipid bilayer 
(Findlay and Pappin, 1986; Dixon et al., 1986). The interaction between 
receptors and G-proteins has to be both transient and specific (Chabre, 1987), - 
for this reason, it was thought that G-proteins and receptors must interact at the 
inner surface of the plasma membrane. Both proteolysis and deletion mutagenesis 
experiments have shown that the third intracellular loop is required for receptor 
interaction with G-protein (Kuhn and Hargrave, 1981; Dixon et ai., 1987;
Strader et al., 1987). This region is one of the most divergent (Dohlman et al.,
1987). Interestingly though, substitution of the entire third intraceliular loop and 
the surrounding helices 5 and 6 of the a2 adrenergic receptor (adenylyl cyclase 
Inhibitor) with the analogous region of the beta adrenergic receptor only resulted 
in a small degree of adenylyl cyclase stimulation by the chimeric receptor, 
suggesting that some level of G-protein specificity is controlled by the rest of the 
receptor (Koblika et al., 1988). Further work on this aspect has produced 
contradictory results (Dixon et al., 1987; O'Dowd et al., 1988), which leaves the
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Fig. 1.3 The proposed organisation of the human P2.
adrenergic receptor in the plasma membrane.
Hydropalhy analysis of the amino-acid sequence of G-protein linked 
receptors has revealed the existence of seven hydrophobic stretches of between 20 to 
25 amino-acids. Each of these stretches is proposed to form an a-helical membrane 
spanning domain (section 1.14). The proposed organisation of the human ^2  
adrenergic receptor in the plasma membrane is shown. Potential sites for N-linked 
glycosylation are marked (CHO), along with the cysteine residue which may be 
paimitoylated in this receptor (Cys 341). Figure 1.3 is reproduced from O'Dowd et 
ai., (1989).
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situation presently unresolved.
The activation of G-proteins by a receptor is catalytic in nature, in that one 
receptor may activate numerous G-proteins (Levitzki, 1988). However unlike 
conventional enzymes, receptors which activate G-proteins do not seem to catalyse 
the formation or cleavage of covalent bonds, but instead serve to stabilise a 
conformational change which allows guanine nucleotide exchange on the G-protein 
a-subunit (Wessling-Resnick et al., 1987). The mechanisms of interaction which 
assist guanine nucleotide exchange are not well defined, however reconstitution 
studies with purified proteins suggests that the subunits are required for 
receptor mediated guanine nucleotide exchange , and that one complex may 
recycle between a-subunits, allowing many a-subunits to be activated by a single 
agonist occupied receptor (Fung, 1985). Evidence exists that the p,y subunits have 
a site of interaction with receptor, since both p,y and transducin a-subunits are 
capable of preventing the phosphorylation of the light receptor rhodopsin by 
rhodopsin kinase (Fung, 1985). A single receptor may function cataiyticaily to 
activate many G-proteins, as has been reported for the p-adrenergic receptor 
(Pederson and Ross, 1982). A single photobleached rhodopsin may activate up to 
500 transducins in vertebrate rods (Stryer, 1986).
1 .1 5 Interaction of G-proteins with _ effectors.
The least studied area of G-protein function is the mechanism of interaction 
with effector, it Is generally thought that G-proteins interact with intracellular 
effectors in a transient manner, and that one G-protein may be able to interact 
with more than one effector before the intrinsic GTPase activity of the a-subun it 
deactivates the G-protein. This model allows for signal amplification as well as 
explaining why G-protein activation does not result in the constitutive activation 
or inhibition of an effector under G-protein control. In contrast, the activation of 
atrial K+ channels by Gi3 (see earlier) appears be essentially irreversible, since
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repeated washings do not attenuate the ability of GI3 which has been activated with 
GTPyS ,to open the channel (Yatani et al., 1987a).
Gs is known to co-purify with adenylyl cyclase at a stoichiometric ratio of 
one mole per mole (Arad et al., 1984), and it is posible to immunoprecipitate 
adenylyl cyclase with antisera which identify the C-terminal region of Gsa, when 
Gs is in the activated state (Simonds et al., 1989b). This suggests that Gsa may 
form a strong association with adenylyl cyclase and that the G-terminal region of 
Gs is not the site of interaction with effector. The recent isolation of cDNA's which 
encode adenylyl cyclase should aid research in this neglected area (Krupinski et 
al., 1989) and thus assist in our understanding of G-protein function.
1 . 1 6  Regulation of G-protein levels
Few studies have addressed the regulation and control of G-protein levels in 
signal transduction model systems, however it has been appreciated that the 
expression of G-proteins may alter during aging (Green and Johnson, 1989), and 
organ development (Luetje et al., 1987). It is not known whether these changes 
represent alterations in mRNA transcription, translation or stability, or in 
protein degradation. A recent study addressed to the steady state levels and 
degradation rate of Go in GH4 cells and rat cardiocytes suggests that protein 
transiational controls may be important in determining the concentration of G- 
protein a-subunit in a given tissue (Gilbert et al., 1990).
In several tissues, corticosteroids have been shown to play a role in 
regulating G-protein levels. Dexamethasone has been shown to increase the 
expression of Gsa in GH3 cells as measured by an increase in both mRNA and 
protein (Chang and Bourne, 1987). This is In keeping with the ability of 
glucocorticoid hormones to enhance hormonal stimulation of cyclic AMP 
accumulation in a variety of cells and tissues (Davies and Lefkowitz, 1984). The 
glucocorticoid hormone corticosterone has also been shown to increase the levels of
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Gs {both 45 and 52kDa forms) at both mRNA and protein levels, and to decrease 
protein and mRNA levels of both'G il and GI2 in rat cerebral cortex. The levels of 
both Go and P'SUbunits did not change (Saito et al., 1989).
Treatment of a variety of cells with "differentiation' agents has been 
demonstrated to dramatically alter the steady state G-protein levels. The 3T3-L1 
fibroblast cell line may be induced to differentiate into a more adipocyte-like cell 
type, using the glucocorticoid dexamethasone (Watkins et al., 1987). Accompaning 
this differentiation is an apparent increase in Gsa, p-subunits and Gia, however, 
these a-subunit increases were assessed by cholera and pertussis toxin catalysed 
ADP-ribosylation, which may be unreliable indicators of G-protein levels 
(Mullaney et al., 1988). Treatment of NG108-15 cells with the cyclic AMP 
analogue dibutryl cyclic AMP, which is capable of traversing the plasma 
membrane, results in a four-fold increase in Go levels and a concomitant 2 to 3 
fold decrease in Gi levels (Mullaney et al., 1988). In a similar manner, 
differentiation of HL-60 ceils with dimethyl sulphoxide produces an increase in 
the levels of Gi2 (Uhing et al., 1987). Functional correlates between changes in 
G-protein levels and changes in the ability to Interact with Intracellular effectors 
have not been convincing enough to determine the functional role for each G- 
protein.
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1 . 1 7  Research Aims
It is therefore apparent that although G-proteins play a pivotal role in the 
process of transmembrane signalling, the mechanism by which they functionally 
interact with other protein members of the signal transduction cascade is largely 
unresolved. The aim of this thesis is to examine both the mechanism and the 
specificity of interaction between G-proteins receptors and effectors in a widely 
used signal transduction model system, and thus ascertain if G-proteins are 
-selective in their interactions or if they are more promiscuous and able to interact 
with a variety of different effectors in the same tissue. The model system under 
study, along with the strategy employed to investigate G-protein specificity will be 
described in detail in chapter three.
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Chapter 2
and MethodSu
2.1 . M a t e r i a l s
All reagents employed were of the highest quality available and were obtained 
from the following suppliers;
a.General reagents
Sigma Chemical Co. 
Poole, Dorset.
Cholera toxin
Bovine Serum Albumin
NAD
Naloxone hydrochloride 
TEMED 
T rypsin
Norit-A charcoal
Ouabain
Theophylline
Arginine hydrochloride
N-ethylmaleimide
DADLE
DALAMID
0-dianisidine hydrochloride 
ATP disodium salt 
cAMP sodium salt 
Keyhole limpet Haemocyanin 
Freund's complete adjuvant 
Freund's incomplete adjuvant 
Coomassie blue R-250.
Bromophenol Blue.
Thimerosal.
Protein-A Sepharose.
Tween 20
Dowex AG50W-X4 (200-400 mesh)
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Alumina (neutral) 
Imidazole
Boehringer (U.K.) Ltd 
Lewes, East Sussex
GTP
GTP^
Gpp(NH)P.
GDP
GDPpS
App(NH)p
D ith io thre lto l
Creatine phosphate.
Creatine phosphokinase 
Triethanolamine hydrochloride 
T ris
Thymidine
Calbiochem
Cambridge.
Forskolin
National Diagnostics
Aylesbury,
Buckinghamshire
'Ecoscint" scintillation fluid
Porton Products 
Porton Down 
Salisbury ■ 
W iltsh ire .
Pertussis toxin
Koch-Light Lab. Ltd
Haverhill
Suffolk.
DMSO
sodium potassium tartrate
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F.S.A. Lab. Supplies N.N'-meîhylenebisacrylamide
M & B 
Dagenham.
Ammonium persulphate
Camlab
Cambridge, England
Polygram Sil-G 20cm x 20cm precoated 
plastic sheets
Polygram CEL 300 PEI/UV 5cm x 20cm 
precoated plastic sheets
Whatman International Ltd. GF/C Glassfibre filters 
Maidstone 3mm Chromatography paper.
No. 1 Filter paper.
B.R.L.
Paisley, Scotland.
, Prestained molecular 
weight markers.
b.Tissue culture._plas.ti.c_w_are
Costar Biofreez vials
205 Broadway, Cambridge 
M.A., U.S.A..
Bibby Science Products Ltd 75cm^ tissue culture flasks. 
Stone, Staffordshire.
Elkay Products 
Shrewsbury, 
M.A., U.S.A.
50ml centrifuge tubes
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2.2.Cell  cul ture media
Gibco Life Technologies 
Paisley, U.K.
Dulbecco's modification of Eagle's 
medium (lOx)
Foetal Calf Serum 
Glutamine (200mM)
Sodium Bicarbonate 
Hypoxanthine (0.1 mM), Aminopterin 
( I j iM ),  Thymidine (1 GpM) (50x). 
Penicillin (100 I.U./ml), 
Streptomycin (100mg/ml) (lOOx)
Imperial Labs Foetal Calf Serum
West Portway, Andover, Hants.
2 .3 .Rad ioch em ica ls
Amersham pic,
Amersham,
Buckinghamshire
y[32r ]GTP
[S', 8-2H] Adenosine 3', 5'-cycIic
phosphate
a[32p]ATP
[15, 16 (n)-2H] Diprenorphine
New England Nuclear, 
Boston, Mass., U.S.A
(2-D-Alanine-5-D-Leucine),  [Tyrosyl- 
3,5-2 H(N}] -Enkephal in.  
Adenylate-[22p] NAD.
All other reagents used were obtained from BDH (Dorset, Poole, 
England),
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2 .4 . Radiochemical  Puri ty
a DADLE.
Purity of the radiolabelled enkephalin DADLE, was determined by thin later 
chromatography. 5|_il of stock radiolabelled peptide was spotted onto plastic-backed 
plates of silica-gel (polygram sil-G), which were then placed jn a chromatography 
tank lined with filter paper which had been saturated with so-lvent (chloroform; 
methanol; ammonia, 12:9:4 by volume) for at least one hour before development 
of the chromatograms. Plates were removed after the solvent had moved 10cm from 
the origin, and the gel sectioned into vertical strips of 0.5cm tall x 2cm wide. Each 
strip was placed in a scintillation viai with lOmls of ecoscint scintillation fluid 
and counted in the tritium channel of a rackbeta scintillation counter. The above 
resolving conditions give an RF value of 0.55 for DADLE (James, I., 1980, PhD. 
thesis, Glasgow University). Routinely approximately 90% of the radioactivity in 
the sample was the appropriate radiolabelled peptide.
b^aZplGTP
1 nl of slock Y[32p]GTP was spotted onto a 10cm x 5cm sheet of PEI 
cellulose which had been pre-run in water to take most of the yellow soluble 
material to the top, and left to dry at room temperature for 5 minutes. The sheet 
was placed in a chromatography tank containing 0.75M potassium phosphate buffer 
(pH 3.5) until the solvent front had travelled three-quarters of the way up the 
sheet. The cellulose was then sectioned vertically into 0.5cm tall x 2cm wide strips 
which were put in scintillation vials with lOmIs of ecoscint scintiliation fluid and 
counted in the 22p channel of a rackbeta scintillation counter. Under these 
conditions 7[22p]GTP migrates with a RF value of approximately 0.15 to 0.20, 
with the major contaminant being 22pj, Typically,greater than 80% of the total 
radioactivity present in the sample was -y[22p]GTP.
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c.ara^PlATP
a[22p]ATP purity was assessed in a manner identical to that for y[22p]GTP 
described above, however a[22p]ATP migrated with an RF value of approximately 
0.35,and typically greater than 70% of the total radioactivity present was 
a[22p]ATP.
2.5 .Standard Buffers
Phosphate Buffered Saline. 
(PBS) 2g potassium chloride
80g sodium chloride
2g potassium dihydrogen
orthophosphate
21.6g of disodium hydrogen
orthophosphate heptahydrate
to a final volume of 1 litre, pH7.4.
Tris Buffered Saline (TBS) 500mM sodium chloride,
20mM Tris-HCL pH 7.5.
Tris Buffered Saline 
with Tween 20 (TTBS)
SOOmM sodium chloride, 
20mM Tris-HCL pH 7.5, 
0.05% (v/v) Tween 20.
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Methods
2 . 6 . Cel! cultur_e
a.Cell growth.
NG108-15 neuroblastoma x glioma hybrid cells were a kind gift from Dr. W. 
Klee (N.I.H., Bethesda, M.D. USA) and were grown in TScm^ tissue culture flasks 
in 0.0375% (w/v) sodium bicarbonate buffered Dulbecco's modification of Eagle's 
Medium (DMEM), containing 10% (v/v) foetal calf serum (PCS) which had been 
heat inactivated at 56^0 for 30 minutes. The medium was supplemented with 
glutamine (2mM), hypoxanthine (0.1 mM), aminopterin (IpM ) and thymidine 
(16 |iM ). Both penicillin (100 units/ml) and streptomycin (1 OOpg/ml) were 
routinely included. The growth media will henceforth be termed DMEM/10%
(v/v) PCS. Cells were grown in a humidified atmosphere of 5% 0 0 2 /95% air.
b.Cell. subculture.
Confluent cells (typically 10^ cells per 75cm2 flask) were passaged using a 
trypsin solution containing 0.1% (w/v) trypsin, 0.67mM EDTA and lOmM 
glucose in PBS. Growth media was removed from the cells and 2mls of trypsin 
solution added. When the cells had been removed from the surface of the flask, 
trypsinisation was stopped bt the addition of two volumes of DMEM/10% (v/v) 
PCS. The cells thus removed from the surface of the flask were collected and 
centrifuged at 800 x g in a MSE centaur for two minutes to pellet the cells. The cell 
pellet was resuspended in DMEM/10% (v/v) PCS and plated out as required.
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c.Cell maintenance.
Confluent cells were removed from the surface of the flask by trypsinisation 
as described above and the cells resuspended in freezing medium, which consisted 
of 8% (v/v) DMSO in PCS. The suspension was aliquoted into 0.5 ml volumes into 
biofreez vials, frozen overnight at -80°C packed in cotton wool, and then 
transferred to liquid nitrogen for storage. Cells to be brought up from liquid 
nitrogen storage were thawed immediately at 37°G, resuspended in 10 mis of 
DMEM/ 10% (v/v) PCS, and centrifuged at 800 x g in a MSE centaur for two 
minutes to pellet the cells. The cell pellet was resuspended in DMEM/ 10% (v/v) 
PCS and plated out in a final volume of lOmls of DMEM/ 10% (v/v) PCS in a 75 
cm2 flask.
d.Toxin treatment of cells.
Confluent cells to be treated with toxin were given a change of media into 
DMEM/10% (v/v) PCS, supplemented with either pertussis toxin to a final 
concentration of 25ng/ml or cholera toxin to a final concentration of lOOng/mi. A 
parallel set of control flasks were treated with an equal volume of toxin vehicle. 
After 16 hours treatment, cells were harvested as described below.
e.Cell Harvesting.
When confluent, growth medium was removed from the cell culture flask and 
lOmls of ice -cold PBS added. Cells were gently washed from the surface of the 
flask, collected in a 50ml conical tube and centrifuged at 800 x g in a Beckman TJ6 
centrifuge for 10 minutes. The resulting cell pellet was washed with ice-cold PBS 
and re-centrifuged. The final pellet was stored at -80^C until use. Pellets which 
had been stored for up to one year were found to retain full activity.
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f.Production of plasma membranes.
Membranes were produced according to Koski and Klee (1981). Frozen cell 
pellets were thawed and suspended in 5 volumes of ice cold lOmM Tris-HCL,
0.1 mM EDTA pH 7.5 and homogenised with 15 strokes of a Potter homogeniser.
The homogenate was centrifuged at 500 x g for 10 minutes in a Beckman L5- 
50B centrifuge with a Ti 50 rotor, to remove unbroken cells and nuclei. Plasma 
membranes were collected by centrifugation of the supernatant fluid at 48,000 x g 
for 10 minutes, washed in 10 volumes of the same buffer and after a second 
centrifugation, were resuspended in the same buffer to a final protein 
concentration of between 2 to 4 mg/ml, aliquoted, and stored at -SO^C until 
required.
2 . 7 .Prote in D e te rm in a t io n .
The method used is based on that described by Lowry and co-workers,
(Lowry et al, 1951).
Stock Solutions;
A) 2% (w/v) sodium carbonate in 0.1 M sodium
hydroxide.
B ) 1% (w/v) copper sulphate,
C) 2% (w/v) sodium potassium tartrate.
Just prior to use, the stock solutions were mixed in the following ratio,
A:B:C, 100:1:1, to produce solution D.
Protein standards were prepared using a 1 mg/ml bovine serum albumin 
fraction 5, and a standard curve constructed for a maximum of 30|ig of protein per 
sample. Unknowns were assayed in 2, 4 and 8\i\ volumes in duplicate. 1ml of
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solution D was added to each sample, mixed and left to stand for 10 minutes. 100pl 
of Folin's Ciocalteau reagent diluted 1:1 with H2O was added to each sample, mixed 
and allowed to stand for a further 20 minutes. The absorbance of light by each 
sample was assessed spectrophotometrically at 750nm in a LKB Ultrospec 2.
2 .8 .A n tib o d y  P roduc tion .
All antisera used were generated against synthetic peptides, essentially as 
described by Goldsmith and colleagues, {Goldsmith et al., 1987). Synthetic 
peptides were obtained from Dr. C.G. Unson, the Rockerfeller University, New 
York, U.S.A. with the exception of the peptide NLKLEDGISAAKDVK, which was 
synthesised by Dr. A. I. Magee, N.I.M.R., Mill Hill, London, and the peptide 
KNNLKECGLY which was obtained from Biomac Ltd., Glasgow, U.K.
3mg of the appropriate peptide and lOmg of keyhole limpet haemocyanin 
were dissolved slowly in 1ml of 0.1 M phosphate buffer pH 7.0. 0.5ml of 21 mM 
glutaraldehyde (also in 0.1 M phosphate buffer pH 7.0) was then added dropwise 
with stirring and the combined 1.5mt incubated overnight at room temperature.
The 1.5ml solution was mixed with an equal volume of complete Freund's 
adjuvant and briefly sonicated with a Branson 'soniprobe' (Type 7532B).1ml 
aliquots of the resulting emulsion were injected in multiple subcutaneous sites in 
New Zealand white rabbits. Four weeks later each animal received a booster 
immunization with material identically prepared, except one half as much keyhole 
limpet haemocyanin and peptide were injected in incomplete Freund's adjuvant.
Bleeds were performed monthly with approximately 15ml taken from the ear 
artery and collected Into a glass universal. Blood was left to clot overnight at 4°C 
and the plasma removed and centrifuged at 1000 x g in a Beckman TJ 6 for 10 
minutes to pellet any remnants of the clot. The supernatants so produced were 
aliquoted into 250pl volumes and stored at -80°C until use.
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A range of different antisera were produced in the manner described, as 
summarised in Table 2.1 below;
Ta bl^ 2 -J .
Antiserum Peptide Used G-protein sequence Antiserum Identifies
AS7 KENLKDCGLF Tda 341-350 Td, G il, GI2
001 ANNLRYOGLY Goa 345-354 Gb
I3B KNNLKECGLY Gi3a 345-354 Gi3
CS1 RMHLRQYELL Gsa 385-394
LE2 , LERIAQSDYl Gi2a 160-169 Gi2
110 LDRIAQPNYi G ila 159-168 G il
BN1 MSELDQLRQE Gp. 1-10 p1, p2
2 .9 .Ant ibody Puri f icat ion
Crude antisera were chromatographed on a 1.5cm x 2 cm column of protein- 
A-sepharose 4B. A 5mI volume of antiserum in glycine buffer (1.5M Glycine, 3M 
NaCl, pH 8.9) was added to the column and allowed to equilibrate. The column was 
washed with glycine buffer until the eluate had an A28O of 0.0 and was then eluted 
with lOOmM citric acid, pH 4.0 into 2M Tris/HCL, pH 7.5. The eluted IgG 
fractions were dialysed overnight against 1000 volumes of lOmM Tris-HCt,
0.1 mM EDTA pH 7.5, and lyophilised. Just prior to use, samples were 
reconstituted to the required dilution with the same buffer.
In some cases, antisera AS7 was affinity purified on a column of bovine 
transducin as described by Gierschik and colleagues (Gierschik et al.,1986b). 1.5 
mg of purified bovine transducin was coupled to cyanogen bromide activated 
sepharose 4B to a final concentration of 1mg of protein per mg of settled gel. Whole 
serum diluted 1 : 3 with 50mM Glycine, SOOmM NaCl, pH 7.5 was incubated
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overnight at 4^C with the transducin linked sepharose and after washing with the 
same buffer, specifically bound immunoglobulins were eluted with lOOmM 
glycine, SOOmM NaCl, pH 2.5 The eluate was immediately restored to pH 7.5, 
aliquoted and stored at -80^C until use.
2 . 1 0 .Gel Electrophoresis
Gel electrophoresis was carried out according to the discontinuous system 
described by Laemmli (1970).
a. Resol vino Gel Preparation.
Stock Solutions; (stored at 4°C and filtered through Whatmans No.1 
filter paper prior to use)
Solution A 1.5M Tris,0.4% (w/v) SDS, pH 8.8 with HCL.
Solution B 0.5M Tris,0.4% (w/v) SDS, pH 6.8 with HC-L.
Solution C 30% (w/v) Acrylamlde,0.8% (w/v) N,N'-
methylene bisacrylamide.
Solution D 30% (w/v) Acry!amide,0.15% (w/v) N,N'-
methylene bisacrylamide.
Solution E 50% Glycerol.
Solution F 10% (w/v) Ammonium persulphate (made daily)
Solution G Temed.
Reservoir buffer; 0.025M Tris, 0.192M Glycine, 0.1% (w/v) SDS, pH 7.5.
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10% (w/v) Acrylamide/0.25% (w/v) N,N'-methyienebisacrylamide gels 
were prepared from stock solutions as follows;-
Solution Volume (ml)
A 6
C 8
E 1.6
F 0.09
G 0.008
To a final volume of 24ml with HgO.
The solution was immediately mixed and poured Into a LKB gel casting 
apparatus, which consisted of 180 x 160 mm glass plates with 1.5mm spacers. 
The gel was layered with 0.1% (w/v) SDS to exclude air, and left to set at room 
temperature for approximately 2 hours.
12.5% (w/v) Acrylamide/0.0625 % (w/v) N,N'-methylene Bisacrylamide 
gels were prepared from the stock solution as follows;
Solution Volume (ml)
A 1 2
D 20
E 4
F 0.160
G 0.015
To a final volume of 36ml with H2O
The solution was immediately mixed and poured into a Biorad protean II gel
casting apparatus, which consisted of 200 x 200 mm glass plates with 1.5mm
spacers. The gel was layered with 0.1% (w/v) SDS to exclude air, and left to set at 
room temperature for approximately 2 hours.
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b.S tacKLng o^ i,_pre pam iion,
Stacking gels were prepared from the stock solutions as follows;-
Solution Volume (ml)
B 3.75
C 1.5
F 0 .150
G 0.008
To a final volume of 15 ml with HgO.
The solution was mixed, layered on top of the resolving gel and allowed to 
polymerize around a 15 well teflon plate.
Electrophoresis was performed overnight at either 50V (Bio-rad system) or 
100V (Protean II system).
■c.Sample preparation. 
f lT Protein precipitation
Samples were prepared for gel electrophoresis by sodium deoxycholate/ 
trichloroacetic acid precipitation;- 6.25pl of 2% (w/v) sodium deoxycholate was 
added to each sample, followed by 750p.l of HgO, and then 250|il of 24% (w/v) 
trichloroacetic acid. Samples were centrifuged in a Hettich Mikro Rapid/K 
at12000 X g for 20 minutes, after which time the supernatants were removed and 
the pellets dissolved in 20^1 of 1M Tris base followed by 20jil of Laemmli buffer 
which consisted of 5M Urea, 0.17M SDS, 0.4M DTT, 50mM Tris-HCI pH 8.0, 
0.01% Bromophenol Blue.
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füTProte in  A lkyla tion
As a means of obtaining better resolution of the pertussis toxin sensitive G- 
proteins, samples to be run on 12.5% (w/v) Acrylamide 0.0625% (w/v) N,N'- 
methylenebisacrylamlde gels were firstly alkylated by treatment with N- 
ethylmaleimide (NEM) (Sternweis and Robishaw, 1984).
Samples were centrifuged in a Hettich Mikro Rapid/K at12000 x g, the 
supernatants discarded and the pellets resuspended in 20}i! of 10mM Tris- 
HCL,1mM EDTA pH 7.5. lO jil of 5% (w/v) SDS,50mM DTT was added to each 
sample, mixed, and placed in a boiling water bath for 15 minutes. Samples were 
then cooled to hand temperature and 10|il of lOOmM NEM added. After 15 minutes 
at room temperature 20)il of Laemmli buffer was added to each sample, leaving the 
samples ready for gel electrophoresis.
d.Gel protein staining.
After electrophoresis, the gel was placed in a tray on a stirring table and 
covered in stain solution which consisted of 0.1% (w/v) Coomassie blue in 50% 
(v/v) H2O, 40 % (v/v) Methanol, 10% (v/v) Glacial Acetic acid for 1 hour. The 
stain solution was discarded and the gel soaked in destain solution (identical to stain 
solution, but lacking coomassie blue) until excess stain had been removed to leave a 
clear background, and proteins were apparent on the gel as discrete bands.
e.Autoradi.ograp_hy,
Gels to be autoradiographed were firstly stained for protein with coomassie 
blue as described above, and dried down onto Whatman 3mm chromatography paper 
at 60°C for 1 hour under vacuum. The dried gel was placed next KODAK X-OMAT X- 
ray film in a cassette with intensification screens for up to 1 week at -80^C. Films 
were developed by hand using Kodak LX 24 developer and FX 40 fixer.
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f. Pensitom_etrv.
Analysis of incorporation of radioactivity into polypeptides of interest was 
performed by scanning the autoradiograms with a Bio-rad scanner driven by an 
Olivetti M24 personal computer. Absorption was measured in arbitrary units as 
detailed by Gawter and co-workers (Gawler et al., 1987).
2 .11.W este rn  b lo tt in g .
Proteins were separated under appropriate resoiving conditions on 
SDS/polyacrylamide gels overnight at 50V. The proteins were transferred to a 
nitrocellulose sheet (Schleicher and Schuell) for 2 hours at 1.5mA in a LKB 
transblot apparatus (Towbin et al., 1979). with blotting buffer which consisted of 
0.192M Glycine, 25mM Tris, 20% (v/v) methanol. The sheet was then "blocked" 
for 2 hours in 3% (w/v) gelatin in TBS, after which time, gelatin was washed off 
with distilled H2O, and the nitrocellulose sheet incubated overnight at 50°G with 
the appropriate dilution of antisera in 1% (w/v) gelatin in TBS. Next day, the 
antisera was removed and the sheet subjected to a series of washes in distilled H2O; 
TTBS, and TBS for 10 minutes each, after which, the blot was incubated with a 
second antibody (peroxidase conjugated goat anti-rabbit IgG) for 2 hours at room 
temperature. The second antibody was then removed, and the sheet subjected to the 
series of washes in distilled H2O, TTBS and TBS as before. The blot was then 
developed in 40mls of lOmM Tris pH 7.5 with 0.025% (w/v) 0-dianisidine as 
substrate.
Both first and second antibodies could be reused for up to four times, and 
were stored at 4^C using 0.004% (w/v) thimerosal as an anti-bacterial agent.
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2 . 1 2 . A D P - R i b o s v ! a t î o n .
Membranes to be ADP-ribosylated were diluted in 10mM Tris-HCL,0.1mM 
EDTA pH 7.5, to a protein concentration of between 1 to 3 mg/ml. 20pl aliquots 
were assayed in a final volume of 50p.l containing the following;-
250mM potassium phosphate buffer pH 7.0
3|iM 32p isiad (4 X 10® c.p.m.)
20mM Thymidine
1mM ATP pH 7.5
100|iM  GTP pH 7.5 ('When the presence of GTP was required)
20mM Arginine/HCL
The appropriate toxin was added at a final concentration of 10|ag/ml 
(pertussis toxin) or 50|ig/ml(cholera toxin). Both toxins were activated prior to 
use by preincubating with an equal volume of lOOmM DTT for 1 hour at room 
temperature.
The ribosylation assay was initiated by addition of membranes and 
transferral of tubes to a 37°C water bath. Assays proceeded for either 1 hour, or 
for 2 hours (in the absence of GTP) and were terminated by removal to Ice followed 
by sodium deoxycholate/ trichloroacetic acid precipitation as detailed (2.10c). 
Samples were then resolved under appropriate SDS/polyacrylamide gel 
electrophoresis.
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2.13.GTPase assays,
The assay is used to monitor the release of ®^Pi from "y[^^P]GTP and is 
essentialy performed as by Koski and Klee, (1981), which is a modification of the 
method described by Cassel. and Selinger, (1976). except the concentration of 5' 
adenyl imidodiphosphate (App(NH)P), was lowered to O.ImM.
The assay system contained 0.5|iM 7[32p ]G jp  (approx. 50,000 c.p.m.),
ImM App(NH)P, ImM ATP, ImM ouabain, 10mM creatine phosphate, 5 units 
creatinephosphokinase, lOOmM sodium chloride, 5mM magnesium chloride, 2mM 
dithiothreitol, 0.1 mM EDTA, 12.5 mM Tris. HCI and 3 to lOpg membrane protein 
In a final volume of lOOjil at pH 7.5.
Aliquots of the reaction mixture (50|il) were added to tubes on ice containing 
membrane protein and the appropriate drug. Low affinity hydrolysis of t (3 2 p ]g tp  
was assessed in the presence of 1 0 0 GTP,  blank values were determined by the 
replacement of membrane protein with buffer. Hydrolysis of 7[®^P]GTP at O^C 
was negligible.
The reaction was initiated by transferring the tubes to a 37^C water bath. 
After 20 minutes, the tubes were immersed in an Ice bath and 900(il aliquots of 
20mM phosphoric acid (pH 2.3) containing 5% (w/v) activated charcoal were 
then added. After centrifugation for 20 minutes at 12000 x g in a MSE 
microcentaur, radioactivity was measured In 500|il aliquots of the supernatant 
fluids, by Cerenkov counting in a rackbeta scintillation counter set to the tritium 
counting channel.
In some experiments, membrane protein was preincubated with synthetic 
peptides which were homologous to, or corresponded to the C-terminal 
decapeptides of Gi2a and Goa for 30 minutes at 37°C, in the presence of the GTPase 
assay reagents, with the exception of t[32p]GTP and receptor ligands. After this 
time, both 7[32p]GTP and suitable ligands were added, and the assay proceeded as 
normal. In other experiments, antibodies which had been purified on a column of 
either bovine transducin or protein-A sepharose and reconstituted to the required
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concentration were preincubated with membranes from NG108-15 cells at 37®C 
for 1 hour in the presence of the GTPase assay components excluding 
and receptor ligands. After this time, both T f^^p jQ jp  gnd suitable ligands were 
added, and the assay proceeded as normal.
2.14 .Binding assays.
Binding assays were performed by the rapid filtration method as described by 
Pert and Snyder, (1973), in lOmM Tris-HCL, 50mM sucrose, 20mM magnesium 
chloride pH7.5, containing 50-150^g of membrane protein and suitable 
radiolabeiled ligand in a final volume of 250|il. Non-specific binding was assessed 
in parallel tubes containing an excess of non-radiolabelled ligand. Blank values 
were determined by replacement of membrane protein with buffer.
The assay was initiated by transferral of tubes to a 30°C water bath for 25 
minutes, after which time the tubes were removed to ice and a 20Op I volume 
rapidly filtered through Whatman GF/C glassfibre filters which had been 
presoaked in assay buffer, followed with three 5ml washes of the filter with ice- 
coid buffer. Filters were soaked overnight in ecoscint scintillation fluid, prior to 
counting in a rackbeta scintillation counter. In some assays, membranes were pre­
incubated with an IgG fraction purified from either normal rabbit serum or an 
anti-G-protein antiserum (as detailed in section 2.9) for 60 minutes at 37°C 
prior to addition of radiolabeiled and non-radiolabelled ligand. After the incubation 
period the assay was continued as normal. In binding assays designed to determine 
the rate at which equilibrium binding was achieved, the assay volume was 
increased to lOOOpI, with protein and ligand concentrations altered accordingly. 
After transferr al to a 30°C water bath, aliquots (lOOpI) were removed and 
filtered at varying time intervals, filters were then treated as described.
In some instances, data were manipulated according to Scatchard. (1949)
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2J  5-Ad g.ny ia,tg -£ y gjjg ê  .assgj^ ,
a.Binding protein method
Assays were performed as described by Houslay et al., (1986a,b).
The assay system contained 1.5mM ATP, 5mM magnesium sulphate, 10mM 
theophylline, 1mM EDTA, 20mM creatine phosphate, 600U/ml creatine 
phosphokinase, 25mM triethanoiamine hydrochloride, 1mM dithiothreitol and 0.8 
mg/ml bovine serum albumin final pH 7.4. Membrane protein (10 to 30pg) and 
suitable drugs were added to a final volume of lOOpI.
The reaction was initiated by transferral of tubes to a SO'^C water bath for 15 
minutes and terminated by removing tubes to a boiling water bath for 
approximately 5 minutes. Precipitated protein was pelleted by centrifugation in a 
MSE microcentaur at 12000 x g for 10 minutes and the supernatant liquid 
removed for cAMP determination.
fiTcAMP determination
This was based on the saturation binding assay as described by Brown et ai., 
(1972), as modified by Tovey et al., (1974). All subsequent procedures were 
performed at 4*^C.
A series of unlabelled cAMP standards ranging from 0 to 320 pmoles/ml 
were prepared in assay buffer consisting of SOmM Tris-HCI, 4mM EDTA (pH 7.4 
at 4°C). lOOpi of ^H-cAMP (5,8-3H-adenosine 3': S'-cyclic monophosphate) 
diluted in assay buffer to give approximately 500,000 c.p.m./ml, was placed in an 
eppendorf with 50pl of either unkown sample or cAMP standard,lOOpI of a cAMP 
binding protein (prepared as described by Rubin et al., (1974), and a gift from 
Professor M.D. Houslay) diluted 1:70 in assay buffer, and assay buffer to a final 
volume of 300pl. Tubes were mixed and incubated at 4^0  for 2 to 3 hours. 10 
minutes prior to the end of incubation, a charcoal suspension of 2% (w/v) Norit-A 
Charcoal, 1%(w/v) BSA in ice-cold assay buffer was prepared and allowed to mix 
at 4°C.
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250pl of the charcoal suspension was added to each tube, the tubes were 
mixed and centrifuged at 12000 x g In a MSE microcentaur to pellet the charcoal. 
400pl of the supernatant was counted in ecoscint scintillation fluid in a Rackbeta 
scintillation counter with an RIA curve fitting program. The program constructed a 
standard curve and calculated the cAMP content of each sample. The sensitivity of 
the assay was routinely found to be lower than of the Salomon assay, with cAMP 
levels of and between 5 to 15 pmoles/ml/sample detectable.
b.Two step chromatography (Salomon) Method
This assay monitors the production of [®^P] cAMP from the substrate 
a[32p]ATP and was performed in a manner similar to that described by Salomon 
(1979), except that the amount of a[®^P]ATP was reduced to IpC i per sample
(h.Sample preparation.
Briefly, reaction mixtures of 50pl containing; 5mM creatine phosphate, 
lOOmM NaCt, 100U/ml creatinephosphokinase, 25mM Tris acetate pH7.0, 5mM 
Mg acetate, 0.5mM ATP pH 7.0, 0.05mM cAMP, ImM DTT, 0.1 mg/ml BSA, lOmM 
GTP pH 7.0, a [32p]ATP (1 x 10® c.p.m.), between 5 to 20|ig of membrane 
protein., together with the ligand(s) of interest. Reactions tubes were kept on ice 
at all times and the reaction started by removal to a 30°C water bath. After 15 
mins, the reaction was terminated by removal to ice and the addition of 100|il of 
stopper solution which was 2% (w/v) SDS, 45mM ATP, 1.3mM 3'5'cAMP. 50ml 
of [8-®H]3'5’cAMP (approx. 13,000 c.p.m) was added to each tube prior to 
boiling for 15 mins. 750)j.I of water was then added to each sample, and the ®^P 
cAMP content of each tube determined immediately.
61
fii).Preparation of dowex and alumina columns..
The method used to quantitate the amount of cAMP produced by each sample 
was identical to that of Salomon (1979) and involves the separation of cyclic AMP 
from other nucleotides by Dowex and then alumina chromatography. Dowex H+ 50 
X 4 (200-400) was washed in twice its packed volume with 1M Hydrochloric acid 
and then with the same volume of water four times. The Dowex was mixed with 
water to a slurry (1:1 v/v ratio) and then 3mls removed and added to glass wool 
stoppered columns. The water was allowed to drain out and the columns washed with 
2mls of 1M hydrochloric acid and stored at room temperature. Prior to use, the 
columns were washed with 1 ml of 1M hydrochloric acid followed by 20mls of 
water.
The alumina coiumnswere prepared by the addition of 0.6g of dry neutral 
alumina to glass wool stoppered columns and the columns washed with 12mls of 1M 
Imidazole buffer pH 7.3 followed by 15mls of 0.1 M imidazole buffer pH 7.3 and 
then stored at room temperature. On the day of use, each column was washed with 
8mls of 0.1 M Imidazole pH 7.3.
fill).Separation of cAMP on dowex columns
Prior to sample chromatography, the nucleotide elution profiles for each 
column were determined. This was performed by applying a mixture of [®H] cAMP 
and [32p)ATP to the column and determining the elution volume.
Freeze-dried cAMP was reconstituted in water to give approximately 10,000
c.p.m. in 50|il. [32p]ATP was diluted from stock of 1m Ci/ml to give 
approximately 2000 c.p.m. in 50jil. 50|il of each of the cAMP and ATP solutions 
were added to 900 pi of water and the mixture applied to a dowex column. The ATP 
and cAMP were eluted from the column by successive washes of the column with 
O.SmIs of water. Fractions were collected in a vial with 5mls of ecoscint and 
radioactivity determined by scintillation counting in a dual label programme.
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The elution volumes required to elute the cAMP from the Dowex columns were 
then determined from a graph as shown (Figure 2.1). Typical recovery from the 
Dowex columns was always greater than 90%.
The elution volume required to elute the cAMP from the alumina columns was 
determined as for the Dowex columns except only [3h ]cAMP was used, and the 
eluting buffer was 0.1 M Imidazole. Recoveries were similar to that obtained for 
the Dowex columns.
fivTDetermination of cAMP produced bv membrane fractions.
Samples (total volume 950pl) were added to prepared Dowex columns and the 
ATP eluted with 1.8mls of water. 3.5mls of water was then added to the Dowex 
columns and this eluate allowed to run directly onto the alumina columns. The 
cAMP fraction was eluted into vials containing 12mts*of ecoscint, with 6mls of 
0.1 M Imidazole pH7.3. The recovery of cAMP from the columns was routinely 
greater than 75%, when recovery fell below 60% the columns were discarded and 
fresh columns prepared. This gave a column life of approximately 6 months.
The cAMP fractions obtained were counted on a dual label scintillation 
counting programme which automatically corrected for 'spillover' from each 
channeI.The amount of cAMP produced by each sample was calculated by taking into 
account the recovery from each column, based on the recovery of the [^HJcAMP 
Internal standard. Data was thus calculable In pmoles of cAMP produced per minute 
per milligram of membrane protein, and the assay was sensitive to approximately 
5 pmoles/min/mg.
2 .1 6 .Data Analysis
Where appropriate, data were analysed for statistical significance using 
either Student's two-tailed t-test (paired) or by a one way analysis of variance.
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Fig. 2.1 The elution profiles of ATP and cAMP standards from 
dowex SOW fH±- forml and neutral alumina 
columns.
The elution profiles of [a^^pjATP and [^HJcAMP from dowex (SOW H+ 
form) columns (2.1a) and the elution of {^HJcAMP from neutral alumina columns 
(2.1b) was determined. Firstly, by the addition of a [^HjcAMP standard (15,000
c.p.m., 500|il)(closed circles) and a [a^^p jATP standard (18,000 c.p.m,, 
500|il)(open circles) to a dowex column (as detailed in section 2.15(iii)), followed 
by elution from the column by repeated addition of 1ml volumes of H2O (Figure 
2.1a). Secondly, a [^HjcAMP standard (14,000 c.p.m., 1000p.I)(2.1b) was added to 
a dowex column and eluted by the addition of 3.5mls of H2O, into an alumina column. 
The standard was eluted from the alumina column by repeated addition of 1 ml 
volumes of 0.1 M imidazole/HCI, pH7.3 (Figure 2.1b). The progress of both 
standards was monitored by counting 1 ml fractions of eluate in a scintillation 
counter as detailed in section 2,15(iv).
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Chapter 3
The NG108-15 cell line as a model system to 
study G-protein signal transduction mechanisms.
In t ro d u c t io n .
The neuroblastoma x glioma hybrid cell line, NG108-15, (also called 
108CC15) was generated by the fusion of the 6-thioguanine-resistant clonal mouse 
neuroblastoma cell tine N1BTG2 with the bromodeoxyuridine-resistant rat glioma 
cell line C6-BU1, followed by selection with hypoxanthine, aminopterin, thymidine 
(HAT) medium and cloning (Hamprecht et al., 1977, 1985). These cells display a 
considerable range of neuronal features and possess many of the functions of 
differentiated neurones, including the expression of excitable membranes, the 
formation of functional synapses and the presence of neurotransmitter enzymes. In 
addition, NG108-15 cells are able to synthesise neurotransmitters such as 
acetylcholine, leucine and methionine enkephalins, and are known to secrete both 
adenosine and catecholamines (Mochly-Rosen et al., 1988).
The NG108-15 cell line has been widely used as a model system to examine 
transmembrane signalling processes in the nervous system. These cells are 
particularly suitable for such studies as they express a considerable range of 
receptors which can be demonstrated to couple to a variety of effector 
systems including the stimulation and inhibition of adenylate cyclase (Klee et al., 
1985), activation of phosphoinositidase C (Higashida et al, 1986), regulation of 
voltage-sensitive Ca^+ channels (VOGC) (Tsunoo et al., 1986) and activation of a 
Ca^+ dependent K+ channel (Fukuda et al., 1988). Each of these effector systems is 
coupled to relevant receptors by members of the family of guanine nucleotide binding 
proteins (G-proteins), as detailed in chapter 1.
The best characterised receptors expressed by NG108-15 cells are coupled 
to the inhibition of adenylyl cyclase and include those for 6-opioids (Sharma et al., 
1975; Klee and Nirenberg, 1974; Chang et al., 1978; Chang and Cuatrecasas, 1979;. 
Law et al., 1985a,b) and a -2 adrenergic receptors (Sabo! and Nirenberg, 1979) 
which have been designated as the a-2B subtype (Bylund, 1988; Bylund et al.,
1988). In addition, bradykinin (Higashida et al., 1986; Osugi et al., 1987),
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adenosine A2 receptors (Kenlmer and Nirenberg, 1981), and muscarinic receptors 
(Nathanson et al., 1978) of the M4 designation (Fukada et al., 1988; Peralta et al., 
1988) are expressed by this cell line. NG108-15 cells do not express a wide 
variety of receptors linked to stimulation af adenylyl cyclase, however prostanoid 
receptors of the IP classification are expressed (Carroll and Shaw, 1989) as well as 
receptors for glucagon (Traber et al., 1975a), and secretin (Traber et al.,
1975a,b).
Prior to undertaking a study of the nature of receptor- G-protein coupling in 
NG108-15 cells, it was felt necessary to firstly characterise which members of the 
G-protein family are expressed by NG108-15 cells. This was accomplished by using 
both pertussis and cholera toxins, whose effects have been described in chapterl, as 
well as employing immunological methods, utilising the antisera which are described 
in table 2.1 in chapter 2. As detailed in chapter 1, the G-protein a-subunits and the 
three p-subunits which have been sequenced to date are highly homologous at the 
primary sequence level, and it was felt that the most worthwhile approach to adopt in 
attempting to produce specific antisera, was to employ synthetic peptides rather than 
purified protein, since proteins which are highly homologous at the primary 
sequence level are likely to have similar epitopes, which in turn would lead to a high 
degree of G-protein antisera cross reactivity (Milligan, 1989). The peptides 
utilised corresponded to either regions of variation between the G-protein a- 
subunits, or regions which have been proposed to represent sites of functional 
interaction between the G-protein and other polypeptides of the signal transduction 
pathway (Masters et al., 1987). In the case of the {3-subunits, a peptide 
corresponding to the extreme amino-terminal region of the protein was chosen since 
it was likely to produce antisera which demonstrate cross-reactivity with all 13- 
subunits. The N-terminal peptide had little homology to any known sequence in the 
G-protein a-subunits which have been cloned and sequenced to date, and as such was 
more likely to produce specific p-subunit antisera.
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Fia. 3.1 Pertussis toxm -cataivsed ADP-rlbosvtation  
of membranes of neuroblastoma x glioma 
hybrid NG108»15 cells.
NG108-15 membranes (20 jxg) from either untreated cells (lanes a,c) or 
cells which had been pretreated in vivo with pertussis toxin (lane b) as described 
in section 2.6d were ADP-ribosylated with thiol-preactivated pertussis toxin and 
{32p]|MAD+ as described in section 2.12. The sample was resolved on either SDS- 
PAGE (10% acrylamide, 0.25% bisacylamide, 18cm x 16cm resolving gel) (Figure
3.1 a, b), or SDS-PAGE (12.5 % acrylamide, 0.0625% bisacrylamide, 20 x 20 cm 
resolving gel) (Figure 3.1 c) as detailed in section 2.10a. The dried gel was 
autoradiographed for 24 hours with intensifying screens exactly as described in ■ 
section 2.1 Of.
None of the polypeptides identified incorporated radioactivity in the absence 
of activated pertussis toxin.
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Fig. 3.2 Cholera toxin-catalvsed ADP-ribosvlation of 
membranes of neuroblastoma x glioma hybrid 
N G 108-15  cells .
NG1Û8-15 membranes (20 jig) from either untreated cells (lanes a,c) or 
cells which had been pretreated in vivo with cholera toxin (lanes b,d) as described 
in section 2.6d, were ADP-ribosylated with thiol-preactivated toxin and
[32p]|\jAD+. The sample was resolved on either SDS-PAGE (10% acrylamide,
0,25% bisacylamide, 18cm x 16cm resolving gel) (Figure 3.2 a,b), or SDS-PAGE 
(12.5 % acrylamide, 0.0625% bisacrylamide, 20 x 20 cm resolving gel) (Figure 
3.2 c,d). The dried gel was autoradiographed for 24 hours with intensifying screens. 
All procedures were performed as detailed in the legend to Figure 3.1.
None of the polypeptides Identified incorporated radioactivity in the absence 
of activated cholera toxin.
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Fiq,__3.3 Expression of multiple pertussis toxin-sensitive
G-proteins In neuroblastoma x alioma hybrid cells. 
immunological demonstration of their molecular 
Id e n t i ty .
Membranes of NG108-15 cells and of rat glioma C6 BU1 cells, rat cerebral 
cortex and rat white adipocytes were resolved on SDS-PAGE as detailed in the legend 
to Figure 3.1 and transferred to nitrocellulose. The choice of tissue to compare to 
NG108-15 membranes was based on previous identification of particular G- 
proteins in those tissues {Goldsmith et al., 1987; Mitchell et ai., 1989). 
Immunoblotting was performed as detailed in section 2.11) with 1: 200 dilutions of 
(A) antiserum 0C1 (1; 100 ug NG108-15 membranes, 2; 10 pg rat cerebral 
cortex), (B) antiserum CS1 (1; 100 pg NG108-15 membranes, 2; 50 pg rat white 
adipocyte membranes), (C) antiserum I3B (1; 100 pg NG108-15 membranes, 2 ; 
50 pg rat white adipocytes, 3; 100 pg rat glioma C6 BU1 cell membranes) (D) 
antiserum AS7 (1; 100 pg NG108-15 membranes, 2; 50 pg rat'cerebral cortex, 3; 
50 pg rat glioma C6 BU1 membranes).
Detection of the primary antiserum was achieved using an IgG fraction from 
a donkey anti-rabbit antiserum which was coupled to horseradish peroxidase as 
detailed in section 2.11. The substrate for the enzyme was o-dianisidine.
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Figure 3.3
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Fia. 3.4 Immunological detection of Gi2 but not Gi1 in
NG108-15 cell membranes.
Membranes of NG108-15 cells (100pg, panels A.B.G , lane 1) and rat cortex 
{75pg, panels A.B.C, lane 2) were resolved on SDS-PAGE as described in the legend 
to Figure 3.1 and transferred to nitrocellulose. Immunoblotting was performed with 
a 1: 200 dilution of either antiserum LE2 (panel A), SGI (panel B) or antiserum 
l ie  (panel C) as detailed in section 2.11. The primary antiserum was detected as 
described in the legend to Figure 3.3.
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Immunological detection of the G-protein [3-subunit
in NG108-15 cell membranes.
Membranes of NG108-15 cells (100pg, lane a ) and rat glioma C6BU1 cells 
(75pg, lane b) were resolved on SDS-PAGE as detailed in the legend to Figure 3.1 
and transferred to nitrocellulose. Immunoblotting was performed as described in 
section 2.11, with a 1: 200 dilution of antiserum BN1. The primary antiserum was 
detected as described in the legend to Figure 3.3.
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Fig. 3.6 fmmunoblottina of NG108-15 membranes with
affinity purified antibodies from antiserum AS7.
Membranes of NG108-15 cells (50|ig, lane a) or rat cortex (60^g, lane b) 
were separated on a SDS 10% polyacrylamide gel at 50V'overnight as described in 
section 2.10. The resolved proteins were transferred to nitrocellulose and blocked 
and immunoblotted with a 1:100 dilution of antibodies affinity purified from 
antiserum AS7 as detailed in section 2.9. The primary antiserum was detected as 
described in the legend to Figure 3.3.
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Fig. 3.7. loG purified from antiserum AS7 displays the same 
specificity for G-protelns as the crude antiserum.
Membranes from NG108-15 cells and of rat glioma C6BU1, rat cerebral 
cortex and rat wfiite adipocytes were resolved on 20cm x 20cm SDS-PAGE gels as 
described in the legend to Figure 3.1. Immunoblotting was performed as described in 
the legend to Figure 3.3 .except an IgG fraction purified by passage over protein-A 
sepharose was used as the primary reagent (section 2.9). Immunoblotting was 
performed with 1: 200 dilution of an IgG fraction from AS7 (1; 100 pg NG108-15 
membranes, 2 ; 50 pg rat cerebral cortex, 3; 50 pg rat glioma C6 BUI membranes).
The primary antiserum was detected as described in the legend to Figure 3.3.
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Fia. 3.8 Iden tifica tion  of the pertussis tox in  substra tes
expressed in NG108-15 cell membranes as Gi2. Gi3 
and-Go.,
NG108-15 membranes (20 pg) from untreated cells were ADP-ribosylated 
with thiol-preactivated pertussis toxin and [32p]NAD+ as detailed in section 2.12. 
The sample was resolved by SDS-PAGE (12.5 % acrylamide, 0.0625% 
bisacrylamide, 20 x 20 cm resolving gel) as detailed in the legend to Figure 3.1. The 
gel obtained was then western blotted and probed with a combination of a 1:200 
dilution of antiserum, I3B, a 1: 1000 dilution of antiserum 0C1 and a 1: 3000 
dilution of antiserum AS7. The primary antiserum was detected as described in the 
legend to Figure 3.3 (Figure 3.8, a). After development, the dried nitrocellulose was 
autoradiographed for 24 hours with intensifying screens as detailed in section 2.1 Of 
(Figure 3.8, b). None of the polypeptides shown were labelled in the absence of 
activated pertussis toxin.
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Fia. 3.9 identification of the cholera toxin substrates
expressed in NG108-I5_.ceil membranes as two_  
distirrct forms of Gs
NG108-15 membranes {20 pg) from untreated cells were ADP-ribosylated 
with thiol-preactivated cholera toxin and [^^PjNAD"'’ . The sample was resolved by 
SDS-PAGE (12.5 % acrylamide, 0.0625% bisacrylamide, 20 x 20 cm resolving 
gel) as detailed in the legend to Figure 3.1. The gel obtained was then western blotted 
and probed with a 1:200 dilution of antiserum GS1. The primary antiserum was 
detected as described in the legend to Figure 3.3 (Figure 3.9, b). After development, 
the dried nitrocellulose was autoradiographed for 24 hours with intensifying screens 
(section 2.1 Of) (Figure 3.9, a). None of the polypeptides shown were labelled in the 
absence of activated cholera toxin.
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The treatment of membranes of NG108-15 cells with activated pertussis 
toxin and [^^P]NAD+ led to the Incorporation of radioactivity into an apparently 
single, broad band of 40kDa, presumably representing "Gi" (Figure 3.1 a). Several 
other polypeptides incorporated radioactivity, however in no case was the 
Incorporation as great as that demonstrated in the 40kDa region. When membranes 
produced from cells which had been pretreated in vivo with pertussis toxin (as 
described in section 2.6d) were challenged with fresh pertussis toxin and 
[32p]|\iAD+, no incorporation of radioactivity into the 40kDa band was 
obtained.(Figure 3.1 b). This demonstrated that the entire complement of pertussis 
toxin sensitive G-proteins had been ADP-ribosylated by in vivo treatment with 
pertussis toxin. If the SDS-PAGE resolving conditions were altered to obtain better 
resolution of proteins with a molecular mass of between 35 to 45kDa, then the single 
broad band of radioactivity seen at approximately 40 kDa in Figure 3.1a, could be 
resolved into three separate polypeptides with molecular masses of 41, 40 and 
39kDa (Figure 3.1 c), the labelling of which was dependent on the presence pf 
pertussis toxin {marshov^A). This demonstrated that NG108-15 cells express at 
least three different pertussis toxin sensitive G-proteins.
When membranes produced from NG108-15 cells were treated with thiol- 
activated cholera toxin in the presence of [^^P]NAD+, incorporation of radioactivity 
into two polypeptides with molecular masses of 45 and 42kDa was routinely 
obtained. These presumably represent two of the four possible variants of Gsa 
(Figure 3.2a). Several other polypeptides also demonstrated incorporation of 
radioactivity, however it was difficult to routinely demonstrate radiolabelling of the 
same polypeptides from different NG108-15 membrane preparations in a toxin- 
dependent manner. In membranes produced from NG108-15 cells which had been 
pretreated in vivo with cholera toxin, re-exposure to cholera toxin along with 
[32p]NAD'*' did not result in the incorporation of radioactivity Into the two 
polypeptides (Figure 3.2b), demonstrating that pre-treatment of NG108-15 cells 
in vivo with cholera toxin ADP-ribosylated the entire pool of the stimulatory G-
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protein, Gs. When the SDS-PAGE resolving conditions were altered to increase the 
resolution of proteins with molecular masses of approximately 35 to 45kDa (Figure 
3.2c), a result essentially identical to that shown in Figure 3.2a was obtained, 
where only two bands of approximately 45 and 42 kDa incorporated radioactivity in 
a toxin dependent manner.
In an attempt to identify the pertussis toxin sensitive G-proteins which were 
expressed by NG108-15 cells, a series of immunobiots were performed using the 
antisera described in chapter 2, (Table 2.1). Antiserum 0C1 specifically identifies 
the a-subunit of Go, and identified a single polypeptide of 39kDA in NG1G8-15 
membranes which co-migrated with an equivalent polypeptide in rat brain (Figure 
3.3a), a tissue known to express high levels of this polypeptide (Milligan and Klee, 
1985). Antiserum AS7 interacts equally with the a-subunits of G il and Gi2 as these 
G-proteins have identical G-terminat decapeptides (Goldsmith et al., 1987). This 
antiserum identified two polypeptides of 41 and 40kDa in'both rat brain and 
adipocytes, but identified only a single polypeptide in NG108-15 membranes 
(Figure 3.3d). This polypeptide co-migrated with the polypeptide of greater 
mobility in adipocytes and brain, which has previously been shown to be GI2 
(Mitchell et al., 1989). A Gi2 specific antiserum (LE2) also identified the 40kDa 
polypeptide in NG108-15 cell membranes (Figure 3.4, panel A, lanel) and in 
adipocytes (results not shown) but did not identify the 41 kDa polypeptide of brain 
(Figure 3.4, panel A, tane2). It has been demonstrated previously that the 41 kDa 
polypeptide of brain and adipocytes corresponds immunologically to Gil.(Mitchell et 
al., 1989). The G il specific antiserum 11G was able to specifically recognise this 
polypeptide in membranes derived from brain, but not from NG108-15 cells 
(Figure 3.4, panel B, lanes 1, 2). Antiserum I3B identifies Gi3a; this antiserum 
identified a single polypeptide of 41 kDa In NG108-15 membranes which co­
migrated with a polypeptide in rat glioma G6BU1 cells and in rat adipocytes (Figure 
3.2c), which has been demonstrated to be Gi3a (Mitchell et al., 1989). This 
immunological data confirmed that the antisera described are indeed selective and can 
be used as specific probes to monitor the expression of the various G-proteins. In 
addition, it may also be noted that NG108-15 cell express immunologically 
detectable levels of Gi2, G13, Go and Gs, but do not express G il.
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A similar range of western blots to those described in Figure 3.3 were 
carried out using IgG fractions derived from primary antisera by chromatography on 
a column of protein-A sepharose as described in section 2.9. This purification was 
carried out for two reasons. Firstly, due to a desire to employ these antisera in 
functional assays {see chapters 5 and 6) and thus obtain a purer starting material, 
and secondly to remove the antibodies from the serum they were in, since serum is a 
potent activator of certain G-proteins (see chapter 5). The specificity of each 
purified IgG fraction, as compared to the primary antiserum had to be determined 
prior to use. Figure 3.7 demonstrates that IgG fractions purified from antiserum 
AS7, showed the same specificity for G-proteins as the crude antiserum. IgG 
fractions purified from antisera CSI, I3B, 0C1 and BN1 also demonstrated the same 
G-protein specificity (results not shown). In some instances, functional assays were 
performed using a fraction affinity purified from antiserum AS7 (see later). When 
immunobiots were performed using a fraction from antiserum AS7 which had been 
affinity purified on a column of bovine transducin, a polypeptide corresponding to 
Gi2 was identified, demonstrating that the affinity purified fraction retained the 
same specificity as the primary antiserum (Figure 3.6).
In order to rigorously identify the three pertussis toxin sensitive G-proteins 
identified in Figure 3.1 as Gi2, G13 and Go, NG108-15 cell membranes were ADP- 
ribosylated with pertussis toxin and resolved by SDS-PAGE. The resultant gel was 
then immunoblotted with a combination of antisera AS7, I3B and 0C1. Figure 3.8 
demonstrated that the most slowly migrating pertussis toxin sensitive G-protein in 
NG108-15 cell membranes was solely recognised by antiserum I3B, the antiserum 
which specifically identifies Gi3. The G-protein which migrated the greatest distance 
under these conditions is recognised by the antl-Go antiserum 0C1, and the G- 
protein which migrated between these two polypeptides was exclusively recognised 
by the Gi2 specific antiserum AS7.
When similar ADP-ribosylation/immunoblotting experiments were carried 
out on NG1G8-15 cell membranes which had been ADP-ribosylated with cholera 
toxin and then immunoblotted with antiserum CSI, which exclusively recognises
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Gsa, we see that two forms of Gsa are expressed in this cell line, and that the cholera 
toxin substrates co-migrate with the polypeptides which are specifically identified 
by antiserum CS1.
79
Discussion.
As cDNA cloning experiments have demonstrated the potential expression 
(outwith photoreceptor containing tissues) of four distinct G-proteins which are 
substrates for pertussis toxin, namely Gi1, Gi2, Gi3 and Go (Jones and Reed, 1987; 
Itoh et al., 1988) along with the cholera toxin substrate, Gs and the toxin insensitive 
Gz (x), it is apparent that a given cell type may express a considerable repertoire of 
highly homologous G-proteins.
Few studies have attempted a rigorous definition of the members of the G- 
protein family which may be expressed by a given cell line or tissue. This is 
primarily due to difficulty in selectively identifying each member of the G-protein 
family. However, the generation of a series of antipeptide antisera which are able to 
discriminate between each of the currently identified G-proteins, along with the 
development of electrophoresis conditions able to resolve the Individual a-subun its , 
has allowed several groups to examine a variety of cell lines which are commonly 
used as a model of signal transduction (Mitchell et al., 1989; Scherer et al., 1987; 
McKenzie and Milligan, 1990).
The major pertussis toxin sensitive G-proteins expressed by neutrophils and 
other haemopoietically derived cells have thus been identified as Gi2 and Gi3 
(Murphy et a!., 1987). Antipeptide antisera have failed to detect either Gil or Go in 
such cells, a conclusion supported by the detection of mRNA*s corresponding to Gi2 
and Gi3, but not G il or Go (Murphy et al., 1987). In a similar manner, the G- 
proteins which are expressed by human platelets have been identified by antipeptide 
antisera as being Gs, Gi2 , Gi3 and Gx(z). Gi1 and Go cannot be detected (Simonds et 
al., 1989a).
It can therefore be appreciated that the distribution of the Individual G-protein a- 
subunits is not universal, with the exception of Gs, Gi2 and G13 (Milligan, 1989).
The NG108-15 cell line has been widely used as a model system to study 
signal transduction since it expresses a variety of receptors which are able to 
modulate the level of activity of various intracellular effectors through G-protein
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activation {Hamprecht et al., 1985). The most widely studied signal transduction 
system in NG108-15 cells is adenylyl cyclase, which may be both stimulated or 
Inhibited by a variety of transmembrane receptors {Klee et al., 1985). Receptor 
mediated inhibition of adenylyl cyclase is always attenuated by prior treatment with 
pertussis toxin, defining a role for a pertussis toxin sensitive G-protein(s) in 
mediating the response (Glapham and Neer, 1987).
In order to rigorously assess which of the pertussis toxin sensitive G- 
proteins is coupled to the inhibition of adenylyl cyclase in NG108-15 cells, the 
complement of G-proteins which are expressed by this cell line were firstly defined. 
This was accomplished by the generation of anti-peptide antisera against synthetic 
peptides which correspond to the C-termina! decapeptides of the pertussis toxin 
sensitive G-proteins, and the stimulatory G-protein, Gs. Using these antisera it has 
been possible to demonstrate the expression of three pertussis toxin sensitive G- 
proteins, G12, Gi3 and Go in the NG108-15 cell line, as well as two forms of Gs. 
High-titre antisera which have been demonstrated to recognise the a-subunit of G i1 
(Figure 3.4, panel c, lane 2), fail to detect G il in NG108-15 cell membranes 
(Figure 3.4, panel c, lane 1).
The characterisation of human cDNA's corresponding to four different forms 
of Gsa has been reported, suggesting that in a given tissue, two larger and two 
smaller forms of Gsa may be present (Bray et al., 1986). The exact complement of 
Gsa expressed by NQ108-15 cells has not yet been fully defined, although one 
dimensional gel electrophoresis suggests that two forms are expressed, with 
molecular masses of 45 and 42kDa. It may be noted that based upon both 
immunoblotting and ADP-ribosylation, the 45kDa form is more prevalent than the 
42kDa form.
In addition to the immunological techniques described, a recent report has 
examined Northern blots of total RNA isolated from NG108-15 cells, using synthetic 
oligonucleotide probes derived from the coding sequence for amino-acids 125-135 
of the a-subunits of each of G il, Gi2 and Gi3. These probes confirmed the presence of
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mRNA coding for Gi2 and GI3 in NG108-15 ceils, however mRNA corresponding to 
Gi1 could not be detected (McKenzie and Milligan, 1990). These observations are 
therefore in agreement with the immunological data presented in this chapter.
The data presented herein demonstrate that NG10B-15 cells express 
detectable levels of Gi2, Gi3 and Go, as well as two forms of the stimulatory G- 
protein Gs. Gi1 is either not expressed by these cells, or the levels of both peptide 
and relevant mRNA are below current methods of detection. In addition it may be 
noted that it is possible to generate antisera which can specifically recognise 
members of the G-protein family. It is of interest to note that IgG fractions produced 
as detailed in section 2.9 demonstrate the same specificity as the primary anti-G- 
protein antisera and as such may be employed as specific tools to study G-protein 
function (chapters 5 and 6).
The aim of this thesis is to examine the interaction of G-proteins with 
effectors, with a view to determining whether G-proteins are specific signal 
transducers or whether they are more promlscous and can interact with a wide 
variety of intracellular effectors. In the NG108-15 cell line, a variety of receptors 
are coupled to the inhibition of adenylyl cyclase in a pertussis toxin sensitive 
manner, this means that the G-protein which mediates the inhibition of adenylyl 
cyclase in NG108-15 cells must be one of Gi2, Gi3 or Go, or a combination therof. 
The data presented in the following chapters will attempt to define which of these G- 
proteins is the true 'Gi" of the adenylyl cyclase system and thus ascertain whether 
individual G-proteins can be defined as having a specific role in transmembrane 
signalling.
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Chapter 4
Cholera tox in  catalysed AD P-ribosvia tion  of Gi,
In t ro d u c t io n
The original identification of Gs and Gi, the G-proteins which stimulate and 
inhibit adenylyl cyclase respectively, was aided by the isolation of both cholera toxin 
from cultures of Vibrio cholerae and pertussis toxin, from cultures of Bordetella 
pertussis.
Pertussis toxin catalyses the mono-ADP-ribosylation of Gia at a cysteine 
residue four amino acids removed from the C-terminus. This covalent modification 
attenuates receptor mediated inhibition of adenylyl cyclase (Katada and Ui, 1982; 
Hsia et al., 1984). With the exception of the protein product of the ras 
protooncogene, all G-protein a subunits with a cysteine in this position have been 
demonstrated to be pertussis toxin substrates, Gsa does not have a cysteine residue in
this position and is not a substrate for pertussis toxin. In contrast, cholera toxin
catalyses the mono-ADP-ribosylation of Gsa at an arginine residue, which is either 
at position 187 or 188 (short forms of Gs), or position 201 or 202 (long forms of 
Gs), This results in the permanent activation of Gsa (Casset and Pfeuffer, 1978; 
Northup et al., 1980). It is generally held that cholera toxin does not affect Gia, 
however the arginine residue modified by cholera toxin in Gsa, is conserved in an 
apparently equivalent position in all G-protein a subunits which have been isolated 
to date by cDNA cloning, and indeed under the appropriate-conditions, Tda may be 
ADP-ribosylated by both pertussis and cholera toxins. It would therefore appear that
cholera toxin's lack of ability to ADP-ribosylate Gia Is not a consequence of Gia
lacking a suitable acceptor site, but is due to either constraints imposed by the three 
dimensional structure of Gia, or by the use of assay conditions which are not 
conducive to the mono-ADP-ribosylation of Gia by cholera toxin.
The data presented in this chapter will attempt to analyse whether cholera 
toxin may catalyse the ADP-ribosylation of Gi in membranes derived from NGIOB­
IS cells under appropriate conditions and thus determine possible constraints which 
prevent cholera toxin from ADP-ribosylating a homologous region of Gi to that of Gs 
which is subject to cholera toxin catalysed ADP-ribosylation.
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ADP-rîbosvIatfon of NG108-15 membranes bv__ 
cholera or pertussis toxin in the presence q1_ 
guanine nucleotides.
Membranes (30pg) of NG108-15 cells were treated with [32p]NAD+ and 
activated cholera toxin {lane a), activated pertussis toxin (lane b) or vehicle (lane c) 
in the presence of tOOjiM GTP for 2 hours at 370C, as detailed in section 2.12. The 
incubation was terminated by removai to ice, followed by protein precipitation with 
sodium deoxycholate/TCA (section 2.10c). The membranes were then resolved on a 
10% polyacrylamide / SDS gel as detailed in section 2.10. An autoradiogram (section
2.1 Oe) of a dried gel which is similar to at least ten others obtained.is displayed.
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Figure 4.1
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Fia. 4.2 ADP-rlbosv!ation of membranes of untreated
NG108-15 cells by cholera or pertussis toxin in 
the absence of guanine nucleotides.
Membranes (SOpg) of NG108-15’cells were treated with [32p]NAD+ and 
activated cholera toxin (a), activated pertussis toxin (b) or without toxin (c) in the 
absence of exogenously added guanine nucleotide for 2 hours at 37^C as detailed In 
section 2 .12. The incubation was terminated by removal to ice, followed by protein 
precipitation with sodium deoxycholate/TCA (see section 2.10c) Samples were then 
resolved on a10% polyacrylamide/SDS gel. An autoradiogram of the dried gel, which 
is typical of three others obtained, is displayed. The only bands labelled in a toxin 
dependent manner were of apparent molecular mass 45, 42 and 40kDa.
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Fig. 4.3 ADP-ribosylation of NG108-15 cell membranes by 
cholera and pertussis toxin In the absence of 
exogenously added guanine nucleotides.
Membranes were prepared from NG108-15 cells which had been pretreated 
with either pertussis toxin, cholera toxin, or without toxin, as described in section 
2 .6d.
These membranes (40pg) were then treated with [32p]nad+  and activated 
cholera or pertussis toxin, and resolved on a 10% polyacrylamide/SDS gel and 
autoradiographed as described in the legend to Figure 4.1.
Lanes (a) and (d) contain membranes prepared from untreated cells, lane 
(b), membranes prepared from cells pretreated in vivo with cholera toxin (section 
2,6d) and lanes (c) and (e), membranes from cells pretreated in vivo with 
pertussis toxin (section 2.6d). Lanes (a), (b) and (c) show the labelling of 
membranes with cholera toxin, lanes (d) and (e) show labelling of membranes with 
pertussis toxin. The autoradiograph shown is representative of three others which 
gave essentially identical results.
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Fig. 4.4 Pharmacology of the opiotd-peptide stimulation of 
cholera toxin catalysed ADP-rlbQ_sylatiojL of a _’G i-  
like'* protein in membranes of untreated NG108-15  
c e lls .
4.4 (a) Membranes of untreated NG108-15 cells (30pg) were treated with 
either pertussis toxin {lane a) or cholera toxin (lanes b to f) in the absence of 
guanine nucleotides for 2 hours at 37°C as described in section 2.12.
Lanes (a) and (f) contained no ligand, lane (b) contained naloxone (ImM), 
lane (c) naloxone (1mM) plus DADLE (O.IpM), lane (d) contained DADLE (O .IpM ), 
and lane (e) DADLE (lOpM). The samples were resolved on a 10% 
polyacrylamide/SDS gel and autoradiographed as described in the legend to Figure 4.1; 
D.F., Dye Front. 4.4 (b) Incorporation of radioactivity was assessed densitometrically 
as described in section 2.1 Of, Taking the incorporation of radioactivity catalysed by 
pertussis toxin under these conditions (lane a) as 100%, and incorporation of 
radioactivity by cholera toxin into this band in the absence of ligand (lane f) as a 
blank, then lane (b) = 4%, lane (c) = 7%, lane (d) = 41% and lane (e) = 66%. 
Similar data was obtained in three separate experiments.
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Fia. 4.5 Pharm acology of the op io id -peptlde  s tim u la tion  of 
cholera tox in  cata lysed _ A P P -ribosy la tion  o f a *GI- 
like" prote in in membranes of cholera tox in  
p r^ tre a te d  NG108-15 ce lls .
4.5 (a) Membranes of cholera toxin pretreated NG108-15 cells (30pg) 
were treated with either pertussis toxin (lane a} or cholera toxin (lanes b-f) In the 
absence of guanine nucleotides for 2 hours at 37®C as described in section 2.12.
Lanes (a) and (f) contained no ligand, lane (b) contained naloxone (ImM), 
lane (c) naloxone (1mM) plus DADLE (O.IpM), land (d) contained DADLE (O.IpiM), 
and lane (e) DADLE (lOiiM). The samples were collected and autoradiographed as ■ 
detailed in the legend 1o Figure 4.1; D.F., Dye Front. 4.5 (b) Incorporation of 
radioactivity was assessed densitometrically as described in section 2.1 Of. Taking the 
incorporation of radioactivity catalysed by pertussis toxin under these conditions 
(lane a) as 100%, and incorporation of radioactivity by cholera toxin Into this band 
in the absence of ligand (lane f) as a blank, then lane (b) = 3%, lane (c) = 8%, lane 
(d) =; 51% and lane (e) = 69%. Similar data was obtained in three separate 
experiments.
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Fig 4.6 Dose/response curve of DADLE stimulation of the
cholera toxin cataivsed ADP-ribosviation of a Gi-llke
rLLO,tMn_ in membranes of untreated NG108-15 ceils.
4.6(a) Cholera toxin catalysed ADP-ribosylation of membranes of untreated 
NG108-15 cells (25p.g) was carried out in the absence of guanine nucleotides as 
described in section 2.12. DADLE was Included at a final concentration of; 0.01 nM (lane 
b), 0.1 nM (lane c), 1 nM (Lane d), 10nM (Lane e), 0.1|iM (Lane f), IpM  (Lane g) and 
10)iM (Lane h). Densitometric analysis of the 40kDa band was performed as in section '
2.1 Of and incorporation of radioactivity into this polypeptide in the absence of ligand 
(Lane a) was subtracted as a blank. In three separate experiments, a representative 
example of which is shown, the estimated EC50 for DADLE was 16±10nM. (mean ± S.D.y
4.6 (b).
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Fig 4.7 Dose/response curve of DADLE stim u la tion  of the
cholera to xin ca ta ivsed AD P -ribosy la tion  of a G i-llke „ 
pro te in  in membranes of cholera tox in  pretreated 
NG108-15 c e lls .
4.7 (a) Cholera toxin catalysed ADP-ribosylation of membranes of cholera toxin 
pretreated NG108-15 cells (30[ig) {section 2.6d) was carried out in the absence of 
guanine nucleotides as described in section 2.12. DADLE was included at a final 
concentration of; 0.01 nM (lane b), 0.1 nM (lane c), InM  (Lane d), lOnM (Lane e), 
O.IpM (Lane f), I j iM  (Lane g) and lOpM (Lane h). Densitometric analysis of the 40kDa 
band was performed as described in section 2.1 Of and incorporation of radioactivity into 
this polypeptide in the absence of ligand (Lane I) was subtracted as a blank (Lane a 
contained no toxin). In three separate experiments, a representative example of which is 
shown, the estimated ECgg for DADLE was 18 ± 9nM (mean ± S.D.) 4.7 (b).
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Resul ts
When NG108-15 cell membranes were ADP-ribosylated, In the presence of 
added guanine nucleotide (GTP), cholera toxin catalysed the incorporation of 
radioactivity from [^^P] NAD^ predominantly into a 45kDa polypeptide. (Figure 
4.1, lane a), This band co-migrated with the a-subunit of Gs, as determined by 
immunological means (chapter 3, Figure 3.7). In addition, a 42kDa polypeptide was 
also seen to be labelled, and could be identified immunologically as being a smaller 
form of Gsa. However, due to the low abundance of this 42kDa protein in comparison 
to the 45kDa form of Gsa, it was difficult to routinely observe the 42kDa form of 
Gsa in NG108-15 membrane preparations. In addition to cholera toxins' effect, 
under these conditions, pertussis toxin was able to catalyse the incorporation of 
radioactivity from [32p] NAD+ into a 40kDa polypeptide, (Figure 4.1, lane b), It 
can be noted that cholera toxin was unable to catalyse the incorporation of 
radioactivity into this polypeptide, and similarly, pertussis toxin was unable to 
catalyse the incorporation of radioactivity into either the 45 or 42kDA poiypeptides 
which were modified by choiera toxih. It is therefore apparent that in the presence of 
GTP, both cholera and pertussis toxins are apparently specific in their ability to 
ADP-ribosylate Gs and Gi respectively
When a similar experiment was performed in membranes from NG108-15 
cells In the absence of any exogenously added guanine nucleotides, a different picture 
emerged. Cholera toxin catalysed the incorporation of radioactivity from [32p] 
NAD+ into two polypeptides with apparent molecular weights of 45 and 42kDa and in 
addition a 40kDa poypeptide was modified in a cholera-toxin dependent manner 
(Figure 4.2, lane a). Radioactivity was incorporated into certain other polypeptides, 
but in no other case was this dependent on the presence of toxin in the assay. The 
40kDa band modified by cholera toxin co-migrated with the only apparent 
polypeptide to be specifically ADP-ribosylated by pertussis toxin in these 
membranes (Figure. 4.2, lane b).
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After pretreatment of NG108-15 cells in vivo with pertussis toxin, cholera 
toxin in the absence of GTP was able to catalyse ADP-ribosylation of both the 45 and 
42kDa polypeptides, but could no longer modify the 40kDa species in membranes 
prepared from these cells (Figure. 4.3, lane c). Pertussis toxin equally, was unable 
to catalyse incorporation of radioactivity into the 40kDa band in vitro following 
treatment of the cells in vivo with pertussis toxin, (Figure 4.3 lane e). In contrast, 
however, after treatment of the cells in vivo with cholera toxin, fresh cholera toxin 
in the absence of GTP was able to Incorporate radioactivity from [3^P]NAD+ into the 
40kDa polypeptide but not the 45 and 42kDa proteins in membranes prepared from 
these cells (Figure 4.3 , lane b). Pertussis toxin also catalysed ADP-ribosylation of 
a 40kDa protein under these conditions (Figure 4.3, lane d). This data suggests that 
the polypeptide modified by both cholera and pertussis toxin in the absence of GTP 
was identical.
Addition of the synthetic opioid peptide DADLE, enhanced the cholera-toxin- 
catalysed ADP-ribosylation of the 40kDa polypeptide, but did not substantially affect 
the incorporation of radioactivity into either the 45 or 42 kOa bands when the 
reaction was performed on membranes of untreated control NG108-15 cells in the 
absence of exogenously added GTP (Figure.4.4 , lane e). Over the time course 
employed in these experiments 0.1 pM DADLE promoted less incorporation of 
radioactivity into the 40 kDa band than did lOpM DADLE (Figure. 4.4, lanes,d,e). 
This effect was not mimicked by the opioid antagonist naloxone, and the antagonist 
blocked the DADLE-mediated effect (Figure. 4.4, compare lanes c and d). Essentially 
the same results were obtained in membranes of NG108-15 cells produced from 
cells which had been pretreated in vivo with cholera toxin, except that the 45 and 
42kDa polypeptides no longer supported cholera toxin catalysed incorporation of 
radioactivity (Figure. 4.5). Dose-response curves of the enhancement of cholera- 
toxin-catalysed ADP-ribosylation of the 40 kDa polypeptide showed that no effect of 
DADLE could be observed at concentrations below 1 nM and that a maximal increase in 
the cholera-toxin-catalysed ADP-ribosylation of the 40kDa polypeptide was 
achieved by 1pM. The EC 50 for DADLE was estimated to be some 16 ±10 nM (mean 
± S.D.) (Figure 4.6 b), a value in close agreement with the EG 50 estimated for
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DADLE-mediated stimulation of high-affinity GTPase activity in these membranes as 
detailed in chapter 5. Similar results in terms of both the pharmacological profile of 
the response and the dose-response curves to DADLE (Figure 4.6 a,b) were obtained 
when membranes of cholera-toxin-pretreated NG 108-15 cells were used as the 
acceptor system for the cholera toxin catalysed ADP-ribosylation in vitro in the 
absence of GTP (Figure 4.7 a,b). The cholera-toxin-pretreated system had, 
however, the distinct advantage that essentially no radioactivity was incorporated 
into the 45 and 42 kDa bands. Thus the 40 kDa band was the sole polypeptide to be 
ADP-ribosylated in a cholera-toxin-sensitive manner in membranes from the 
cholera-toxin-pretreated cells.
In contrast to the effect of DADLE on cholera toxin labelling of the 40kDa 
polypeptide, DADLE had no effect on pertussis toxin catalysed ADP-ribosylation of 
the 40kDa polypeptide (results not shown).
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Discussion
In classical terms, it has been assumed that pertussis toxin catalysed ADP- 
ribosylation provides a specific means of identification of Gi, and cholera toxin 
ribosylation allows a similar identification of Gs. Particularly with pertussis toxin, 
this is now recognized to be an oversimplification. Three genes coding for 'Gi-like' 
proteins have been identified (Jones and Reed, 1987; Suki et al.., 1987), as well as a 
gene for Go (Itoh et al., 1986). All of the polypeptides are potential substrates for 
pertussis toxin. The amino acid substrates of cholera and pertussis toxin have been 
identified as being Arg-174 and Cys-347 respectively in Transducin a.(Van Dop et 
al., 1984; West et al., 1985). The corresponding amino-acid residue modified by 
cholera toxin in Gsa is arginine 187/188 or 201/202 (Medynski et al., 1985); 
the exact number of this residue depends on which of the four splice variants of this 
protein is under study (Bray et al., 1986).
The target site for cholera toxin modification is conserved in ail G-protein 
a-subunits which have been cloned to date, wheras the pertussis toxin substrate is 
found in G il, Gi2, Gi3, Go, Tdl and Td2. and not in Gs or Gx (Kaziro, 1990). The 
precise toxin recognition sequences are unknown, which means that the ability or 
inability of a particular toxin to ADP-ribosylate a G-protein may not simply depend 
on the presence of the substrate amino-acid In a homologous position. In experiments 
designed to address whether Gs may be modified to become a pertussis toxin 
substrate, the extreme C-terminal region of Gsa has been altered from the wild type 
(Gln-Tyr-Glu-Leu-Leu) to a more Gi-like C-terminus containing a cysteine 
residue four amino-acids removed from the C-terminus, (Asp-Cys-Gly-Leu-Leu). 
Despite these changes, the mutant protein was a poor substrate for pertussis toxin 
(Freissmuth and Gilman, 1989). Gz is thought not to be a substrate for pertussis 
toxin since It does not have a cysteine residue in the appropriate location. However 
this remains to be rigorously assessed as it does have a cysteine residue three 
amino-acids removed from the cysteine position in the identified pertussis toxin 
sensitive G-proteins.
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The possibility that cholera toxin was not absolutely specific in its action on 
Gsa, but was also able to ADP-ribosylate Gla, was firstly raised by Graves and co­
workers (Graves et al., 1983). In rat adipocyte membranes, cholera toxin was 
demonstrated to catalyse the incorporation of radioactivity from [32p]NAD+ into 
two proteins with molecular masses of 54 and 45kDa, presumably representing two 
forms of Gsa. However, when the assay was carried out in the absence of GTP, 
choiera toxin was also found to catalyse the incorporation of radioactivity into a 
41 kDa polypeptide. The 41 kDa protein labelled by cholera toxin was identified as 
being Gia (Owens et al., 1985), since ADP-ribosylation of the 41kDa protein by 
both choiera and pertussis toxin had the same functional consequence of attenuating 
receptor mediated inhibition of adenyiyi cyclase.
It has previously been demonstrated in a macrophage cell line (Aksamit et al., 
1985), neutrophils (Verghese et al., 1986) and the rat glioma cell line C6BU1 
(Milligan, 1987) that cholera toxin can catalyse ADP-ribosylation of a 40kDa 
protein in assays to which no guanine nucleotide has been added. It has also been noted 
that cholera toxin can produce functional effects on transducin (Fung, 1985). 
Transducin may be ADP-ribosylated by both cholera and pertussis toxins, an effect 
which is dependent upon the guanine nucleotide bound to the G-protein a -subun it. 
Indeed it is possible to ADP-ribosylate transducin with both toxins, but only in the 
sequence pertussis toxin, followed by cholera toxin, if cholera toxin is used first, 
transducin is no longer a substrate for pertussis toxin (Stryer, 1988).
The data presented in this chapter demonstrate that cholera toxin can indeed 
catalyse ADP-ribosylation of a G-protein which is aiso a substrate for pertussis 
toxin, namely the inhibitory G-protein of the adenyiyi cyclase system, Gi. The 
evidence presented in support of this is threefold. Firstly; cholera toxin in the 
absence but not in the presence of guanine nucleotides, catalysed ADP-ribosylation of 
a 40kDa protein which co-migrated with a 40kDa pertussis-toxin substrate in 
membranes of the neurobiastoma x giioma hybrid ceii line NG108-15. Secondly, In 
membranes prepared from N G I08-15 cells which had been pretreated in vivo with 
pertussis toxih before cell harvest, to inactivate the pertussis toxin sensistive G-
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proteins present, cholera toxin was unable to catalyse ADP-ribosylation of the 
40kDa protein. However, this toxin was still able to modify the 45 and 42kDa 
polypeptides which represent forms of Gs (chapter 3). Thirdiy, activation of the 
population of 6-opioid receptors on the surface of these cells with synthetic 
enkephalin agonists enhanced the cholera-toxin modified ADP-ribosyiation of the 
40kDa band. This effect was blocked by the opioid antagonist naloxone. In addition, it 
is noteworthy that the EC50 for DADLE promotion of cholera-toxin catalysed ADP- 
ribosylation of Gia was very similar to that for DADLE stimulation of high-affinity 
GTPase activity in this system (chapter 5, Figure 5.13a).
Although pertussis toxin pretreatment of NG108-15 ceils in vivo prevented 
both pertussis and cholera-toxin-cataiysed ADP-ribosylation of Gia in vitro, this 
effect Is not because both toxins have the same target amino-acid. As stated above, 
pertussis toxin catalyses the transfer of ADP-ribose onto a cysteine residue, and 
cholera toxin onto an arginine residue. The explanation, may lie in the preferred 
states of the substrates for each toxin. The ability of either cholera or pertussis 
toxin to cataiyse the ADP-ribosylation of their respective substrates has been 
demonstrated to be modified by the state of association of the G-protein a -subun it 
with the p,y subunits (Tsai et al., 1984). The ability of pertussis toxin to covalently 
modify the purified a-subunit of Gi is negligible, however, upon addition of purified 
p,Y subunits, a ten fold increase in ADP-ribosylation is apparent (Neer et al.,
1988). In the presence of either GTPyS or Gpp(NH)p, non-hydrolysable analogues of 
GTP which have been demonstrated to bind to Gia and promote formation of the 
active, dissociated form of Gi (Katada et al., 1986), the ability of pertussis toxin to ■ 
ADP-ribosylate Gia is reduced, suggesting that the dissociated a-subunit of Gi is a 
poor substrate for pertussis toxin. In contrast, the inclusion of GDPpS, an analogue 
of GDP thought to promote association and hence inactivation of GI (Gilman, 1984), 
increased the ADP-ribosylation of Gia by pertussis toxin. From similar experiments 
on transducin, which is a substrate for both cholera and pertussis toxins, the 
preferred substrate of cholera toxin is thought to be the dissociated form of the a- 
subunit, since cholera toxin catalysed ADP-ribosylation of transducin is increased 
by the presence of either GTPyS or Gpp(NH)p and inhibited by the addition of GDP 
(Abood et al., 1982). In similar experiments, the ability of cholera toxin to ADP-
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ribosylate Gs has been shown to be increased by the presence of Gpp(NH)p, 
suggesting that in addition to transducin, the preferred substrate for cholera toxin is 
the monomeric a-subunit of Gs (Owens et al., 1985). However, the existence of a 
preferred conformational state of Gi to be ADP-ribosylated by pertussis toxin has 
recently been questioned by two reports, which have demonstrated that pertussis 
toxin itself, has a nucleotide requirement (Lim et al., 1985), and that both adenine 
and guanine nucleotides can bind to the toxin and induce a conformational change 
which results in increased ADP-ribosyltransferase activity. This data suggests that 
experiments conducted to assess the ability of guanine nucleotides to alter pertussis 
toxin catalysed ADP-ribosylation of Gi, have to be analysed with care (Mattera et al., 
1986; RIbeiro-Neto et al., 1987).
If it Is assumed that pertussis toxin does indeed prefer to interact with the 
holomeric heterotrimeric forms of its substrates and that cholera toxin interacts 
preferentially with the isolated a-subunit of its substrates then after pertussis 
toxin pretreatment, the holomeric form of Gi will be stabilised and might then 
represent a poor substrate for cholera toxin catalysed ADP-ribosylation. A second 
possibility is based on the observation that, for pertussis-toxin-sensitive G- 
proteins to serve as substrates for cholera toxin, no guanine nucleotide should be 
bound to the protein. Pertussis-toxin catalysed ADP-ribosylation of Gi attenuates 
coupling between receptor and G-protein and therefore prevents the receptor driven 
stimulation of GTP hydrolysis and guanine nucleotide exchange. The ADP- 
ribosylation of Gi by pertussis toxin would therefore be expected to diminish guanine 
nucleotide exchange and thus maintain the presence of GDP in the nucleotide binding 
site of Gia (Gilman, 1987). The presence of GDP in the guanine nucleotide binding 
site of Gia may be sufficient to prevent cholera-toxin catalysed ADP-ribosylation of 
the protein. Further evidence in favour of the requirement for a nucleotide free form 
of Gia as a substrate for cholera toxin was provided by the observation that agonist 
activation of a receptor which stimulates the activity of an inhibitory G-protein(s), 
promoted the cholera toxin mediated ADP-ribosylation of this G-protein. The rate 
limiting step in the cycle of G-protein activation and deactivation appears to be the 
rate of release of GDP (Ferguson et al., 1986). The function of an agonist occupied
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receptor is to promote a conformational change in the G-protein a-subunit which 
reduces its affinity for GDP. This will increase the rate of release of GDP, and 
therefore enhance the rate of binding of the activating guanine nucleotide, GTP 
(Gilman, 1987). In the absence of exogenously added GTP, the GDP will not be 
replaced, producing a protein stripped of bound nucleotide.
Evidence from other signal transduction model systems suggests that cholera 
toxin may stiil be able to ADP-ribosylate 'Gi', even in the presence of guanine 
nucleotides or their analogues. In a macrophage like cell line, RAW 264, 
pretreatment with pertussis toxin has been shown to inhibit receptor mediated 
chemotaxte by the chemotatic peptide formyl-methionyl-leucyl-phenylalanine (F- 
Met-Leu-Phe), suggesting a role for a pertussis toxin sensitive G-protein in 
mediating the response. In membranes produced from RAW 264 cells, pertussis 
toxin has been demonstrated to catalyse the incorporation of radioactivity from 
[32p]NAD+ into a 41 kDa polypeptide, presumably the a-subunit of Gi, wheras 
cholera toxin catalyses the incorporation of radioactivity from [3 2 p ]n a D “*' into a 
45kDa polypeptide, presumably the a-subunit of Gs (Backlund et al., 1985). When 
cholera toxin catalysed ADP-ribosylation Is performed in the absence of guanine 
nucleotide, a different picture emerged. As well as the incorporation of radioactivity 
into Gs, radioactivity is also incorporated into Gi. Interestingly, when the non- . 
hydrolysable guanosine triphosphate analogue Gpp(NH)p is present, labelling of Gi 
by cholera toxin still occurs. Pretreatment of RAW 264 cells in vivo with cholera 
toxin prevented incorporation of radioactivity into Gs, but did not prevent the 
incorporation of radioactivity into Gi. However, pretreatment of the cells with 
pertussis toxin, whilst not altering ADP-ribosylation of Gs, prevented the in vitro 
ADP-ribosylation of Gi by cholera toxin.
In HL60 cells, F-Met-Leu-Phe has been shown to bind to specific 
receptor(s) and stimulate the activity of phosphoinositidase .C and hence protein 
kinase C, in a pertussis toxin sensitive manner (Dougherty et al., 1984), suggesting 
that the receptor(s) for F-Met-Leu-Phe stimulate the activity of Intracellular 
effectors by interacting with a pertussis toxin sensitive G-protein(s). Gierschik and
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Jacobs (1987) have demonstrated that in membranes produced from HL 60 ceils, 
cholera toxin is able to ADP-ribosylate a 40kDa protein which migrates in an 
identical manner to the 40kDa polypeptide(s) which becomes ADP-ribosylated after 
pertussis toxin treatment. Interestingly, the ability of cholera toxin to ADP- 
ribosylate what was originally thought to be a single polypeptide but has since been 
resolved into a doublet of Gi2-and Gi3 (Gierschik et al., 1989a) is absolutely 
dependent upon the presence of the G-protein activating ligand, F-Met-Leu-Phe. 
Prior treatment of HL60 cells with pertussis toxin in vivo prevented the in vitro 
ADP-ribosylation of Gi2a and Gi3a by both toxins, suggesting that the substrates for 
both cholera and pertussis toxin were identical.
The data discussed above was obtained from membrane preparations, in 
contrast, a recent report from Katada and co-workers has examined the ability of 
cholera toxin to ADP-ribosylate Gi in both whole HL-60 cells and membranes (liri 
et al., 1989). In membranes produced from HL60 cells a 40kDa protein was ADP- 
ribosylated by cholera toxin, but only in the presence of the chemotactic peptide 
agonist, F-Met-Leu-Phe. Prior treatment of HL60 cells in vivo with pertussis 
toxin prevented subsequent incorporation of ADP-ribose into the 40kDa protein by 
either cholera or pertussis toxins, suggesting that the target protein for each toxin 
was the a-subunit of Gi. Cholera toxin mediated ADP-ribosylation of Gi was found to 
be stimulated by guanine nucleotides such as GTPyS, Gpp(NH)p and GTP and also by 
the inclusion of Mg2+, in a biphasic manner, such that low concentrations of both 
guanine nucleotide and Mg^+ were stimulatory and higher concentrations inhibitory. 
Interestingly, in membranes produced from cells pretreated with both cholera toxin 
and F-Met-Leu-Phe, it was no longer possible to ADP-ribosyiate Gi with cholera 
toxin although the protein still supported ADP-ribosylation by pertussis toxin. This 
led the authors to conclude that cholera toxin couid cataiyse the ADP-ribosylation of 
the a-subunit of Gi in vivo. However, it should be noted that when the cells were 
pretreated with both cholera toxin and F-Met-Leu-Phe, the chemotactic peptide was 
only present in the assay for five minutes. Based upon data obtained in membrane 
systems where the timecourse of ADP-ribosylation of both Gsa and Gia has been 
examined, it does not seem feasible to ADP-ribosylate a significant proportion of the 
G-protein pool in a five minute time span (Milligan, 1987). This data is more
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con with an alternative G-protein modification, such as a
phosphorylation. It has recently been appreciated that treatment of rat hepatocytes 
with agents which stimulate the activity of protein kinase C, results in the 
phosphorylation of the a-subunit of Gi2 {Bushfield et al., 1990). In addition, 
treatment of human monocyte U937 celts with lipopolysaccharide for five minutes 
elicits the phosphorylation of Gi2a and attenuates the ability of Gi2a to support 
pertussis toxin catalysed ADP-ribosylation (Issakani et al., 1989). The effect of 
treating HL-60 cells with both cholera toxin and F-Met-Leu-Phe may not be due to 
the in vivo ADP-ribosylation of Gia by cholera toxin, but may instead be due to the 
pfiosphorylation of Gia, Induced by agonist stimulation of protein kinase C,
In membranes produced from HL-60 cells, cholera toxins' ability to ADP- 
ribosylate the classically defined pertussis toxin sensitive G-proteins is not limited 
to Gia, since in the presence of F-Met-Leu-Phe the toxin was able to ADP- 
ribosylate purified ,a-subunlts of G il, GI2 and Go, In the order; endogenous Gia > 
Gi2a = G ila  >Goa, when each a-subunit was reconstituted into membranes 
produced from pertussis toxin pretreated HL60 cells (liri et al., 1989). The 
differing degree of ADP-ribosylation may reflect differing abilities of each G- 
protein a-subunit to couple to the F-Met-Leu-Phe receptor and hence suggest that 
some measure of specificity is maintained in this reconstitution system.
A range of pertussis toxin sensitive G-proteins are known to be expressed in 
the NG108-15 cell line, these are Gi2, G13 and Go (Chapter 3). The data presented 
in this chapter do not define which of these G-protein a-subunit(s) is represented 
by the 40kDa polypeptide(s) which is ADP-ribosylated by pertussis toxin and also 
by cholera toxin in a manner which is enhanced by opioid peptides. This was 
primarily due to the difficulty of incorporating sufficient radioactivity into the 
40kDa cholera toxin substrate to allow resolution and identification using 
polyacrylamide gel electrophoresis. It may be noted that the stoichiometry of cholera 
toxin catalysed ADP-ribosylation of Gia, was considerably lower than that of 
pertussis toxin labelling of Gia in NGI 08-15 cell membranes. The reason for this 
discrepancy is unclear, however it may simply be a reflection of the difficulty in 
converting the entire pool of Gia into a suitable substrate for cholera toxin catalysed
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ADP-ribosylation.
Although the precise nucleotide requirements and the mechanism by which 
cholera toxin Is able to ADP-ribosylate 'Gi-like' G-proteins in membrane systems 
remains to be resolved, agonist stimulation of the cholera-toxin catalysed ADP- 
ribosylation of Gia may be a general phenomenon for receptors coupled to 'Gi-like' 
G-proteins. In this regard, it has recently been noted that foetal calf serum 
activation of a poorly characterised growth factor receptor on C6BU1 cells 
stimulated cholera-toxin-catalysed ADP-ribosylation of Gi2 {Milligan, 1988). If 
some degree of specificity is maintained, as is suggested from the work of liri et al., 
(1989) then experiments similar to those described in this chapter may be of 
general use in defining the nature of receptor to G-protein coupling.
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Chapter 5
The interaction of receptors linked to 
adenyiyi cyclase inhibition with G-proteins  
In the NG108-15 ceii line.
In t ro d u c t io n
The control of ceil growth is mediated by the concerted action of a variety of 
growth factors and hormones which regulate the level of activity of intracellular 
effectors such as adenyiyi cyclase, phosphoinositidase-C, or various ion channels. It 
may therefore be appreciated that the control and regulation of the second messenger 
systems which are modulated by hormones and growth factors must be subject to a 
high level of control (Pouyssegur, 1989).
With G-proteins acting as central mediators in the signal transduction 
process, one of the most important questions relating to G-protein function lies 
within the specificity of interaction between G-proteins, transmembrane, receptors 
and the effector systems with which they interact. Although it has been assumed that 
all receptors which regulate the activity of one type of effector do so through the 
activation of only one species of G-protein, it is currently unclear whether one 
receptor will interact exclusively with one G-protein species, or if more than one 
G-protein may interact with the same receptor.
In membrane systems, there appears to be tight regulation of G-protein 
coupling, whereby receptors which are known to interact with different effectors do 
so through the activation of different G-proteins, as assessed by measurements of 
GTP hydrolysis (Houslay et al., 1986a,b; McKenzie et al., 1988a,b). However, 
studies which employ the reconstitution of purified G-proteins, receptors and 
effectors into phospholipid vesicles, suggest that one type of receptor may interact 
with a large number of homologous, but non-identical G-proteins {Florio and 
Sternweis 1985; Cerione et al., 1986; Kurose et al., 1986; Asano et al., 1984). 
Coupling of a given receptor-G-protein pair in artificial phospholipid vesicles 
cannot be taken as evidence for a physiologically relevant interaction {Okajima et 
ai., 1985), but may simply reflect a high degree of structural similarity in the 
domains involved in receptor to G-protein coupling and as such, describe 
possibilities of interaction rather than giving a definition of interaction. In addition, 
it should be noted that the early reconstitution studies described were performed
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using purified "Gi" which was in all probability a non-homogeneous population of 
'G i-like' G-proteins.
In chapter 3, an immunological approach has been employed to define the 
various species of G-protein expressed by NG108-15 cells, these are Gs, Gi2, Gi3 
and Go. Gz (Gx) may also be expressed, but current techniques have not as yet 
allowed its rigorous identification in this cell line. The most widely studied effector 
system which functions in NG108-15 cells is adenyiyi cyclase, which is subject to 
both stimulatory and inhibitory inputs from a variety of G-protein linked receptors 
(Klee et al., 1985). Receptor mediated inhibition of adenyiyi cyclase in NG108-15 
cells is attenuated by pretreatment with pertussis toxin (Kurose et al, 1983), thus 
defining a role for a pertussis toxin sensitive G-protein in mediating the response. 
The G-protein which mediates inhibition of adenyiyi cyclase in NGI 08-15 cell must 
be one of GI2, Gi3, Go or a combination thereof. The data presented in this chapter 
will address the specificity of receptor to G-protein interactions in membranes 
produced from the N G I08-15 cell line and thus ascertain which of the pertussis 
toxin sensitive G-proteins is linked to the inhibition of adenyiyi cyclase.
103
Fia. 5.1 Stimulation of hiah-affinitv GTPase activity in
membranes of NG108-15_cells In response to GTP.
5.1(a) High-affinity GTPase activity was measured in membranes of 
N G I08-15 cells (8|ig) in response to increasing concentrations of GTP, as 
described in section 2.13, except that GTP was excluded from the mix. 5.1(b) The 
data obtained were replotted in the manner described by Hofstee (1952). Points 
represent means ± S.D. for quadruplicate determinations obtained from four 
Independent experiments (n=16).
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Table. 5.1 Stimulation of hiah-affinitv GTPase activity in
N G I08-15 membranes by various agents.
High-affinity GTPase activity was measured in membranes (8|ig) of NGI OB­
IS cells in response to a range of different agonists, as described in the legend to 
Figure 5.1, except GTP was included in the assay at a final concentration of O.SjiM. 
The data shown are means.± S.D. taken from quadruplicate determinations in a single 
experiment which is representative of five others performed. These gave essentially 
Identical results.
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Table 5.1
Addition Cone.
used
GTPase activity Stimulation
(pmoi/min/mg protein) (pmol/min/mg protein)
None 14.2 + 0.1
DADLE (10)4M) 23.1 ± 0.15 8.9
DALAMID ( lO jiM ) 22.9 ± 0.76 8.7
Bradykinin (10ixM) 18.6 ± 0.1 4.4
Adrenaline ( lO p M ) 15.8 ± 0.12 1.6
FOB (10%, v/v) 20.7 ± 1.0 6.5
PGE1 (10pM ) 14.4 ± 0.4 0.2
Stimulation of H iah .aff in tv  GTPase activity in 
NG108-15 membranes: the effect of pertussis 
toxin pretreatm ent.
High affinity GTPase activity was measured in NG108-15 cell membranes 
(7pg) which had been pretreated with vehicle {empty bars) or pertussis toxin 
(hatched bars) as detailed in section 2.6d. Ligands were either; vehicle (A); DADLE 
( 10pM) (B), bradykinin (lOpM) (C), adrenaline (lOpM) (D) or PCS (10% v/v) 
(E). The assay was conducted as described in the legend to Table 5.1. The data shown 
are means ± S.D. pooled from quadruplicate determinations obtained in three 
separate experiments (n=12).
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Fia. 5.3 Stimulation of hiah-affintv GTPase activity In
NG108-15 membranes: additivity studies with
DADLE. bradykinin and adrenaline.
High-affinity GTPase activity was assessed in NG108-15 cell membranes 
(7|ig) exactly as described in the legend to Figure 5.2. Ligands were; DADLE (1), 
bradykinin (2), adrenaline (3), DADLE + bradykinin (4), DADLE + adrenaline 
(5), bradykinin + adrenaline (6) and DADLE + bradykinin + adrenaline (7). All 
ligands were used at a final concentration of 10|xM. Data represent means ± S.D. 
from quadruplicate determinations obtained from a single experiment which was 
repeated three times with essentially identical results. In the experiment shown, 
basal high-affinity GTPase activity (in the absence of added agonist) was 15.8 ± 0.2 
pmoles/min/mg protein.
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Fig. 5.4 Stimulation of high-affinity GTPase activity by
DADLE in NG108-15 ceil membranes is
s p e c I f LcaJ J y bio eke d__by _ria Ip x o ne.
High-affinity GTPase activity was assessed in NG108-15 ceil membranes 
(7)1 g) exactly as described in the legend to Figure 5.2, In the presence of vehicle 
(A), or concentrations of DADLE (B), bradykinin (C) or adrenaline (D) which 
elicited the maximal stimulation of high-affinity GTPase activity which could be 
produced by that ligand (10)iM). Naloxone was either absent (empty bars) or 
included (hatched bars) in parallel tubes at a final concentration of 1mM. Data 
represent means ± S.D. from quadruplicate determinations obtained from a single 
experiment which was repeated twice with essentially identical results.
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Fia. 5.5 Stimulation of hiah-affinitv GTPase activity bv
adrenaline in NG108-15 cell membranes is
specifically blocked bv yohimbine.
High-affinity GTPase activity was‘assessed in NG108-15 celi membranes 
(7)1 g) exactly as described in the legend to Figure 5.2, in the presence of vehicle 
(A), or a concentration of either DADLE (B), bradykinin (C) or adrenaline (D) 
which elicited the maximal stimulation of high-affinity GTPase activity which could 
be produced by that ligand (lOpM). Yohimbine was either absent (empty bars) or 
included (hatched bars) in parallel tubes at a final concentration of 1pM. Data 
represent means ± S.D. from quadruplicate determinations obtained from a single 
experiment which was repeated twice with essentially identical results.
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Table  5.2 The stimulation of adenylyl cyclase activity In 
membranes of NG108-15 ceils in response to a 
variety of agents.
Adenylyl cyclase activity was measured in membranes of NG108-15 cells 
(20)1 g) by the method of Salomon (1979), as described In section 2.15b. The 
agonists present were used either singly or in concert at the following final 
concentrations; forskolin (10)iM), PGE1 (10)iM), NaF (lOmM), MnCl2 (10mM). 
The data shown represent means ± S.D taken from quadruplicate determinations 
pooled from three independent experiments (n=12).
111
Table 5.2
Addition Adenylyl cyclase activity 
(p mo l/m in/m g protein)
Stimulation 
(pmol/m in/mg protein)
None
Forskolin
PGE1
NaF
MnCI2
Forskolin + PGE1 
Forskolin + MnCL*
40.0 ± 2.1 
613.9 ± 7.2 
219.4 ± 5.8 
106.2 ± 4.9
65.8 ± 2.0
915.8 ± 21.0 
721.6 ± 17.8
573 .9
179.4
66.2
25.6
875 .8
681 .7
Fia. 5.6 The stimuiatlon of adenvivi cvciase in NG108-15  
cell membranes in response to increasing 
concentrations of forskoiin.
Adenylyl cyclase activity was measured in membranes of NG108-15 cells 
(20 iig ) as described in the legend to Table 5.2, in response to concentrations of 
forskolin ranging from 0.1 nM to lOOjiM. Results shown are means ± S.D taken from 
quadruplicate determinations in a single experiment which was performed twice 
with essentially identical results being obtained.
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Fig. _5.7 The stimulation of adenvivi cyclase in N G I08-15 ,
cell membranes in response to increasing
concentrations of Prostaglandin E1,
Adenylyl cyclase activity was measured in membranes of NG108-15 cells 
(20|ig) as described in the legend to Table 5.2, in response to concentrations of 
PGE1 which ranged from 0.1 nM to lOpM. Results shown are means ± S.D taken 
from quadruplicate determinations in a single experiment which was performed 
three times with essentially identical results being obtained.
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Table 5.3 The inh ib ition  of s tim ula ted adenylvl cyclase
activity in NG108-15 cell membranes: the effect 
of DADLE. bradykinin and adrenaline.
Adenylyl cyclase activity was measured in membranes of NGI 08-15 cells 
{20 ja.g) as described In the legend to Table 5.2. Adenylyl cyclase activity was 
stimulated by the inclusion of either forskoiin (lO iiM) or PGE1 (lOjiM), and the 
effect of each of; DADLE , bradykinin, adrenaline (all at a final concentration 
o f10|iM) and PCS (10% v/v final concentration) was assessed. In the experiment 
shown, the unstimulated adenylyl cyclase activity was 43.1 ± 2.0 pmoles/min/mg 
protein. Data shown are means ± S.D. of quadruplicate determinations taken from a 
single experiment which was performed three times with identical results.
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Table 5.3
Addition Porskolin PGE1
stimulation % Stimulation %
{p m o l/m in / Inh ib ition (pm o i/m in Inhib ition
mg protein) mg protein)
None 675.8 ± 15.5 243.4 ± 1.6
DADLE 459 ± 9.2 32 179.1 ± 5.4 26.4
Bradykinin 472 ± 14.2 30 174.0 ± 7.9 28.5
Adrenaline 456 ± 6.0 33 166.5 ± 6.6 ■ 31.3
PCS 680 ± 17.2 - 0.1
DADLE +
Bradykinin 463 ± 9.6 31.8 167.3 ± 8.5 31 .3
DADLE +
Adrenaline 461.1 ± 10.1 32.1 161.5 ± 12.1 33.8
Adrenaline +
Bradykinin 462.4 ± 9.1 32 170.0 ± 5.8 30.1
DADLE +
Bradykin in+
Adrenaline 470.9 ± 5.0 30.0 175.8 ± 4.5 28.0
The effect of pertjj_esj-S_toxin _pretreatment__Q^_n^  ^
adenvivi cvciase activity in NG108-15 cell
Adenylyl cyclase activity was assessed in N G I08-15 ceil membranes which 
had been pretreated with vehicle (empty bars) or pertussis toxin (hatched bars) as 
detailed in section 2.6d, in response to; vehicle (A), forskolin (B), forskolin and 
DADLE (C), forskolin and bradykinin (D) or forskolin and adrenaline (E). All 
ligands were present at a concentration of lOpM. The assay was performed as 
described in the legend to Table 5.2. Data shown are means ± S.D.(n=4) taken from 
a single representative experiment which gave essentially identical results to three 
others performed.
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Fia. 5.9 The inhibition of adenyivi cvciase activity in
NG108-15 celi membranes in response to
increasing concentrations of DADLE.
Adenylyl cyclase activity was assessed In membranes produced from NG108- 
15 cells (20|ig), in response to concentrations of DADLE which ranged between 
0.1 nM and lOpM, as described in the legend to Table 5.2. Adenylyl cyclase activity 
was amplified by the inclusion of forskolin (10)iM). The data shown are means ± 
S.D. taken from quadruplicate determinations obtained In a single experiment which 
was repeated three times. In the experiment shown, the basal adenylyl cyclase 
activity was 43.2 ± 3.5 pmoles/min/mg protein.
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Em. 5,10 The inhibition of adenylyl cyclase activity In
NG108-15 cell membranes in response to
Increasing concentrations of bradykinin.
Adenylyl cyclase activity was assessed in membranes produced from NG108- 
15 cells (20jig), in response to concentrations of bradykinin which ranged between 
0.1 nM and 10|iM, as described in the legend to Table 5.2. Adenylyl cyclase activity 
was amplified by the Inclusion of forskolin (lOpM). The data shown are means ± 
S.D. taken from quadruplicate determinations obtained in a single experiment which 
was repeated three times. The basal adenylyl cyclase activity in the experiment 
shown was 40.6 ± 2.8 pmoles/min/mg protein.
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Fig. 5.11 The inhibition of adenylyl cvciase activity in
NG108-15 cell membranes In response to
increasing concentrations of adrenaline.
Adenylyl cyclase activity was assessed in membranes produced from NG108- 
15 cells (20fig), in response to concentrations of adrenaline which ranged between 
0.1 nM and lOfiM, as described in the legend to Table 5.2. Adenylyl cyclase activity 
was amplified by the inclusion of forskolin (10|iM). The data shown are means ± 
S.D. taken from quadruplicate determinations obtained in a single experiment which 
was repeated three times. The basal adenylyl cyclase activity in the experiment 
shown was 45.5 ± 1.4 pmoles/min/mg protein.
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Fig. 5.12 Inhibition of adenvJvl cvciase activity in NG108-
15 ceil membranes: additivity studies with
DADLE. bradykinin and adrenaline.
Adenylyl cyclase activity was measured in membranes of NGI 08-15 cells 
(20|ig ) exactly as described in the legend to Table 5.2, in response to either 
forskolin (10|iM) (A), or forskolin and either; DADLE (B); bradykinin
(C); adrenaline (D); DADLE + adrenaline (E); DADLE + bradykinin (F); adrenaline 
+ bradykinin (G) or DADLE, bradykinin and adrenaline (H). DADLE, bradykinin and 
adrenaline were used at a concentration which produced 50% of the maximum 
observable inhibition of forskolin (lO jiM ) stimulated adenylyl cyclase activity 
which could be obtained by that ligand (5nM, 50nM and 50nM respectively)
(Figures 5.9, 5.10 and 5.11). Data represent means ± S.D. of quadruplicate 
determinations taken from three pooled independent experiments (n=12). The basal 
adenylyl cyclase activity for the data shown was 35.7 ± 1.7 pmoles/min/mg protein.
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Fig, 5.13 Stimulation by PADLE and foetal calf serum
of high affinity GTPase activity in NG108-15
membranes: the effect of pertussis toxin.
High affinity GTPase activity was measured in membranes produced from 
NG108-15 cells (8jig ) which had been treated either with pertussis toxin (open 
circles) or vehicle (closed circles) (section 2.6d) as described in the legend to 
Table 5.2, in response to different concentrations of either; 5.13(a) DADLE (0.1 nM 
to 1|iM). or 5.13(b) foetal calf serum (0.01% to 20%). Data represent means ± 
S.D. of quadruplicate determinations from a single experiment which gave identical 
results to two others performed.
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Fig. 5.14 High affinity GTPase activity in NG108-15
membranes: add itiv ity  studies w ith  DADLE and 
foeta l ca lf serum .
5.14(a) DADLE (0.1 nM to Ijj-M) stimulation of high affinity GTPase activity 
was measured in NG108-15 cell membranes (Bjig) exactly as described in the 
legend to Table 5.2, in the presence (open circles) or absence (closed circles) of a 
concentration of foetal calf serum which gave maximal stimulation of GTPase 
activity by this ligand (20%). 5.14(b) Foetal calf serum (0.01% to 20%) 
stimulation of high affinity GTPase activity was measured in NG108-15 cell 
membranes (8p.g) exactly as described in the legend to Table 5.2, in the presence 
(open circles) and absence (closed circles) of a concentration of DADLE which gave 
maximal stimulation of GTPase activity by this ligand (10|iM). Points are means ± 
S.D. of quadruplicate assays. The experiment was performed three times and yielded 
identical results.
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Fia, 5.15 Preincubation of NG108-15 cell membranes with  
synthetic peptides homologous to the C-terminus 
of Gi2g and Goa, reduces opioid receptor 
mediated high affinity GTPase activity.
NG108-15 cell membranes (7|ig) were incubated with water, or varying 
concentrations {1nM to 0.1 mM ) of synthetic peptides corresponding to the last ten 
C'terminal amlno-acids of either Id a  (5.15a) or Goa (5.15b) as described in 
section 2.13, for 30 minutes at 37®C in the presence of the GTPase assay reagents, 
but in the absence of [ t ^ ^ p jg t r .  After this time both DADLE and [y^^PlGTP were 
added, and the incubation continued for a further 20 minutes. Samples were then 
processed as described in section 2.13. Data which are means ± S.D.are taken from a 
single experiment which is representative of four experiments performed. 'GTPase 
stimulation' represents agonist stimulation over and above the basai high-affinity 
GTPase activities. For the data shown, the basal GTPase activity was 15.8 ± 1.0 
pmoles/min/mg protein.
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Table 5.4 Attenuation of opioid receptor stimulated high
affinity GTPase activity in membranes of NG108- 
15 cells bv affinity purified antibodies from  
antiserum AS7.
NG108-15 membranes (7pg) were incubated with water, normal rabbit 
serum or a 1:100 dilution, in normal rabbit serum, of antibodies which had been 
affinity purified from antiserum AS7 as detailed in section 2.9, for 1 hour at 37*^C 
in the presence of the GTPase assay reagents, but in the absence of [T^^p jQ jp gg 
described in section 2.13. After this time the appropriate receptor ligand and 
[y32p ]q jp  were added, and the incubation was continued for a further 20 minutes. 
Samples were then processed as described in section 2.13. Data which are means ± 
S.D.are taken from a single experiment which is representative of five experiments 
performed which gave identical results.
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Table 5.4
Addition to 
Preincubation
Basai high affinity 
GTPase activity 
(pmot/min/mg protein)
Receptor-stimulated 
high-affinity GTPase 
activity {pmoi/min/mg protein)
DADLE Foetal calf
(1| iM )  sérum (10%v/v)
Water 4.01 ± 0.29
Normal Rabbit Serum 6.50 ± 0.10
AS7 antibodies 5.41 ± 0.69
3.01 ± 0.15 
2.64 ± 0.09 
0.19 ± 0.11
4.22 ± 0.13 
6.27 ± 0.11 
4.21 ± 0.16
Fig. 5.16 Affinity purified antibodies: inhibition of 5 - 
opio id -receptor-s t im ula ted  GTPase activ ity .
Antibodies which were affinity-purified from antiserum AS7 as detailed in 
section 2.9, were diluted with normal rabbit serum. NG108-15 membranes (5 jig) 
were incubated with the GTPase assay mixture except for [ t^ ^ p jq tp  and various 
concentrations of the antibodies for Ihour at 37^0 as detailed in section 2.13. After 
this time, the samples were placed on ice and DADLE (lOjih/l) and [t^ S p jg tP  were 
added. The samples were then incubated for a further 20 minutes at 37°C before 
being processed as in section 2.13. Points represent means ± S.D. of quadruplicate 
assays from a single experiment which was repeated four times.
124
F!gvr.e 5, IS
2 .0 -
O '—' 
CD C
CD CD
CO -M  
CD O  
CL L_d
CD
E
OEw d  0 . 5 -  
LÜ
Q
0 CO
Log a n t ib o d y  d i l u t i o n
Fia. 5 .17 Time course of the loss of basal and 5-opioid
receptor stimulated high affinity GTPase activity  
during preincubation at 37&C.
NG108-15 cell membranes (6|j.g) were preincubated at 37°C for various 
times In the presence of all the components of the GTPase assay except [-)^^P]GTP as 
described in section 2.13. After this preincubation, [^^^PjGTP, and where 
appropriate DADLE (IjiM ), were added, and the incubation was allowed to continue 
for a further 20 minutes. Samples were then processed as in section 2.13. Basal 
(open circles) and opioid stimulated above basal (closed circles) high affinity 
GTPase activities are presented. Points represent means ± S.D. of quadruplicate 
determinations obtained from a single experiment.
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Fia. 5.18. 8 opioid receptor-stimulatlon of high affinity
GTPase activity in membranes of neurobiastoma x 
glioma hybrid ceiis. The receptor interacts  
specifically  with Gi2.
Membranes produced from NG108-15 cells (10|ig) were incubated with IgG 
fractions produced from both normal rabbit serum and from the various antiserum 
described in chapter 2, Table 2.1 by chromatography on protein-A sepharose as 
described in section 2.9. These fractions were incubated with membranes of 
NG108-15 cells for 60 minutes at 37°C in the presence of all reagents used in the 
GTPase assay except It^^p ] q t p  and receptor agonist as detailed in section 2.13. 
Following the preincubation period both [t^^P] GTP and DADLE (IjxM) were added 
and samples incubated at 37^0 for a further 20 minutes. Samples were then 
processed as detailed in section 2.13. Results are presented to display levels of both 
the basal high affinity GTPase activity (open bars) and high affinity GTPase activity 
in the presence of agonist (hatched bars). Results are means ± S.D. from 4 
independent experiments. Quadruplicate determinations were performed for each 
point in each experiment (n=16).
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Table 5.5 Antibodies from antiserum AS7 attenuate opioid 
receptor mediated Inhibition of adenvivi
c y c k .$g,
Membranes of NG108-15 cells (20|ig) were preincubated for 1 hour with 
IgG from either normal rabbit serum or antiserum AS7 (equivalent to a 1:100 
dilution of the original antiserum) as detailed in section 2.15a. After this 
preincubation, the effect of DADLE (lOjiM) on forskolin (lO jiM ) amplified 
adenylate cyclase was assessed by use of a binding protein for the determination of 
cyclic AMP as described in section 2.15. Results are means ± S.D. for assays 
performed in quadruplicate. The results are taken from a single experiment but two 
further experiments produced identical data.
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Table 5.5
Incubation Forskolin stimulated adenylyl % inhibition by
condition cyclase {pmol/min/mg protein) DADLE (lOpM )
(IgG from) - DADLE + DADLE
Normal rabbit serum 83.6 ± 5.6 54.8 ± 4.9 34.5
Antiserum AS7 79.1 ± 2.6 80.2 ±1 . 1  - 1 . 4
RESULTS '
The rate of hydrolysis of GTP by high affinity GTPases In membranes 
produced from NG108-15 cells was Increased in a dose-dependent manner by 
increasing concentrations of the substrate for such reactions, GTP (Figure 5.1.a). 
When this data was replotted as an Eadie-Hofstee plot (Figure 5.1b), it is possibie to 
assess the Km vaiue for GTP by high affinity GTPases in NG108-15 membranes, a 
value of 0.4|j.M being routinely obtained (0.42 ± 0.04 nM, mean ± S.D., n=4). The 
hydrolysis of GTP by high affinity GTPases in NG108-15 cell membranes was linear 
over a 30 minute timecourse and with membrane protein concentrations of between 
2 to 30pg. The totai hydrolysis of GTP never exceeded 15% (results not shown). 
NG108-15 cells possess a wide range of receptors linked to second messenger 
systems, as detailed in chapter 3. When the ability of a variety of agonists to 
stimulate high affinty GTPase activity was assessed in NG108-15 membranes, the 
opioid peptides DADLE and DALAMID gave the greatest stimulation of the rate of 
hydrolysis of GTP (8.9 ± 0.1 pmol/min/mg protein, mean ± S.D., n=4) and 8.7 ± 
0.3 pmol/min/mg protein, respectively) (Table 5.1). Foetal calf serum (FGS), also 
gave a significant stimulation of high affinity GTPase activity (6.5 ± 0.3 
pmol/min/mg protein). Bradykinin and adrenaline, though capable of G-protein 
stimulation (Kurose et al., 1982), routinely gave a measurable, though poor 
response (4.4 ± 0.1 pmol/min/mg protein and 1.6 ± 0.1 pmol/min/mg protein, 
respectively). Prostaglandin El (PGE1) has been shown to stimulate adenylyl 
cyclase activity, presumably through activation of Gs, (Traber et al., 1975.), 
however high affinity GTPase activity in the presence of PGE1 (14.4 ± 0.4 
pmoles/min/mg protein) was not significantly higher than the high affinity GTPase 
activity in the absence of PGE1 (14.2 ± 0.1 pmoles/min/mg protein) (Students' t- 
test, P > 0.3) (Table 5.1). The basal high affinity GTPase activity varied between 
different membrane preparations over an approximately two-fold range from 9.7 ± 
0.2 pmoles/min/mg protein to 19.3 ± 0.2 pmoles/min/mg protein.
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In addition to expressing a -single subtype of opiate receptor of the 5- 
classification (Chang and Cuatrecasas, 1979), NG108-15 cells are known to 
express a-adrenergic receptors of the a -2B designation (Bylund, 1988). NG108- 
15 cells also express bradykinin receptors (Higashida et al., 1986), however the 
identity of the receptor which the factor(s) contained in FGS interacts with is poorly 
defined. To ascertain whether DADLE, adrenaline, bradykinin and FGS were 
stimulating the activity of a pertussis toxin sensitive G-protein(s), NG108-15 
ceils were pretreated with pertussis toxin as described in section 2.6d. After 
pertussis toxin pretreatment of NG108-15 cells in  vivo, DADLE, adrenaline, 
bradykinin and FGS were found to be unable to stimulate high-affinity GTPase 
activity in NG108-15 membranes (Figure. 5.2), thus indicating that each of the 
ligands function through activation of a pertussis toxin sensitive G-protein(s). it is 
of interest to note that the basai GTPase activity is significantly reduced by pertussis 
toxin treatment from a value of 19.3 ± 0.2 pmol/min/mg protein in membranes 
from untreated cells to 16.9 ± 0.1 pmol/min/mg protein in membranes from 
pertussis toxin treated cells (means ± S.D., n=4, Students t-test, P < 0.001). In an 
attempt to analyse whether the agonists DADLE, adrenaline and bradykinin were 
stimulating the rate of hydrolysis of GTP through activation of the same pertussis 
toxin sensitive G-protein, or through activation of different species of pertussis 
toxin sensitive G-protein, additivity experiments were performed (Figure 5.3). 
When either DADLE, adrenaline or bradykinin were assayed for their ability to 
stimulate high-affinity GTPase activity on their own, DADLE always gave the 
greatest stimulation of GTPase activity, with bradykinin producing the second 
highest and adrenaline giving the lowest observable increase in high-affinity GTP 
hydrolysis of the three agonists tested (Figure 5.3, columns 1, 2 and 3). When 
either DADLE and adrenaline or DADLE and bradykinin were assayed together, no 
further increase in hydrolysis was noted as compared to the effect of DADLE on its 
own (Figure 5.3, columns 4 and 5). However, when adrenaline and bradykinin were 
assayed together, the stimulation obtained was fully additive (Figure 5.3, column 6). 
When all three agonists were included in the assay, the stimulation of GTPase 
activity observed (7.7 ± 0.1 pmoles/min/mg protein) was not greater than the 
stimulation produced by DADLE alone (7.8 ± 0.1 pmoles/min/mg protein) (mean ±
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S.D., n=4, Student's t-test P > 0.4) (Figure 5.3, columns 1 and 7). Therefore of the 
ligands tested, DADLE was capable of eliciting the maximal stimulation of GTPase 
activity on its own.
The pharmacology of action of DADLE was examined, by including the opioid 
antagonist naloxone in GTPase assays (Figure 5.4). Naloxone was capable of 
preventing DADLE mediated stimulation of GTPase activity in NG108-15 ceii 
membranes, without affecting the stimulation obtained by either adrenaline or 
bradykinin (Figure 5.4). In a similar manner, inclusion of the a-2 adrenergic 
antagonist yohimbine in GTPase assays resulted in the complete attenuation of 
adrenaline mediated GTPase stimulation with no effect on either DADLE or 
bradyklnln's ability to stimulate GTPase activity (Figure 5.5). Thus DADLE and 
adrenaline stimulate GTPase activity by interacting with a different class of receptor 
in NG108-15 cell membranes. The pharmacological profile of bradykinin receptors 
expressed by the NG108-15 cell line to date, has not been examined in detail. 
Inclusion of the &-\ agonist desArg9-bradykinin, was without effect in stimulating 
GTPase activity, when used at concentrations up to 10|iM. Inclusion of the B-i 
antagonist desArg9-[Leu8] bradykinin in GTPase assays did not attenuate bradykinin 
mediated stimulation (results not shown), suggesting that the bradykinin receptor 
capable of stimulating GTPase activity was not of the B-| designation (Regoli and 
Barabe, 1980). interestingly, the B2 selective bradykinin analogue [Thi5,8-D- 
Phe7]-bradykinin, which has been described as either having the properties of an 
agonist or antagonist, depending on the tissue under examination (Plevin and Owen, 
1988), was found to be a partial agonist, when included in GTPase assays and 
compared to the effect of bradykinin. Thus the pharmacological identification of the 
bradykinin receptor(s) expressed by NG108-15 cell remains elusive.
it is possible to stimulate adenylyl cyclase activity in NG108-15 cell 
membranes in response to a variety of ligands (Table 5.2). Measurements of cAMP 
production by NG108-15 cell membranes using both the binding assay (section 
2.14) and the two-step chromatography assay (section 2.15b) were linear when 
each assay was conducted from between 5 to 30 minutes, and over membrane protein 
concentrations of between 2 to 100 in the case of the binding assay, and between 5
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to 30 |ig for the two-step chromatography method (results not shown). Of the ligands 
tested at saturating concentrations, forskolin (10|iM), which is thought to be able to 
activate the enzyme directly and also in concert with Gsa (Ho and Shi, 1984), 
produced the greatest stimulation, followed by PGE1. NaF was also capable of 
eliciting stimulation of adenylyl cyclase in these membranes, as was manganese 
chloride (Mn CI2), albeit poorly (Table 5.2). Interestingly, when forskolin and 
PGE1 were included in the same assay, the stimulation of adenylyl cyclase obtained 
was greater than when each agent was used singly, similarly, the inclusion of 
forskolin and M nC^ in the same assay, produced a greater stimulation of adenylyl 
cyclase activity than that seen for each agonist on its own (Table 5.2). Forskolin was 
shown to stimulate adenylyl cyclase activity in the concentration range 0.1 nM to 
lOOjaM, half maximal stimulation occurred at approximately 1|iM (Figure 5.6). In a 
similar manner, PGE1 Increased adenylyl cyclase activity in NG108-15 membranes 
in a dose-dependent manner, when concentrations which ranged from 0.1 nM to lOpM 
were applied. The half maximally effective concentration was approximately 50nM 
(Figure 5.7).
In an attempt to further examine the nature of the pertussis toxin sensitive 
G-proteins with which adrenaline, DADLE, bradykinin and FCS interact, the effect of 
each agonist on adenylyl cyclase activity was assessed in NG108-15 membranes. 
Table 5.3 displays the change in activity of adenylyl cyclase in NG108-15 
membranes which have been stimulated with either forskolin or PGET The 
percentage of inhibition of adenylyl cyclase obtained by DADLE, adrenaline and 
bradykinin was in the order of 30%. For the data presented, an analysis of variance 
demonstrated that the inhibition of both forskolin and PGE1 stimulated adenylyl 
cyclase activty was not significantly different, irrespective of the ligands present in 
the assay (one-way analysis of variance, P > 0.5). in contrast to DADLE, adrenaline 
and bradykinin, FGS was unable to inhibit either forskolin or PGE1 stimulated 
adenylyl cyclase activity in these membranes, it may be noted that there is no 
additivity of inhibition when either DADLE, bradykinin or adrenaline are present in 
combination. Each agonist is fully capable of inhibiting adenylyl cyclase activity on
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its own, when used at a saturating concentration (Table 5.3).
Since G-protein stimulation by each of DADLE, bradykinin and adrenaline was 
pertussis toxin sensitive, as assessed by GTPase activity (Figure 5.2), it was 
expected that the inhibition of adenylyl cyclase activity elicited by these agonist 
would also be pertussis toxin sensitive. This was shown to be the case (Figure 5.8).
In membranes produced from untreated NG108-15 cells, DADLE, bradykinin and 
adrenaline were able to inhibit forskolin (IO11M) stimulated adenylyl cyclase 
activity by approximately 30%, In close agreement with earlier observations (Table 
5.3). However, pretreatment of NG108-15 cells in vivo with pertussis toxin 
abolished the ability of each of DADLE, adrenaline and bradykinin to inhibit adenylyl 
cyclase. Pertussis toxin pretreatment was routinely noted to produce a significant 
increase In the basal adenylyl cyclase activity from 41.0 ± 2.8 pmol/min/mg 
protein in membranes produced from untreated cells, to 62.0 ±2.5 pmol/min/mg 
protein in membranes from pertussis toxin treated cells (means ± S.D., n=4) 
(Student's t-test, P < 0.005). In addition, forskolin (lO jiM ) stimulated adenylyl 
cyclase activity was significantly higher in membranes prepared from pertussis 
toxin pretreated cells, 650 ± 7.8 pmol/min/mg protein, compared to 600 ± 9.8 
pmol/min/mg protein in membranes prepared from untreated NG108-15 cells 
(means ± S.D., n=4) (Student's t-test, P < 0.05). The inhibition of adenylyl cyclase 
produced by DADLE was dose dependent within the concentration range 0.1 nM to 
lOpM, the concentration of DADLE which elicited 50% of the maximal Inhibition 
which could be attained by this ligand was approximately 5nM (Figure 5.9). ‘ 
Similarly, the inhibition of adenylyl cyclase produced by bradykinin was dose 
dependent, within the concentration range InM to lOOpM, the concentration of 
bradykinin which elicited 50% of the maximal inhibition which could be attained by 
this ligand was approximately 50nM (Figure 5.10). The inhibition of adenylyl 
cyclase produced by adrenaline showed a similar profile to that obtained with 
bradykinin, within the concentration range InM to lOOpM, the concentration of 
adrenaline which elicited 50% of the maximal inhibition which could be attained by 
this ligand was approximately 50nM (Figure 5.11).
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It can be noted in Table 5.3, that the ability of saturating concentrations of 
DADLE, adrenaline and bradykinin to inhibit either forskolin (lOpM) or PGE1 
(10 |liM) stimulated adenylyl cyclase activity was not additive, maximum inhibition 
was obtainable by each agonist on its own. To examine the lack of additivity of 
inhibition of adenylyl cyclase, the concentrations of each of DADLE, adrenaline and 
bradykinin which produced 50% of the maximal inhibition of adenylyl cyclase which 
could be produced by each ligand (Figures, 5.9, 5.10, 5.11) were employed in 
additivity studies (Figure 5.12). On its own, each agonist produced approximately 
50% of the maximal inhibition of forskolin stimulated adenylyl cyclase which could 
be obtained by that ligand (DADLE, 16 ± 0.5 %; bradykinin, 13 ± 0.5 %; 
adrenaline, 14 ± 0.5 % inhibition, mean ±S.D., n=3) (Figure 5.12, columns, B, C, 
D). When any of the two agonists were used in combination, the inhibition of adenylyl 
cyclase activity obtained was significantly greater than the Inhibition obtained by 
each agonist on its own (DADLE + bradykinin, 21 ± 0.9 %; DADLE + adrenaline, 23 
± 0.5 %; bradykinin + adrenaline, 25 ± 0.4 % inhibition) (Figure 5.12, columns 
E, F, G) (one way analysis of variance, P < 0.05). When all three agonists were 
present(Figure 5.12, column H), the inhibition of adenylyl cyclase activity obtained 
(32 ± 0.9 %, mean ± S.D., n=3) was similar in magnitude to the inhibition of 
adenylyl cyclase which could be obtained by each agonist on its own, when used at a 
saturating concentration (Table 5.3). Thus the ability of each of DADLE, bradykinin 
and adrenaline to inhibit adenylyl cyclase was additive, when each ligand was used at 
a concentration which did not elicit the maximal inhibition of adenylyl cyclase which 
could be produced by that ligand.
Returning to Table 5.2, it can be noted that the stimulation of high affinity 
GTPase activity produced by FCS was greater than all other ligands tested, with the 
exception of the opioid peptides, DADLE and DALAMID. In addition, both FCS and 
DADLE have been demonstrated to stimulate the GTPase activity of pertussis toxin 
sensitive G-proteins (Figure 5.2). It was thus decided to address the specificity of 
interaction between each of these ligands. Stimulation of high affinity GTPase activity 
by DADLE (Figure 5.13a) occurred over concentrations between 0.1 nM and Ip-Mand 
was half maximal at 5nM (Fig 5.13a) Absolute values of the high affinity GTPase 
activity were increased by some 12.5 ± 0.8 pmol/min/mg protein by maximal
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concentrations of the opioid peptides (mean ± S.D., n=4). Foetal calf serum 
stimulation of high-affinity GTPase activity in these same membranes occurred 
between 0.01 and 20% (v/v) foetal calf serum and was half maximal at 0.8% (v/v) 
(Figure 5.13b). Maximal increases in high-affinity GTPase activity in response to 
foetal calf serum were 6.3 ± 1.0 pmol/min/mg of membrane protein (mean ± S.D., 
n = 4).
Membranes of pertussis toxin treated cells displayed decreased basal high-affinity 
GTPase activity, as described previously for the data shown in Figure 5.2, and the 
residual high-affinity GTPase activity was no longer stimulated by either the opioid 
peptide DADLE (Figure 5.13a) or foetal calf serum (Figure 5.13 b).
NG 108-15 cells are known to express three different pertussis toxin 
sensitive G-proteins, Gi2, GiS and Go, as detailed in chapter 3. To examine whether 
both DADLE and foetal calf serum caused stimulation of the GTPase activity of the 
same pertussis toxin sensitive G-protein, additivity studies were performed. When 
dose response curves of GTPase stimulation by foetal calf serum were carried out in 
the presence or absence of a single concentration of DADLE (10|iM) which had 
previously been shown to produce a maximal increase in GTPase activity, then the 
response to foetal calf serum was unaltered (Figure 5.14a). The response was 
merely shifted to higher high affinity GTPase activity owing to the stimulation 
produced by the opioid ligand. In the reciprocal experiment, high-affinity GTPase 
activity was measured in response to increasing concentrations of DADLE, in the 
absence or presence of 20% (v/v) foetal calf serum (Figure 5.14 b). This produced 
similar results to that obtained in Figure 5.14a, indicating that stimulation of high- 
affinity GTPase activity by foetal calf serum and opioid peptides was fully additive. 
As detailed in Table 5.3, DADLE produced inhibition of adenylyl cyclase with-a 
similar concentration dependence to that required for stimulation of GTPase activity 
(Fig 5.9). In contrast however, foetal calf serum did not modulate adenylate cyclase 
activity at concentrations up to 20% (v/v), which produced a maximal stimulation 
of GTPase activity (Table 5.3). Thus, DADLE and foetal calf serum interact with 
receptors which stimulate two different classes of pertussis toxin sensitive G- 
protein; the receptor for DADLE interacts with the G-protein mediating Inhibition of
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adenylyl cyclase, whereas the receptor for foetal calf serum interacts with a 
different pool of G-proteins which do not inhibit adenylyl cyclase and by extension, 
represent a different class of G-protein.
When NG108-15 cell membranes were pre-incubated for 1 hour at 37°G 
with a synthetic decapeptide which was 100% homologous to the last ten C-terminal 
amino-acids of Id a  (KENLKDCGLF), and was one amino-acid different to the last ten 
C-terminal amino-acids of Gi2a (KNNLKDGGLF) (where the highlighted residue is 
not present in the Tda peptide), the ability of DADLE to stimulate GTPase activity is 
reduced by approximately 60%, from 6.33 ± 0.2 pmoles/min/mg protein in the 
absence of peptide, to 2.96 ± 0.1 pmoles/min/mg protein in the presence of Tda 
peptide (means ± S.D., n=4) (Figure 5.15a). In contrast, pre-incubation of the 
same membranes with a synthetic decapeptide 100% homologous to the extreme G- 
terminal region of Goa (ANNLRGGGLY) had no effect on the ability of DADLE 
stimulate GTPase activity (Figure 5.15b). Basal high affinity GTPase activity in the 
absence of added peptide (15.8 ± 1.0 pmoles/min/mg protein) was unaltered by the 
addition of either Tda peptide (14.9 ± 0.3 pmoles/min/mg protein) or Goa peptide 
(15.9 ± 0.5 pmoles/min/mg protein), (means ± S.D., n=4. Student's t-test, P > 0.5 
and P > 0.6 respectively), (Figure 5.15 a,b).
Immunoblotting membranes of NG108-15 cells with antiserum AS7 detected 
a polypeptide of some 40kDa, which has been defined as being the a-subunit of Gi2 
(chapter 3, Figure 3.3). Affinity purified antibodies from antiserum AS7 also 
recognized the a-subunit of Gi2 (chapter 3, Figure 3.4). Pre-Incubation of 
NG108-15 membranes for 1 hour at 37°G with a 1:100 dilution in normal rabbit 
serum of antibodies which had been affinity purified from antiserum AS7 completely 
abolished the ability of DADLE to stimulate high-affinity GTPase activity, but had 
little effect on the foetal calf serum stimulation of high-affinity GTPase activity 
(Table 5.4). Basal GTPase activity of the membranes was not inhibited by the 
affinity purified antibodies, and in a number of experiments the basal GTPase 
activity was higher after preincubation in the presence of normal rabbit serum than 
in its absence. Preincubation of the membranes with normal rabbit serum alone did 
not produce an attenuation of the response to DADLE (Table 5.4). Greater dilutions of
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the affinity purified antibodies into normai rabbit serum decreased the antibody- 
mediated attenuation of opioid stimuiation of GTPase activity (Figure .5.16), half- 
maximal effects of the antibodies affinity purified from AS7 were achieved at a 
1:1000 dilution and were completely abolished at a 1:10.000 dilution (Fig 5.16). 
Preincubation of NG108-15 membranes at 37^C induced a time-dependent ioss of 
both basal and opioid -stimulated high-affinity GTPase activity (Figure 5.17). After 
a pre-incubation of 2 hours, there was a 30% reduction in basal GTPase activity 
from 9.6 ± 0.2 pmoles/min/mg protein to 5.4 ± 0.7 pmoles/min/mg protein and a 
75% loss of DADLE stimulated GTPase activity from 6.6 ± 0.4 pmoles/min/mg 
protein to 1.4 ± 0.2 pmoles/min/mg protein (means ± S.D., n=4), suggesting that a 
proportion of both the G-protein and receptor pool was being inactivated with time.
A more detailed attempt to identify the G-protein species that the 5-opiate 
receptor activates, involved the use of IgG fractions which were purifed from each of 
normal rabbit serum, and antisera AS7, I3B, 0C1, and CSI by passage over protein 
A-sepharose as described in chapter 2, section 9. The IgG fractions displayed the 
same specificity as the original antiserum as defined by immunoblotting procedures 
(chapter 3, Figure 3.5 and results not shown). Membranes of untreated NG108-15 
cells were preincubated with these IgG fractions for 60 minutes at 37°C 
(concentrations corresponding to a 1: 100 dilution of the original antiserum), as 
detailed in section 2.13. Subsequently the ability of a receptor-saturating 
concentration of DADLE (IjiM ) to stimulate high-affinity GTPase activity was 
ascertained. Following treatment of the membranes with the IgG fraction from non- 
immune rabbits, DADLE stimulated high-affinity GTPase activity over the basal 
level (4.7 ± 0.3 pmol/min/mg protein, mean ± S.D., n=4) to the same degree as in 
the absence of the non-immune IgG fraction. IgG fractions from each of 0C1 (anti- 
C^a) (4.1 ± 0.3 pmoi/min/ mg protein. n=4), I3B (anti-GjSa) (4.6 ± 0.4 
pmol/min/mg protein, n=4) and CSI (anti-Ggoi) (4.3 ± 0.3 pmol/min/mg 
protein, n=4) did not affect the function of the opioid peptide. However, the IgG 
fraction purified from antiserum AS7 (anti-G jIa andGj2a ) completely attenuated 
the ability of the agonist to stimulate the high affinity GTPase activity (0.1 ± 0.1 
pmol/min/mg protein, n=4) (Figure 5.18).
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In contrast to receptor-stimulated GTPase activity, the IgG fraction of antiserum 
AS7 did not modulate the basal high-affinity GTPase activity (AS7, 10.5 ± 0.2 
pmol/min/mg protein, n=4, normal rabbit serum, 9.9 ± 0.2 pmol/min/mg protein, 
n=4 ) or the non-G-protein related, low-affinjty GTPase activity of these 
membranes. The same was true of the IgG fractions of all of the antisera employed in 
this study (Figure 5.18). As such, the effect of the IgG fraction of antiserum AS7 was 
solely to prevent receptor activation of high affinity GTPase activity.
If productive coupling between G-protein and receptor has been attenuated, 
then coupling of receptor to effector should also be attenuated. To address this 
question, NG108-15 membranes were incubated for 1 hour with either an IgG 
fraction isolated from normal rabbit serum, or an IgG fraction isolated from 
antiserum AS7. After this preincubation, the inhibition of forskolin stimulated 
adenylyl cyclase activity, in NG108-15 cell membranes by DADLE, which was some 
35% in both the presence and absence of IgG derived from normal rabbit serum, was 
also completely attenuated by preincubation of the membranes of NG108-15 cells 
with a 1:100 dilution of the IgG fraction from antiserum AS7 (Table 5.5). Indicating 
that the opioid receptor was no longer able to alter the activity of adenylyl cyclase.
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Discussion
The Identification of the stimulatory G-protein, Gs, as a protein involved in 
the regulation of adenylyl cyclase activity and the realization that certain hormones 
mediated a GTP dependent inhibition of adenylyl cyclase, led to the hypothesis that a 
similar protein might be involved in the inhibitory regulation of adenylyl cyclase 
(Rodbell, 1980). The purification of Gs, and later Gi, led to the suggestion that a 
wide variety of second messenger regulating effector systems might require a G- 
protein. Recently improved protein purification protocols, along with cDNA cloning 
techniques have revealed that a large family of G-proteins exists (Stryer and 
Bourne, 1987; Clapham and Neer, 1988; Gilman, 1987). These share extensive 
structural homology, indeed amino-acid homology varies from 94% identity between 
G il and G|3 to 68% between Gi2 and Go (Jones and Reed, 1987). On this basis it is 
pertinent to ask whether each of these G-proteins are able to serve distinct functions 
or whether they might be more appropriately viewed as isozymic forms. The 
situation has now been reached where the heterogeneity of G-protein a-subunlts has 
in all probability exceeded the variety of effectors with which they may interact 
(Spiegel, 1987). However, this may simply be a reflection of the massive increase 
in G-protein research in recent years.
In view of the burgeoning numbers of G-proteins available to a cells' signal 
transduction apparatus, it is of prime concern to address the question, are individual 
G-protein species selective in their interactions with protein components of the 
signal transduction cascade, or are G-proteins more promiscuous, being able to 
interact with a wide variety of receptors and effectors. One of the earliest techniques 
employed to examine specificity of receptor to G-protein coupling was the 
reconstitution of purified G-protein and receptor into artificial phospholipid 
vesicles. Functional coupling was observed by the ability of agonist to stimulate 
either high-affinity GTPase activity (Pederson and Ross, 1982), or the binding of 
[35g]GTP'yS (Kurose et al., 1986). Such studies have suggested that Gsa is rather 
specific in that it interacts selectively with receptors which stimulate adenylyl 
cyclase activity but is barely able to interact with either the photon receptor.
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rhodpsin, or the a 2-adrenergic receptor (Cerione et al., 1985; Cerlone et al.,
1986). However It has also been demonstrated that rhodopsin can couple effectively 
with transducin, Gi and Go (Cerione et al., 1985; Cerione et al., 1986). Some 
specificity is preserved in that Gs is more efficient in coupling to the p-adrenergic 
receptor and transducin is relatively ineffective (Cerione et al., 1985).
Surprisingly, Ross and co-workers have demonstrated that p-adrenergic receptors, 
which serve to stimulate adenylyl cyclase and can also stimulate certain classes of 
Ca2+ channel, interact not only with Gs (as expected), but also with Gi (Asano et al.,
1984). More recently, the D2 dopamine receptor has been purified from anterior 
pituitary, where it mediates inhibition of adenylyl cyclase (McDonald et al., 1984), 
and reconstituted into phospholipid vesicles along with purified G il, Gi2, Gi3 and Go 
(Senogles et al., 1990). The G-proteins were isolated from either; bovine brain 
(G il, Gi2, Go), anterior pituitary (GI2) or human erythrocyte (Gi3), and their 
identity and apparent purity established by Western blotting with G-protein subtype 
specific antipeptide antibodies. The D2 receptor was demonstrated to be able to 
functionally interact with each G-protein, as assessed by the stimulation of either 
[35s]GTPyS binding or high affinity GTPase activity, with the exception of Go. 
However, the Go employed was functionally active, as it was able to be stimulated 
after reconstitution with purified rhodopsin. Gi2 was found to couple to the D2 
receptor with a ten fold higher affinity than any other Gi subtype. The source of Gi2 
was not critical as brain and pituitary proteins were Indistinguishable in their 
ability to couple to the D2 receptor. This demonstrates that the D2 dopamine 
receptor may be selective in its interaction with G-proteins, and couple 
preferentially with Gi2 (Senogles et al., 1990).
In addition to the reconstitution of purified G-proteins into phospholipid 
vesicles, it is possible to reconstitute functionally active G-proteins into purified 
plasma membranes, indeed the ability to reconstitute adenylyl cyclase stimulation to 
849 eye- membranes was employed in the initial purification of Gs (Northup et al., 
1980). In HL 60 cells, the chemotactic peptide formyi-methionyl-leucyl- 
phenylalanine (F-Met-Leu-Phe) stimulates the rate of hydrolysis of inositol 
containing phopholipids in a pertussis toxin sensitive manner, thus defining a role
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for a pertussis toxin sensitive G-protein In mediating the response (Ohta et al.,
1985). The addition of both purified Gi and Go to plasma membranes produced from 
cells which had been pretreated with pertussis toxin to inactivate the endogenous 
pertussis toxin sensitive G-proteins, was demonstrated to reconstitute receptor 
mediated inositol phospholipid hydrolysis. Gi and Go were found to be equally 
efficacious in reconstituting the response (Kikuchi et al., 1986). In rat brain 
membranes, the di-peptide kyotorphin (Tyrosine-Arginine) binds to specific 
receptors and stimulates both high-affinity GTPase activity and the activity of 
phosphoinositidase C, in a pertussis toxin sensitive manner (Ueda et al., 1989). it is 
possible to reconstitute kyotorphin mediated stimulation of both GTPase activity and 
phosphoinositidase C in pertussis toxin pretreated membranes by the addition of 
purified G-proteins. Interestingly, activity was recovered by reconstituting with Gi, 
but not with Go. The failure of Go to interact with the kyotorphin receptor was not as 
a result of the G-protein undergoing inactivation during the purification procedure, 
since the purified Go was demonstrated to possess GTPase activity This suggests that 
some specificity is maintained In the ability to reconstitute interaction with 
receptor (Ueda et al., 1989).
As mentioned in chapter 3, when NG108-15 cells are differentiated to a more 
neuronal-like cell type, they express voltage operated Ca2+ channels (Tsunoo et al.,
1986) which are inhibited by agonist occupation of both 8-opioid and a- 2 
adrenergic receptors, and stimulated by the addition of non-hydrolysable guanine 
nucleotides. In a pertussis toxin sensitive manner (McFadzean et al., 1989). The 
addition of purified G-proteins to whole NG108-15 cells using the whole cell clamp . 
technique allows reconstitution of 8-opioid receptor mediated inhibition of the 
calcium current. The a-subunit of purified Go was found to be more efficacious than 
purified Gia in its ability to restore the response, suggesting that Go is involved in 
the coupling of specific receptors to neuronal voltage dependent calcium channels 
(Hescheler et al., 1987)
Reconstitution studies with purified proteins have therefore yielded 
contradictory results. In studies where the Identity and purity of the G-proteins 
involved have been rigorously assessed, G-proteins appear to be selective in their
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ability to interact with receptor. However, the majority of reconstitution studies 
imply that some members of the G-protein family are functionally interchangeable 
In their ability to interact with both receptor and effector. As detailed in chapter 1, 
the pertussis toxin sensitive G-proteins are highly homologous at the primary 
sequence level and as such, It may be expected that the domains of functional 
interaction between G-protein and other protein members of the signal transduction 
system are highly conserved between different members of the G-protein family 
(Masters et al., 1986). It is not unreasonable to suggest that when both G-proteins 
and receptors are removed from their normal enviroment and inserted into either 
artificial phospholipid vesicles or plasma membranes where they would not 
normally be expressed, that the specificity of Interaction may be adversely affected. 
In addition, analysis of the above data is absolutely dependent on the purity of the G- 
protein and receptor fractions employed. The increasing variety of G-proteins which 
can now be identified in any given tissue has only recently been appreciated, as has 
the difficulty in resolving individual members of the G-protein family using current 
purification protocols (Yatani et ai., 1988c). The majority of G-proteins used in 
reconstitution studies have been purified from brain, a tissue now known to express 
at least five different immunologically identifiable pertussis toxin substrates; G il, 
Gi2, Gi3 and at least two forms of Go (Jones and Reed, 1987; Goldsmith et al., 1988) 
It is therefore pertinent to suggest that some purified G-protein fractions employed 
for reconstitution work were in fact mixtures of a variety of highly homologous G- 
proteins, this would of course cast doubt on the results obtained in reconstitution 
systems.
In contrast to the lack of G-protein-receptor specificity observed when 
purified proteins are reconstituted into either phospholipid vesicles or toxin pre­
treated plasma membranes, in native membrane systems, there appears to be tight 
regulation of G-protein coupling. Receptors which are known to interact with 
different effectors do so through the activation of different G-proteins, as assessed 
by the additivity of response to ligands which stimulate GTP hydrolysis (Houslay et 
al., 1986a, b; McKenzie et al., 1988a, b). The rationale for performing GTPase 
additivity experiments is that the activation of the entire population of receptors in
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a membrane preparation with a saturating concentration of a full agonist will 
prospectively lead to the activation of the full complement of G-protein(s) present 
with which that receptor is able to interact. Thus additivity of receptor stimulated 
GTPase activity following the addition of two agonists which interact with 
independent receptors, would indicate the activation of separate pools of G-protein, 
and by extension, different G-proteins. This method has been utilised to examine a 
wide range of receptor-G-protein interactions in human platelets and has led to the 
conclusion that PGE1, adrenaline (in the presence of a p-adrenergic receptor 
antagonist) and vasopressin all stimulate GTPase activity through the activation of 
different species of G-protein (Houslay et al., 1986a, b).
The model system chosen to address the question of G-protein specificity was 
the NG108-15 cell line. Prior to undertaking an examination of the signalling 
pathways which may be assayed in this cell line, the G-protein complement was 
firstly defined. In chapter 3, it has been demonstrated, that within the limits of 
detectability, NG108-15 cells express two forms of the stimulatory G-protein Gs, 
along with three pertussis toxin sensitive G-proteins, Gi2, Gi3 and Go. Gi1 is either 
not expressed, or expressed in amounts not detectable with current western and 
northern blotting techniques. NG108-15 cells express a wide variety of receptors 
linked to the stimulation and inhibition of adenylyl cyclase (Klee et al., 1985), 
stimulation of phosphoinositidase C (Higashida et al., 1986) as well as inhibition of 
voltage operated Ca2+ channels (McFadzean et al., 1989). Therefore the G-protein 
which mediates the inhibition of adenylyl cyclase must be either Gi2, GI3, Go, or a 
combination therof. To unambiguously identify the G-protein which mediates the 
inhibition of adenylyl cyclase, it is necessary to either block or delete the normal 
pathway. It is possible to block the normal pathway of adenylyl cyclase inhibition 
using pertussis toxin, however since the toxin will modify Gi2, Gi3 and Go in 
NG108-15 cells, it is not possible to identify which of these pertussis toxin 
sensitive G-proteins is required for receptor mediated inhibition of adenylyl 
cyclase.
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The studies described in this chapter have attempted to block the regulation of 
adenylyl cyclase by the 6 opioid receptor of neuroblastoma x glioma hybrid, NG1 OB­
IS, cells with antisera which are directed against, and can specifically recognise the 
extreme C-terminus of the a subunit of the various G-proteins. This C-terminal 
region has been focussed upon since it appears to be the domain of functional 
interaction with receptor (as detailed in chapter 1). It was therefore hoped that it 
would prove possible to attenuate productive coupling between G-protein and 
receptor by placing an antibody on the extreme C-terminal region of the G-protein 
a-subunit.
All G-proteins are GTP hydrolysing enzymes (Gilman, 1987). As such, 
high-affinity GTPase activity in a membrane preparation is usually simple to 
assess, particularly when pertussis toxin sensitive G-proteins are known to be 
expressed. The ligands DADLE, adrenaline, bradykinin and PCS, are able to 
functionally interact with a 8-opioid , a 2 adrenergic, bradykinin and a poorly 
characterised growth factor receptor respectively in this cell line. Each ligand is 
capable of stimulating high-affinity GTPase activity in NG108-15 cell membranes 
in a pertussis toxin sensitive manner, thus allowing an assessment of specificity to 
be made. It may be noted that in this cell line, pretreatment with pertussis toxin, as 
well as preventing receptor stimulation of GTPase activity by DADLE, adrenaline, 
bradykinin and PCS, also reduces the basal hydrolysis of GTP by high affinity 
GTPases (Figure 5.11 a, b). By contrast, non-specific hydrolysis of GTP was 
unaffected (results not shown). The effect of ADP-ribosylation of Gi by pertussis 
toxin is believed solely to prevent coupling between receptor and G-protein, indeed 
in the presence of the non-hydrolysable analogue of GTP, Gpp(NH)p it is still 
possible for Gia to dissociate from the p,y subunits (Katada et al., 1986) and inhibit 
adenylyl cyclase (Gosse et al., 1989). After pertussis toxin pretreatment of 
NG108-15 cells, there is no reduction in the levels of either Gi (Law et al., 1985b, 
and results not shown), or in the levels of either the a -2 adrenergic, 8 -opioid 
(Kurose et al., 1982) or bradykinin (Osugi et al., 1987) receptors expressed by 
NG108-15 cells. As such it is difficult to explain the reduction in basal GTPase 
activity seen after pertussis toxin pretreatment. In addition to the effect of pertussis 
toxin on the basal hydrolysis of GTP, pretreatment of NG108-15 cells with the toxin
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was noted to produce an increase in both basal and forskolin stimulated adenylyl 
cyclase activity, when compared to control membranes. A possible explanation is that 
the unoccupied receptor is capable of G-protein activation, which would result in 
both a stimulation of GTPase activity and a concurrent inhibition of adenylyl cyclase. 
According to the original ternary complex model of interaction between agonist, 
receptor and G-protein, agonists but not antagonists promote the association of 
receptor to G-protein in membrane systems. The resulting complex can be de­
stabilised by the addition of guanine nucleotides such as GTPyS and Gpp(NH)p 
(DeLean et al., 1980). The intrinsic activity of a ligand is therefore seen to 
represent its ability to stabilise the ternary complex of ligand, receptor and G- 
protein, and will range from null values for antagonists to positive values for partial 
and full agonists (DeLean et al., 1980). However binding studies on muscarinic 
(Burgisser et al., 1982), D2-dopaminergic (DeLean et al., 1982), and A1- 
Adenosine receptors (Green, 1984), reveal a more elaborate effect of guanine 
nucleotides, where agonist and antagonist binding to these receptors may be 
modulated in a reciprocal manner. To include these observations, the ternary 
complex model was altered to allow for the ability of an antagonist to be able to 
promote dissociation of the ternary complex (Wregget and DeLean, 1984). When 
purified G-proteins are reconstituted into phospholipid vesicles in the absence of 
receptor or effector, it is possible to measure high-affinity GTPase activity. Upon 
addition of purified receptor, an increase in the ability of the G-protein to 
hydrolysed GTP is observed, suggesting that an unoccupied receptor is capable of G- 
protein activation. The spontaneous association of empty receptor with G-protein 
may account for both the basal high-affinity GTPase activity and for the tonic 
inhibition of adenylyl cyclase activity which is observable in membrane systems. 
Receptor purification data support the argument for an interaction of unoccupied 
receptor with G-protein, since both D-2 dopamine and a -2 adrenergic receptors 
co-purify with a tightly bound G-protein (Senogles et al., 1987; Regan et al.,
1 9 8 6 ).
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In further reconstitution experiments, it has been demonstrated that the 
inclusion of antagonist can inhibit receptor mediated G-protein activation in the 
absence of agonist (Cerione et a!., 1984). Recently, it has been demonstrated in 
membranes produced from NG108-15 cells, that there are two types of antagonist 
for the 6 -opioid receptor, antagonists with null activity, and antagonists which are 
capable of preventing interaction of receptor with G-protein. The latter was assessed 
by the ability of the 6 -opioid antagonist 10! 174864 to inhibit basal high-affinity 
GTPase activity in NG108-15 cell membranes (Costa and Herz, 1989). It is thus 
possible to speculate that both the reduction in basal high-affinity GTPase activity 
and the increase in both basal and forskolin stimulated adenylyl cyclase activity 
produced by pretreatment with pertussis toxin is a consequence of Gi's inability to 
interact with unoccupied 6-opioid receptor after being modified by ADP- • 
ribosytatlon.
As mentioned earlier, GTPase additivity experiments provide a means of 
determining whether different classes of receptor interact with different species of 
G-protein, When additivity experiments are carried out using saturating 
concentrations of each of DADLE, adrenaline and bradykinin, then some degree of 
additivity is obtained. The maximal stimulation of GTP hydrolysis is achieved by 
DADLE on its own. The presence of all three ligands does not give a further increase. 
However, adrenaline and bradykinin, which separately are poor stimulators of 
GTPase activity (Figure 5.3), when used in combination, give an additive response. 
This data may be interpreted in several ways; firstly, adrenaline and bradykinin 
although interacting with the same G-protein, are incapable of activating the entire 
pool of G-protein with which the receptors for each ligand interacts, secondly, that 
two receptors exist for DADLE, with each receptor interacting with a different pool 
of G-proteins or lastly, the 6-opioid receptor is capable of interacting with two 
separate pools of G-protein.
When additivity experiments are conducted with DADLE and FCS, a different 
picture emerges, the two ligands are perfectly additive, suggesting that the receptor 
for each of these ligands interacts with a different pool of G-proteins and by 
extension, different G-protein species. When the ability of each of DADLE,
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adrenaline, bradykinin and FCS to inhibit forskolin or PGE1 stimulated adenylyl 
cyclase activity in NG108-15 cell membranes is determined, of the three ligands, 
only FCS is incapable of mediating inhibition, thus adding more weight to the 
hypothesis that DADLE and FCS do not function through activation of the same G- 
protein species. DADLE, adrenaline and bradykinin all inhibit adenylyl cyclase. 
activity in a pertussis toxin sensitive manner. It may be noted that each ligand is 
capable of acheiving the maximal inhibition of adenylyl cyclase when used on its own, 
when the three ligands are used in combination further inhibition is not observed.
An important aspect to be addressed is that of receptor heterogeneity. 
NG108-15 cells are thought to express only a single population of receptors for 
opiates, of the 6-classification. This rationale allowed ease of purification of the 6- 
opioid receptor from this cell line (Simonds et al., 1985). Fewer pharmacological 
studies have foccussed on the a 2 adrenergic receptors expressed by NG108-15, 
however it is apparent that only a single population of a 2 adrenergic receptors is 
expressed of the a2-B classification (Bylund, 1988). The nature of the bradykinin 
receptor(s) expressed by NG108-15 cells is poorly defined. If we examine the 
intracellular effector systems modulated by the binding of DADLE, adrenaline and 
bradykinin to their receptors on NG108-15 cells, we see that in addition to the 
ability to inhibit adenylyl cyclase, bradykinin, in contrast to both DADLE and 
adrenaline, is also able to stimulate an increase in the rate of hydrolysis of inositol 
containing phospholipids (Higashida et al., 1986; F.M. Mitchell, unpublished). 
Bradyklnin’s ability to stimulate phospholipase C is pertussis toxin insensitive 
(Osugi et al., 1987), which is in marked contrast to the ligands ability to inhibit 
adenylyl cyclase. This suggests that either NG108-15 cells express more than one 
type of bradykinin receptor, or NG108-15 cells express a single class of bradykinin 
receptor which is capable of interacting with two distinct G-proteins. One of the G- 
protein species is pertussis toxin sensitve and one is not. The B-| receptor agonist 
desArg-bradykinin is incapable of stimulating either GTPase activity in NG108-15 
cell membranes (results not shown), or of stimulating an increase in the rate of 
hydrolysis of Inositol containing phospholipids in NG108-15 cells (R.J.PIevin, 
personnel communication).If NG108-15 cells express two different bradykinin
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receptors, then there is a rationale-to suggest that each type of receptor is capable of 
Interacting with different effector systems and would do so.through the activation of 
different species of G-protein. It would appear that if heterogeneity exists, then 
NG108-15 cells express more than one type of receptor.
Since DADLE, adrenaline and bradykinin are capable of full inhibition of 
adenylyl cyclase, it is of interest to note that the three ligands do not produce the 
same stimulation of GTPase activity. It may be suggested that full G-protein 
activation is not required for each receptor to maximally inhibit adenylyl cyclase, 
this would be apparent when dose-reponse curves of adenylyl cyclase inhibition 
were compared to the extent of receptor occupancy. In hepatocytes, the ability of 
vasopressin to stimulate the hydrolysis of inositol containing phospholipids occurs 
over a concentration range of 5nM to 1|iM. The EC 50 value for the response is 
approximately 50nM. However when the physiological response, the activation of 
phosphorylase. Is examined, the EC 50 value for phosphorylase activation by 
vasopressin is at least one log order lower than that required for phosphoinositidase 
C activation, suggesting that full receptor and hence full G-protein activation may 
not be required in order to obtain the maximal effect on the intracellular effector 
system under study.(Creba et al., 1983). When dose response curves for inhibition 
of adenylyl cyclase are analysed, the half maximally effective concentration of DADLE 
in inhibiting adenylyl cyclase (I.C. 50) (5nM) is very similar to the half maximally 
effective concentration of DADLE in stimulating GTPase activity (5nM). In addition, 
the concentration of [^H]DADLE which is required to occupy 50% of the available 5- 
opioid receptors on NG108-15 cell membranes is approximately 2nM (see chapter 
6, Figure 6.3). These data argue that receptor occupancy of half the available 
receptors for DADLE leads to activation of 50% of the G-proteins which may interact 
with the receptor and hence gives 50% of the maximal inhibition of adenylyl cyclase 
obtainable through maximal agonist occupancy of the 5-opioid receptor. Thus full 
agonist occupancy of the 5-opioid receptor is required to produce both the maximal 
stimulation of GTPase activity and the maximal inhibition of adenylyl cyclase. 
Unfortunately, the stimulation of GTPase activity produced by adrenaline and 
bradykinin in NG108-15 cell membranes is so low that useful dose-response data of
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GTPase stimulation could not be obtained. Hence, although it may be suggested that 
maximal stimulation of GTPase activity by the receptors for both adrenaline and 
bradykinin is required for maximal inhibition of adenylyl cyclase, the inability of 
both bradykinin and adrenaline to produce a stimulation of GTPase activity which is 
comparable to that produced by DADLE means that this remains an open question. 
When concentrations of DADLE, adrenaline and bradykinin which produce 50% of the 
maximal inhibition of adenylyl cyclase which may be elicited by each agonist are 
used in combination, the inhibition of adenylyl cyclase activity obtained is greater 
than that obtained when each ligand is used singly. The presence of ali three ligands at 
half-maximally effective inhibitory concentrations gives an even greater inhibition 
of adenylyl cyclase, comparable with the Inhibition produced by a saturating 
concentration of any of the three ligands. This data may be explainable by each ligand 
activating a different species of G-protein, however this is not borne out by the lack 
of GTPase additivity seen with DADLE and adrenaline and with DADLE and bradykinin 
(Fig 5.3). A simpler explanation for additivity of adenylyl cyclase inhibition by 
half-maximally effective concentrations of DADLE, adrenaline and bradykinin is that 
the receptors for each ligand are activating the same G-protein species, so that by 
mass action, the greater the number of agonist occupied receptors, the greater the 
G-protein activation and hence the greater the inhibition of adenylyl cyclase activity 
obtained.
The use of synthetic peptides to identify domains of functional interaction 
between the G-protein a-subunit and other protein components of the signal 
transduction process has been employed by several groups (Takemoto et al., 1985; 
Hamm et al., 1988; Palm et al., 1990). Peptides which correspond to the C- 
terminai region of rhodopsin have been demonstrated to inhibit rhodopsin stimulated 
GTPase activity, whilst peptides corresponding to external loop regions were without 
effect. This suggested that a region of rhodopsin close to the C-terminus was required 
for coupling to transducin, a result which is not in total agreement with the current 
opinion that the site of interaction between receptor and G-protein is the third 
intracellular loop (see chapter 1) (Takemoto et a!., 1985). A similar set of 
experiments have demonstrated that synthetic peptides corresponding to two regions 
of the a-subunit of transducin close to the C-terminus were capable of competing
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with transducin for rhodopsin, as assessed by the the ability of transducin to 
stabilise the active metarhodopsin II conformation of rhodopsin (Hamm et al,,
1988). Synthetic peptides homologous to the last sixteen C-terminal amino-acids of 
Gsa, Gi1 a , Goa and Tda have been employed in turkey erythrocyte membranes in an 
attempt to prevent receptor mediated stimulation of adenylyl cyclase activity. 
Preincubation of the turkey erythrocyte membranes for 60 minutes at 4°C with the 
peptide homologous to the C-terminus of Gsa, had little effect on AIF^- stimulated 
adenylyl cyclase activity, but abolished isoproterenol mediated stimulation of 
adenylyl cyclase. In contrast, preincubation with the peptides homologous to the C- 
terminus of Gi1 a, Goa and Tda were without effect (Palm et al., 1990),
The main thrust of these data is to demonstrate that it is possible to examine 
G-protein functional domains using synthetic peptides which correspond to suitable . 
regions on the G-protein a -subun it.
The extreme C-terminal region of the G-protein a-subunit is the site of 
functional interaction with receptor (chapter 1). As such it was felt that anything 
which may disrupt or compete with the G-protein for the receptor at the site .of 
interaction, might prevent the functional interaction of the G-protein with the 
receptor with which it interacts. The last ten amino acids of Tda have the sequence 
KENLKDCGLF, which is one amino-acid different to the last ten amino acids of Gi2a, 
which has the sequence KNNLKDCGLF. Preincubation of NG108-15 cell membranes 
with a synthetic peptide which corresponds to the C-terminal decapeptide of 
transducin reduced DADLE stimulation of GTPase activity in a dose dependent manner. 
In contrast, preincubation with a synthetic peptide homologous to the last ten 0- 
terminai amino-acids of Goa was without effect. An interesting hypothesisis for this 
observation is that the 6-opioid receptor functions through activation of Gi2, and 
that the addition of a synthetic peptide corresponding to the receptor interaction 
domain of Gi2a, results in competition between the peptide and the G-protein for the 
6-opioid receptor, hence the resultant reduction in GTPase stimulation produced by 
DADLE after preincubation with the Gi2a peptide. This approach, whilst suggesting 
the possible interaction of the 6-opioid receptor with Gi2, and not with Go, proved to 
be limiting in that excessively high concentrations of peptide were required to
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produce an attenuation of approximately 50% of receptor stimulated GTPase activity 
{Figure 5.13 a,b).
An antibody which can specificaliy identify and bind to the C-terminus of a 
G-protein a-subunit might be regarded as a potentially more specific tool in 
preventing coupling between receptor and G-protein. As detailed in chapter 3, 
antiserum AS7, which was raised to a synthetic decapeptide corresponding to the 0- 
terminal region of Tda, specifically identifies Gi2a in NG108-15 cell membranes. 
Antibodies affinity purified from antiserum AS7 retain specificity for Gi2a (chapter 
3, Figure 3.4). Preincubation of NG108-15 cell membranes with a 1:100 dilution 
of antibodies affinity purified from AS7 completely abolished the ability of DADLE to 
stimulate high-affinity GTPase activity, whilst having little effect on the ability of 
FCS to stimulate high-affinity GTPase activity (Table 5.5). Normal rabbit serum did 
not mimic the effect of the affinity purified antibodies, whose effect could be 
titrated out. A 1:10,000 dilution of affinity purified AS7 in normal rabbit serum 
was found to be without effect. This data argues strongly that DADLE and FCS bind to 
receptors which function through activation of different G-protein species, but more 
importantly, that Gi2 is the G-protein reponsible for mediating the inhibition of 
adenylyl cyclase in NG108-15 cells.
As a more rigorous immunological definition of the G-protein with which the 
5-opioid receptor interacts to inhibit adenyiyi cyclase, a series of IgG fractions were 
produced from each of normal rabbit serum, antiserum AS7, 001 , 081 and 13B 
(chapter 2, section 2.9). These antisera were raised against synthetic peptides 
corresponding to the 0-terminal region of the G-protein a-subunit and can be used 
as specific tools to identify Gi2, Go, Gs and Gi3 respectively (chapter 3). Both 
opioid-inhibition of adenylate cyclase and opioid-stimuiation of high affinity GTPase 
activity was completely abolished in membranes of these cells by pretreatment with 
an IgG fraction from antiserum AS7. IgG fractions from each of normal rabbit serum, 
the anti-Gj3, anti-Gg and anti-Gg 0-terminal antisera had no effect. These data argue 
strongly that Gj2 must be the true "Gj" of the adenylate cyclase cascade, at least in 
NG108-15 cells. It is not possible to rule out the possibility that G j1 might function
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in a similar manner in other tissues in which it is expressed. I t  should be noted, 
however, that the expression of Gj2 (and Gj3) appears to be universal in mammalian 
tissues, whilst Gj1 is limited in distribution (Milligan, 1989) and as such does not 
mirror the distribution of adenylyl cyclase which is also essentially universal. In 
situ hybridisation experiments in rat brain slices have shown that distributions of 
mRNA for both Gs and Gi2 are very similar, whilst the distributions of mRNA for Go 
and G il are different (Brann et al., 1987). Since adenylyl cyclase is under the dual 
control of both stimulatory and inhibitory hormones, it has been suggested that on 
the basis of the distribution pattern of Gs and Gi2, the inhibition of adenylyl cyclase 
is mediated by activation of Gi2 (Brann et al., 1987). However a similar correlation 
has observed in the distribution of both Go (as assessed immunochemically) and 
protein kinase C (assessed by the binding of phorbol ester), suggesting that Go might 
represent the G-protein linked to receptor mediated stimulation of 
phosphoinositidase C (Worley et al., 1986). This is probably incorrect, since Go is a 
pertussis toxin sensitive G-protein and the stimulation of phosphoinositidase C in 
brain is generally not attenuated by pertussis toxin treatment (Ueda et al., 1989). 
An additional caveat is that there may be little or no correlation between the relative 
abundance of a G-protein mRNA and the corresponding pdypeptide (Silbert et al., 
1990) .
The G-protein antisera described above were employed under the assumption 
that the binding of antibody to the site of receptor Interaction on the G-protein would 
prevent interaction of G-protein with receptor, however it is not possible to 
conclude that the C-terminus of Gi2 is Indeed the domain responsible for receptor 
recognition. The effect of antibodies derived from antisera AS7 may be due to the 
cross linking of antibody to G-protein, which might be expected to produce sufficient 
steric hindrance to prevent interaction of G-protein with effector. This question 
could be resolved by the use of antigen binding fragments derived from the IgG 
fractions described, however this was not performed.
For each anti-G-protein antiserum described, it is not possible to assess the 
proportion of IgG which can specifically recognise the G-protein a-subunit, thus it 
is not possible to determine the stoichiometry of antibody to G-protein which results
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in complete attenuation of coupling to receptor. However, other groups have 
performed a range of other experiments using similar approaches to those described 
in this chapter which may allow stoichiometric measurements to be made. As detailed 
in chapterl, the detection of iight by the photon receptor rhodopsin promotes the 
activation of transducin which then stimulates cyclic GMP phosphodiesterases (cGMP 
PDE). The functional reconstitution of purified transducin, rhodopsin and cGMP PDE 
into phospholipid vesicles by a number of research groups has allowed the direct 
analysis of interactions between transducin and rhodopsin (Fung, 1985). Using this 
system, it has recently been shown that preincubation of purified transducin a- 
subunit with antibodies affinity purified from antiserum AST before incorporation 
into phospholipid vesicles, leads to a diminished ability of rhodopsin to stimulate 
GTPase activity, wheras preincubation with non-specific rabbit IgG had no effect 
(Cerione et al., 1988). Maximal Inhibition of the rhodopsin stimulated GTPase 
activity occurred at a molar ratio of transducin a-subunit to AST of 1:1. Since the 
presence of transducin p,y subunits during the preincubation did not alter the effect 
of AST, it was concluded that the binding of AST to transducin did not alter the ability 
of the a-subunit of transducin to interact with p,y. Further, the intrinsic basal 
GTPase activity of transducin a was not reduced by preincubation with AST. An 
additional point obtained from the above experiments was that preincubation of 
antiserum AST with the a-subunit of transducin which had been pre-activated by 
the addition of the non-hydrolysable GTP analogue, GTPyS, enhanced the ability of 
transducin to interact with the cGMP PDE.
Whilst the interaction of G-proteins with receptors in reconstitution 
systems is more amenable to analysis, a range of similar experiments have been 
performed in plasma membrane systems using a monoclonai antibody, termed 4A, 
raised against the a-subunit of frog transducin (Hamm et al., 1987), which have 
been shown to recognise a region close to the C-terminus. When rod outer segment 
membranes, are preincubated with monclonal antibody 4A, then light activation of 
transducin by rhodopsin is blocked (Hamm et al., 1987; Deretic and Hamm, 1987). 
As the antibody which produced inhibition was able to Immunoprecipitate the 
holomeric transducin a,p,y complex, it is unlikely that the effect was produced by
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preventing the interaction of transducin a with the p j  subunit. In addition, 
monoclonal antibody 4A has been shown to prevent muscarinic receptor activation of 
atrial potassium channels, a process which has ascribed to either the a-subunit of 
Gi3, or p,7 subunits, depending on ones point of view (Yatani et al., 1987a,b). In 
platelet membranes, which have been demonstrated to express Gs, Gi2, GI3 and 
Gz(x), It is possible to attenuate a -2 adrenergic receptor mediated inhibition of 
adenylyl cyclase, by preincubation with antibodies affinity purified from antiserum 
AS7, which specifically recognises the extreme C-terminal region of Gi2 (see 
earlier). Antibodies affinity purified from antisera which specifically recognised 
G13 or Gz were without effect. (Simonds et al.,1989a). The ability of a GI2 specific 
antibody to prevent productive coupling between Inhibitory receptor and adenylyl 
cyclase has therefore been demonstrated in more than one signal transduction model 
system.
In addition to the ability to block receptor interaction with 'Gi"-like G- 
proteins, Simonds and colleagues have demonstrated that antibodies which were 
raised against the C-terminai decapeptide of Gsa, and specifically recognise Gsa, are 
able to block receptor-mediated activation of Gs and adenylyl cyclase in membranes 
produced from wild type S49 cells. The antibodies could also immunoprecipitate 
adenylyl cyclase activity from GTPyS or AIF^- activated bovine brain membranes, 
demonstrating that an activated conformation of Gsa was able to bind both antibody 
and effector (Simonds et al.,1989b).
The conclusions to be made from an analysis of the experiments described 
above, are that the extreme C-terminal region of the G-protein a-subunit is indeed 
the site of interaction with receptor, and that it is possible in membrane systems, to 
identify which G-proteins function through activation of defined receptors to 
interact with identifiable signalling pathways. As such, it is expected that similar 
protocols will allow the dissection of signal transduction pathways other than those 
linked to the stimulation and inhibition of adenylyl cyclase, and the opening of atrial 
potassium channels. Considerable research has been aimed at identifying the G- 
protein which is required for receptor-mediated stimulation of phosphoinositidase
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c, there have been several major obstacles, most notably In the heterogeneity of G- 
proteln(s) which mediate this response (pertussis toxin sensitive and insensitive 
signalling pathways), and in the difficulty in producing a cell free system to study 
inositol lipid breakdown. The development of a cell free system which allows 
measurement of the hydrolysis of inositol containing phospholipids, as has been 
described for membranes produced from HL 60 cells (Kikuchi et al., 1986), will 
facilitate the use of specific antibodies to uncouple G-proteins from receptors and 
will undoubtecily provide a powerful tool in the analysis of G-protein signaP 
transduction.
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Chapter 6
Uncouplma of the 5-opioid receptor in NG108-15  
membranes from the G-protein with which it interacts, 
bv antibodies which identify the C-terminus of the a - 
subunit of GI2.
In tro d u c t io n
One of the initial observations which allowed the identification of G-proteins 
as being involved in receptor mediated transmembrane signalling events, was the 
demonstration that guanine nucleotides such as GTP reduced the binding of glucagon to 
the plasma membrane of rat liver preparations (Rodbell et ai.,1971b). The effects 
of GTP on the binding of ligand to receptor were later shown to be specific for 
agonists, since in rat C6G1A glioma cell membranes, the binding of p-adrenergic 
agonists, but not antagonists was reduced by the presence of the GTP analogue, 
Gpp(NH)p (Maguire et al., 1976). Further studies on p-adrenergic receptors 
suggested the existence of two affinity states for agonist, but only one affinity state 
for antagonist, since competition curves for antagonist versus radiolabelled 
antagonist are steep with pseudo Hill coefficients close to 1 and competition curves 
for agonist versus radiolabelled antagonist are shallower with pseudo Hill 
coefficients less than 1 (De Lean et al., 1980). The affinity state of a receptor for 
agonist has since been demonstrated to be dependent on the identity of the guanine 
nucleotide bound to the G-protein which interacts with the receptor under study. In 
the presence of non-hydrolysable analogues of GTP, such as Gpp(NH)p or GTPyS, a 
low affinity state of receptor for agonist is adopted, whereas in the absence of 
guanine nucleotides the receptor demonstrates a higher affinity for agonist (Wregget 
and DeLean., 1984).
As detailed in chapter 1, the C-terminus of the G-protein a-subunit has been 
identified as the functional domain of interaction with receptor. If NG108-15 cells 
are pretreated with pertussis toxin, then as well as an attenuation of receptor 
mediated inhibition of adenylyl cyclase, there is concomittant loss of guanine 
nucleotide sensitivity of agonist binding (Kurose et al., 1982). This may be regarded 
as an axiom applicable to all receptors which function through the activation of 
pertussis toxin sensitive G-proteins (Milligan, 1988). Thus, if the G-protein is 
prevented from interacting with its receptor, either by modifying the C-terminal 
region of the a-subunit, or by promoting the dissociation of the a-subunit from the 
p,Y subunits, a form of receptor with a lowered affinity for agonist is produced.
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In chapter five, the effect of pre-incubating membranes from NG108-15 
cells with antiserum AS7, an antiserum which specifically identifies the C-terminus 
of Gi2 in this cell line, was described. The preincubation had the same functional 
effect as pretreatment with pertussis toxin, in that receptor mediated inhibition of 
adenyiyi cyclase via the 6-opioid receptor was abolished. This led to the speculation 
that the antibody uncoupling of the 6-opioid receptor from Gi2, may also be 
identified as it would result in an altered afffinity state of the receptor for agonist.
To examine this hypothesis directly, a series of binding assays on membranes 
produced from NG108-15 cells have been performed with the aim of assessing the 
effect of the range of G-protein specific antisera described in chapter 2, on the 
affinity state of the 6-opioid receptor in this ceil line.
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Fia. 6.1 Timecourse of binding of r^HIPADLE to membranes 
Qf N (3109:1$ cell?,
Membranes of NG108-15 cells (lOOpg) were incubated with a fixed 
concentration of [^HjDADLE (10 nM), as described in section 2.14. At times varying 
between 0 and 3 0  minutes, incubations were terminated by removal to ice, followed 
by rapid filtration through Whatman GF/C filters, and three 5ml washes with 
buffer, as detailed in section 2.14. A further series of incubations were performed 
in the presence of lOpM DADLE to define non-specific binding. Data shown are means 
± S.D. from eight replicates taken from two separate experiments.
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Fig. 6.2 The binding of f^HI DADLE to NG108-15 cell
membranes in response to increasing protein
con cen tra t io n .
NG108-15 cell membranes (0 - 300p,g) were incubated with a fixed 
concentration of [^HjDADLE {10 nM). After 30 minutes, incubations were 
terminated by removal to ice, followed by rapid filtration through Whatman GF/C 
filters and three 5ml washes with buffer, as detailed in section 2.14. A parallel 
series of incubations were performed in the presence of lOp-M DADLE for each 
membrane concentration used, to define non-specific binding. Data shown are means 
± S.D. from eight replicates taken from two separate experiments.
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E m  Saturation binding analysis of PADLE to
membranes of NG108-15 cells.
Membranes of NG108-15 cells (100|ig) were Incubated with varying 
concentrations of [^H]DADLE (0.5-20 nM), as described In section 2.14. A further 
series of incubations were performed in the presence of lOjxM DADLE to define non­
specific binding.(Figure 6.3 a). Specific binding data was treated as described by 
Scatchard (1949). and replotted (Figure 6.3 b). Scatchard analysis of the data 
presented in Figure 6.3 b indicated the presence of some 390 fmoles receptor/mg 
membrane protein, with an apparent dissociation constant (Kd) for the ligand of 2.2 
± 0.2nM . Data are means ± S.D. taken from quadruplicate determinations in a single 
experiment which was performed four times and gave essentially identical results.
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F ig . 6 .4  The binding of r^HIDADLE to membranes of
NG108-15 cells: the effect of GpprNHIp.
Membranes of NG108-15 celis (100|j.g) were incubated with varying 
concentrations of [^H]DADLE (0.5-20 nM), as described in section 2.14, in the 
absence (open circies) or presence (closed circles) of Gpp[NH]p (100 pM). A 
further series of incubations were performed in the presence of 10|iM DADLE to 
define non-specific binding. Specific binding data was treated as described by 
Scatchard (1949). In the experiment shown, binding parameters were; Bmax 309 ± 
7 fmol/mg protein, Kd 3.2 nM, in the absence of Gpp[NH]p and Bmax 283 ± 15 
fmoi/mg protein, Kd 6.4 nM in the presence of Gpp[NH]p. Data are means ± S.D. 
taken from a single experiment which gave essentially Identical results to three 
others performed.
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F ig . 6 .5  The binding of r^HIDADLE to membranes of
untreated and pertussis toxin pretreated NG_1_08- 
15 ceils.
NG108-15 cell membranes (lOOjig) from either untreated cells (open 
circles) or from cells which had been pretreated in vivo with pertussis toxin 
(closed circles) as detailed in section 2 .6d, were incubated with varying 
concentrations of [^H]DADLE, in the absence of Gpp[NH]p, as described in the legend 
to Figure 6.4. Non-specific binding was defined as in Figure 6.1. Binding parameters 
in the experiment displayed were: membranes from untreated cells, Bmax. 331 ± 6 
fmol/mg protein, Kd 1.8 nM, membranes from pertussis toxin-pretreated cells, 
Bmax. 293 ± 16 fmol/mg protein, Kd 4.2 nM. Data are means ± S.D. from pooled 
determinations from three separate experiments (n=12).
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Figure 6.5
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F ig .  Tlmecourse of reduction in available 5-opioid
receptors produced bv pre-incubation of NG108- 
15 cell membranes at 37&C
Membranes (lOOjig) of NG108-15 cells were incubated either on ice for 75 
minutes (A), or at 37^0 for 0 minutes (B), 15 minutes (C), 45 minutes (D), 60 
minutes (E) or 75 minutes (F), in the presence of binding assay buffer but in the 
absence of radiolabelled or non-radioiabelled ligand as described in section 2.14. 
After pre-incubation, binding assays were performed as described in the legend to 
Figure 6.2. Data are means ± S.D. taken from a single experiment.
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F ig . 6 .7  P re incubation of membranes of NG108-15 ce lls  at 
3 7 ° C produces a reduction in available 5 opioid 
receptors, w ith  no a lte ra tion  In a ffin ity  fo r 
a g o n is t.
Membranes (lOOpg) of NG108-15 cells were incubated for 60 minutes 
either on ice {open circles) or at 37°C (closed circles) in the presence of binding 
assay buffer but in the absence of both [^H] DADLE or DADLE as detailed in the legend 
to Figure 6.6. Binding assays were then performed as described in section 2.14. 
Binding parameters In this experiment were: Bmax 578 ± 11 fmol/mg protein, Kd 
2.5 nM for the samples preincubated on ice and Bmax. 429 ± 9 fmol/mg protein, Kd 
2.4 nM for the samples preincubated at 37°C. Data are means ± S.D. from 
quadruplicate determinations in a single experiment which was performed twice 
with identical results.
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Ela- Êxfi Antiserum AS7 specifically reduces the binding 
of r—HTDADLE to membranes of NG108-15 cells.
Membranes of NG108-15 cells (lOOjig) were Incubated for 60 minutes at 
37®C in the presence of (2) Gpp[NH]p (IOO11M) or the IgG fractions (equivalent to 
a 1:100 dilution of the original antiserum) isolated from either (1) normal rabbit 
serum (control) , (3) antiserum AS7 (anti- Gj2a) , (4) antiserum 0C1 -(anti- 
C^a) or (5) antiserum I3B (anti- Gj3a) as detailed In section 2.9. The binding of a 
single concentration of [^H] DADLE (2 nM) close to the calculated Kd for this ligand 
was measured and the non-specific component of this binding defined by parallel 
incubations in the presence of 10 |iM DADLE. Only the IgG fraction isolated from 
antiserum AS7 was able to mimic Gpp[NH]p In reducing the specific binding of the 
pH]DADLE. Data are presented as means ± S.D. for quadruplicate determinations in a 
single experiment which was repeated four times and gave identical results.
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F ig . 6 .9  The effects of GpprNHlo and antiserum AS7 on 
[^HIDADLE binding to membranes of NG108-15  
celis. Lack of additivity.
Membranes of NG108-15 cells (lOOpg) were pre-lncubated for 60 minutes 
at 37°C with either; (1) the IgG fraction of normal rabbit serum (concentration 
equivalent to a 1:100 dilution of the original serum), (2) IgG fraction from normal 
rabbit serum (as in 1) + Gpp[NH]p (lOOpM), (3) The IgG fraction of antiserum 
AS7 (equivalent to a 1:100 dilution of the crude antiserum) or (4) The IgG fraction 
of antiserum AS7 (as in (3) ) + Gpp[NH]p (lOOpM). as detailed in the legend to 
Figure 6.8. Following the preincubation, specific binding of a single concentration of 
I^HjDADLE (2 nM) was assessed as in Figure 6.1 Results are presented as mean 
±S.D. for quadruplicate determinations pooled from three independent experiments 
( n = 1 2 ).
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F i a . 6 . 1 0  Antiserum AS7 converts 5 opioid receptors in
membranes of NG108-15 ceils from high affinity  
for agonist binding to low affinity.
Membranes of NG108-15 cells (lOOiig) were pre-incubated at 37°C for 60 
minutes with an IgG fraction from either normal rabbit serum (open circles) or 
antiserum AS7 (closed circles) as in the legend to Figure 6.8. The. specific binding of 
a range of concentrations of pH] DAD LE were then assessed as detailed in section 
2,14. Binding parameters in this experiment were Bmax. 481 ± 12 fmol/mg 
protein, Kd 2.4 nM for membranes incubated with normal rabbit serum and Bmax. 
510 ± 23 fmol/mg protein, Kd. 5.6 nM for membranes incubated with antiserum 
AS7. Data are means ± S.D. from pooled triplicate determinations from three 
independent experiments.(n=9).
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Figure 6.10
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E m  6, 11  [3.H] diprenorphîne binding to membranes of
NG108-15 cells is reduced both bv GpprNHIp and
an.1ise,r.u.m__AS7^ .
NG108-15 cell membranes (lOOiig) were treated as detailed in the legend to 
Figure 6.6 except that the opioid receptor ligand was [^H] diprenorphîne (2nM). 
The apparent Kd for this ligand in this system was estimated in saturation binding 
experiments to be some 2.4 nM (see Table 6.1). (A) membranes preincubated with 
the IgG fraction of normal rabbit serum. (B) preincubation with normal rabbit 
serum IgG + Gpp[NH]p (100pM). (C) preincubation with the IgG fraction of 
antiserum AS7. (D) preincubation with AS7 IgG + Gpp[NH]p (lOOuM). Data for the 
specific binding are presented as means ± S.D. from quadruplicate determinations in 
a single experiment.
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Table 6.1 The effect of GpprNHIp on the specific binding of 
f—HI diprenorphîne to membranes of NG108-15  
celis .
Membranes of NG108-15 cells (lOOfig) were Incubated with varying 
concentrations of pH ] diprenorphîne {0.5-20 nM), as described in section 2.14, in 
the absence or presence of Gpp[NH]p (100 pM). A further series of incubations 
were performed in the presence of lOpM DADLE to define non-specific binding. 
Binding parameters were calculated as described by Scatchard (1949). Data are 
means ± S.D. from quadruplicate determinations in a single experiment. Two further 
experiments produced essentially identical results.
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l abJg 6 ,1 The, effect of GppfNHlp on the specific binding
of A m  diprenorphîne to membranes of NG108-15  
c e l ls .
pH ]d ip renorph ine  
BMax. Kd
(fmol/mg protein) (nM )
Untreated 471.0 2.6
+ Gpp[NH]p 462.0 4.5
R esul ts .
The binding of pH ] DADLE (10nM) to NG108-15 cell membranes reached an 
equilibrium after approximately 15 minutes incubation at 30°C (Figure 6.1). The 
data shown in Figure 6.1 and for all subsequent figures is for specific binding of 
pH ] DADLE. All subsequent binding assays were performed with an incubation 
period of 20 minutes, to ensure that a binding equilibrium had been reached. The 
equilibrium obtained is related to both the rate of association and dissociation of the 
ligand. The rates of association and dissociation have previously been assessed in 
membranes produced from NG108-15 cell membranes, the rate of association, kon 
of, pH ] DADLE has been shown to be linear with respect to time, with an observed 
constant of 0.022+/- 0.0007 min'"*, being obtained when DADLE was used at a 
concentration of 2.1 nM, close to the apparent Kd. In the presence of 20mM 
magnesium, the dissociation curve of pH ] DADLE is monophasic, indicative of a 
single binding component (Law et al., 1985a). Both the specific and non-specific 
binding of pH ] DADLE to NG108-15 membranes was linear between membrane 
protein concentrations of 25 to 250pg (Figure 6.2). All subsequent assays were 
performed using lOOpg of membrane protein.
In saturation binding experiments, in the presence of Mg^+ (20 mM), 
specific binding of pH ] DADLE to membranes of neuroblastoma x glioma hybrid, 
NG108-15, cells could be adequately defined as being to a single population of high 
affinity sites (Figure 6.3). Scatchard analysis of the data indicated the presence of 
some 400 fmols receptor /mg membrane protein which displayed an apparent 
dissociation constant (Kd) for the ligand of 2.2 ± 0.2 nM (mean ± S.D., n = 9). In a 
series of membrane preparations from individual cultures, the apparent number of 
receptors varied from 290 to 580 fmoles/mg protein. When a similar assay was 
performed in the presence of Gpp[NH]p (100 p.M), Scatchard analysis of the specific 
binding Indicated a reduction in affinity of pH ] DADLE binding but no alteration in 
the total number of available sites (Figure 6.4).
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Specific binding of pH ] DADLE to membranes of NG108-15 cells which had been 
pretreated with pertussis toxin as detailed in section 2.6d also produced a reduction 
in pH ] ligand affinity in comparison to that in membranes from untreated, control 
cells but did not alter the total number of sites (Figure 6.5). These two pieces of data 
confirmed previous studies (Milligan et al., 1985; Burns et ai., 1983) and indicated 
that the opioid receptor in these cells interacts with a pertussis toxin-sensitive G- 
protein(s) (Koski and Klee, 1981; Milligan et al., 1985; Kurose et al., 1982).
Immunoblotting membranes of NG108-15 cells, as well as membranes of a 
series of other cells and tissues in which the complement of G-proteins expressed 
has previously been defined with a series of antipeptide antisera which are able to 
identify the extreme C-terminal region of the individual pertussis toxin-sensitive 
G-proteins, demonstrated the expression of Gi2, Gi3 and Go in these cells (see 
chapter 3). By contrast it was not possible to detect expression of G il.
To define which of these G-proteins was linked to the 5 opioid receptor, a 
similar technique to that used in chapter 5 was employed. Membranes of NG108-15 
cells were incubated either with Gpp[NH]p (100 pM) or with IgG fractions isolated 
from each of normal rabbit serum, and antisera AS7 (anti-Gj2a), 001 (anti-G^a) 
and I3B (anti- G j3a) for 60 minutes at 37°C, after which time the ability of a 
single concentration of pH ] DADLE (2nM), which was close to the apparent Kd for 
the ligand, to bind specifically to the 5 opioid receptor was assessed. As anticipated, 
Gpp[NH]p reduced the specific binding of this concentration of the opioid ligand, 
however, of the various IgG fractions, only that derived from antiserum AS7 was 
able to produce a similar inhibition (Figure 6.8). The IgG fractions from each of 
normal rabbit serum and antisera 0C1 and I3B did not affect the binding of 
[3h]DADLE (Figure 6.8).
The prelnoubatlon phase Itself had only a small Inhibitory effect on [^H] 
DADLE binding (< 20%), which occurred in a time and temperature -dependent 
manner (Figure 6.6). Pre-incubation of NG108-15 membranes at 4°C had no 
apparent effect on the binding of pH [ DADLE (Figure 6.6). Scatchard analysis of the
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specific binding (Figure 6.7) demonstrated the reduction in pH ] DADLE binding was 
due to a reduction in the total number of available receptors without effect on the 
affinity of the pH ] ligand for the remaining receptors. Indeed after the pre­
incubation at either 4°C or 37°C, it was still possible to observe a Gpp(NH)p 
(100pM ) mediated reduction in affinity of pH ] DADLE binding with no alteration in 
the total number of available sites (data not shown)
The effects of Gpp[NH]p and the IgG fraction of antiserum AS7 on reduction of 
pH]DADLE binding were not additive, indeed no further reduction in binding of pH ] 
DADLE was achieved by the combination of these agents in comparison the effects of 
either in isolation (Figure 6.9).
In an attempt to assess whether the inhibitory effect of IgG from antiserum AS7 on 
the binding of pH ] DADLE was due to an alteration in the affinity of the ligand for 
receptor as would be anticipated if the antibodies were producing a functional 
uncoupling of the receptor from the G-protein signalling system, saturation binding 
experiments were performed. Scatchard analysis of the specific binding of a range of 
concentrations (0.5 - 20nM) of pH]DADLE to membranes of NG108-15 cells 
following preincubation in the presence or absence of the IgG fraction of antiserum 
AS7 indeed indicated that the affinity of the receptor for ligand was reduced but that 
the total number of binding sites was not affected (Figure 6.10). Equivalent results 
were produced when each of the experiments detailed above were repeated using [^H] 
diprenorphîne as ligand (Table 6.1, Figure 6.11 and results not shown).
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Discussion.
Although the ternary complex model was originally proposed to account for 
the effect of guanine nucleotides on agonist binding to receptors linked to stimulation 
of adenylyl cyclase, ligand binding experiments performed, on receptor signalling 
systems linked to the inhibition of adenylyl cyclase yielded similar results 
(U'Prichard and Snyder, 1978; Koski and Klee, 1981) and led to the general 
conclusion that if the affinity of a receptor for agonist is altered by the presence of 
guanine nucleotides, then that receptor functions through activation of a G-protein.
Although there are several examples to the contrary, (Rojas and 
Birnbaumej, 1985; Ott et al., 1988), there appears to be a direct relationship 
between the ability of guanine nucleotides to activate a G-protein and the ability to 
produce a negative allosteric effect on binding of agonist to receptor. Analogues of 
GTP such as GTPyS and Gpp(NH)p which are known to promote dissociation 
(Hildebrandt et al., 1984; Godina et al., 1983) and hence activation of G-proteins, 
are able to elicit a reduction in the affinity of receptor for agonist. However binding 
studies on muscarinic (Burgisser et al., 1982), D2-dopaminergic (DeLean et al., 
1982), and A I -Adenosine receptors (Green, 1984), reveal a more elaborate effect 
of guanine nucleotides, where agonist and antagonist binding to these receptors may 
be modulated in a reciprocal manner. To include these observations, the ternary . 
complex model was altered to allow for the ability of an antagonist to be able to 
promote dissociation of the ternary complex (Wregget and DeLean, 1984). Thus the 
effects of guanine nucleotides on ligand binding may be complex, depending on the 
receptor type under study
Opioid receptors of neuroblastoma x glioma cells appear to be comprised only 
of the 5 subtype (Chang and Cuatrecasas, 1979). This receptor is able to produce 
both a stimulation of high affinity GTPase activity and a GTP-dependent inhibition of 
adenylate cyclase activity (Koski and Klee, 1981). Both of these effects are 
attenuated by pretreatment of the cells with pertussis toxin (Milligan et al., 1985; 
Kurose et al., 1983) and as the effects of a range of opioid ligands in each assay
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correlate very highly in terms of both potency and efficacy of the agonist (see 
chapter 5), it is believed that the two effects represent consecutive stages of the 
same signalling cascade. Pertussis toxin is able to catalyse an NAD+-dependent 
mono-ADP-ribosylation of a series of G-proteins which as a common feature have a 
cysteine residue located 4 amino acids from the C-termlnus of the a subunit 
(Gilman, 1987; Jones and Reed, 1987). Whilst pertussis toxin prevents opioid 
peptide-mediated inhibition of adenylate cyclase and hence must cause ADP- 
ribosylation of "Gj", the presence of multiple substrates for this toxin in NG108-15 
cells means that it cannot be used as a diagnostic probe to identify which of these G- 
proteins functions to couple the opioid receptor to adenylyl cyclase. The expression 
of three distinct pertussis toxin sensitive G-proteins in these cells and their 
identification as products of the Gi2, Gi3 and Go genes has been described in chapter 
3.
The data described in this chapter, in addition to chapter 5, demonstrates 
through studies on the alteration of affinity of the 0-opioid receptor for agonist, that 
the receptor Interacts directly and specifically with Gj2 .
The first indications for the presence of G-proteins as transducers of 
information between a receptor and an effector system has frequently been produced 
by noting the ability of guanine nucleotides to reduce the affinity of agonists 
(Milligan, 1988), but not antagonists, for the receptor. This is usually interpreted 
to imply that a receptor-G-protein complex displays higher affinity for an agonist 
than does the receptor in isolation (DeLean et al., 1980). Pretreatment with 
pertussis toxin, which prevents productive coupling between receptor and G- 
protein, equally reduces the affinity of ligand for a receptor which is coupled to a 
pertussis toxin sensitive G-protein, and attenuates the ability of guanine nucleotides 
to alter the binding of agonist to receptor (Hsia et al., 1984). As detailed in chapter 
one, the extreme C-terminal region of the a subunit of all G-proteins appears to be a 
key region for interaction of G-protein and receptor. As such a range of antipeptide 
antisera against the individual pertussis toxin-sensitive G-proteins have been 
produced by using synthetic peptides corresponding to the C-terminal decapeptides of 
these polypeptides as antigen. These antisera have been employed in an attempt to
173
interfere with receptor-G-protein interactions. It is postulated that these antisera 
would be able to interfere with the coupling of particular G-proteins with receptors 
which interact with them and hence produce a low affinity state of the receptor for 
agonists which could be detected in ligand binding assays.
These experiments were performed in the presence of a high concentration of 
Mg2+ (20mM) as under such conditions ail the receptors in untreated membranes 
are converted into a high affinity state for agonists (Costa et al., 1990) and hence 
are all presumably coupled to a G-protein. The mechanism by which magnesium ions 
mediate this effect is currently unknown and open to debate. It is well established 
that Mg2+ is a requirement for G-protein function (Iyengar and Birnbaumer,
1982), however the concentration of Mg2+ required for GTPase activity is vastly 
different from the concentration of Mg2+ required for hormonal stimulation of 
adenylyl cyclase (5nM and 10|iM, respectively) which may indicate that Mg^+ can 
affect G-protein function by two distinct mechanisms (Gilman, 1987). When GTP or 
GTPyS is bound to the G-protein a-subunit, the interaction of Mg2+ at the active site 
occurs with high affinity, and is presumably sufficient for G-protein activation 
(Higashijima et al., 1987), however the presence of a high concentration of Mg2+ 
seems to be a requirement for dissociation of GDP, association of GTP and subunit 
dissociation (Brandt and Ross, 1986). it has recently been demonstrated that 
neomycin, an inositol phospholipid binding aminoglycoside antibiotic is able to exert 
a similar effect on the binding of agonist to receptor as that produced by Mg2+ 
(Herrmann et al., 1989). The HL 60 ceil line expresses a receptor(s) for the 
chemotactic peptide N-formyl-methionyi-leucyl-phenylalanine (F-Met-Leu-Phe), 
which is coupled via a G-protein, to the stimulation of the rate of hydrolysis of 
inositol-containing phospholipids (Gierschik and Jabobs, 1987). in membranes of 
differentiated HL60 cells, neomycin was found to Induce high-affinity binding of 
[3h] F-Met-Leu-Phe, an effect attenuated by prior treatment with pertussis toxin, 
in close agreement, high affinity binding of isoproterenol to p-adrenoceptors in 
guinea-pig lung membranes was induced by both magnesium and neomycin, in 
contrast to magnesium, neomycin did not induce G-protein activation in the presence 
of GTP, suggesting that the induction of high-affinity binding was not a. consequence 
of an ability to promote G-protein dissociation. The effect of neomycin was also noted
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for two other aminoglycoside antibiotics, gentamycin and streptomycin. These 
cationic compounds are commonly employed as inhibitors of phospholipid hydrolysis 
(Cockcroft and Gomperts, 1985) and have been shown to specifically interact with 
inositol phospholipids, an ability also observed for magnesium (McLaughlin and 
Whitaker, 1988). It is possible to speculate that the induction of a high affinity state 
of receptor for agonist is not as a consequence of a direct interaction of Mg^+ with 
either G-protein or receptor, but instead is as a result of the binding of magnesium 
(and neomycin) to membrane lipid components, to produce an alteration in the local 
lipid enviroment surrounding the receptor and G-protein which facilitates the 
coupling of G-proteins to agonist bound receptors (Herrmann et al., 1989).
in addition to the effect of magnesium on G-protein function, It has been well 
documented that sodium chloride is a requirement for agonist-mediated inhibition of 
adenylyl cyclase (Koski et al., 1982; Klee et al., 1985). Recent data indicate that 
chloride and other monovalent cations, but not sodium, modulate the affinity of 
guanine nucleotides for purified G-proteins (Higashijima* et al, 1987). The effects 
of both Na+ and Cl" can be resolved into distinct components, since in membrane 
systems, Na+ in the presence of Mg^+ lowers GTPase activity in a manner which is 
reversed by the addition of inhibitory agonists (Koski et al., 1982). However studies 
on Gi purified from brain are contradictory, suggesting that Na+ is able to stimulate 
GTPase activity in the absence but not in the presence of Mg^+ (Milligan and Klee, 
1985). it is therefore unclear as to whether Na+ is required to facilitate G-protein 
function, receptor function or the Interaction between receptor and G-protein. It has 
been proposed that the effect of Na+.is to prevent the activation of G-proteins with 
unoccupied receptors (as discussed in chapter 5), since in membranes produced 
from HL60 cells, basal GTPase activity is inhibited by the presence of Na+ in a 
manner similar to the reduction elicited by pertussis toxin, and agonist stimulation 
of GTPase activity is markedly enhanced In the presence of Na+ (Gierschik et al., 
1989b). These observations are in agreement with the effect of Na+ on GTPase 
activity in membranes produced from NG108-15 cells (Koski et al., 1982). Na+ 
has been shown to increase the dissociation of agonist from opiate binding sites 
(Blume, 1978; Costa et al., 1990), suggesting that the ion may be acting at the
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ligand binding component, or via a membrane sodium-binding component which can 
interact with the opiate receptor. The sodium binding site may be located 
intracelluiariy because the concentration of sodium required for haif-maximai 
activity is 20mM (Blume, 1978), the intracellular sodium concentration, and in 
whole cell experiments removal of extracellular sodium does not attenuate opiate 
mediated inhibition of adenylyl cyclase (Law et al., 1982). Target size analysis 
experiments have suggested that the Na+ effect is mediated by a component distinct 
from G-proteins and receptor, with an apparent molecular weight of 168kDa. The 
identity of the putative Na+ binding component is unknown (Ott et ai., 1988). Na+ 
can therefore be seen to have complex effects on both the binding of inhibitory 
agonist to receptor, and in the activation of G-proteins.
Within currently defined receptor theory, a decrease in the affinity of a 
receptor for a ligand may result from several circumstances; 1) a decrease in the 
rate of association, kon. 2) an increase in the rate of dissociation, koff, or 3) a 
decrease in the association rate and an increase in the dissociation rate as the 
receptors are being occupied. In most studies of alterations in the affinity state of 
receptor for agonist, an observed decrease in the kon rate is rare and an increase in 
koff is responsible for decreased affinity of receptor for agonist (DeLean and 
Rodbard, 1979). This is in agreement with the mechanism by which the 5-opioid 
receptor expressed by NG108-15 ceils alters its affinity for agonist. In the 
presence of magnesium, the dissociation rate of [^HJDADLE -receptor complexes is 
slow, however, upon addition of Gpp(NH)p, dissociation is more rapid, a 
characteristic of G-protein linked receptors, resulting in a decrease in affinity for 
agonist.(Law et al., 1985a) The alteration in affinity produced by either Gpp(NH)p, 
pertussis toxin pretreatment, or pretreatment with an IgG fraction derived from 
antiserum AS7, was only of the order of two-fold. This is somewhat less than has 
been previously reported for the 5-opioid receptor in this ceil type (Law et ai., 
1985a), and for other G-protein linked receptors (Brandt and Ross, 1986). The 
reason for this discrepancy is unclear, however using the assay conditions described, 
a greater than two-fold alteration in affinity for either DADLE or diprenorphine was 
never observed.
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In the uncoupling experiments it was only antibodies derived from antiserum 
AS7 which converted the opioid receptor to a low affinity state. Whilst antiserum 
AS7 is able to identify both Gj1a and G|2a equally (Goldsmith et al., 1987) as the 
C-terminal sequences of these two G-proteins are identical; G jla  is not expressed in 
NG108-15 ceils (chapter 3). Based on this observation, then the effect of antiserum 
AS7 must be due to its interaction with Gj2a. Further, as pretreatment with the IgG 
fraction of antiserum AS7 produces a maximal degree of uncoupling, i.e. the effect 
mimics completely those produced both by Gpp[NH]p and by pretreatment of the ceils 
with pertussis toxin, then these results imply that the 6-opioid receptor must 
interact selectively with Gj2. Since the effects of both IgG derived from AS7, and 
Gpp(NH)p were not additive, then it may be speculated that each agent elicits an 
alteration in affinity of the 6-opioid receptor for agonist by the same mechanism, 
the uncoupling of Gi2 from the receptor.
In parallel experiments using pHjdiprenorphine as the opioid receptor 
ligand, equivalent results were obtained. Diprenorphine is not a full agonist at the 
opioid receptor in NG108-15 cells, but neither does it display antagonist 
characteristics. Indeed it appears to display an intrinsic activity of some 60% as 
compared to full agonists such as the opioid peptides and alkaloids such as etorphine 
(Koski and Kiee, 1981). it would have been instructive to have performed the same 
set of experiments using a [^H] antagonist as the receptor ligand because it would 
have been anticipated that each of Gpp[NH]p, pertussis toxin treatment and the IgG 
fraction of antiserum AS7 would be unable to reduce the affinity of such a ligand. 
However, pHjnaloxone is the only readily available antagonist for this receptor and 
it is of sufficiently low affinity as to make it difficult to achieve a ratio of specific to 
non-specific binding in NG108-15 membranes which would allow the generation of 
useful data.
It has been demonstrated in chapter 5 that both opioid peptide-mediated 
stimulation of high affinity GTPase activity and inhibition of adenylate cyclase 
activity in membranes produced from NG108-15 cells are attenuated by an IgG 
fraction isolated from antiserum AS7, an antiserum which specifically recognises 
GI2 in this cell line. The data presented in this chapter demonstrates that it is
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possible to selectively uncouple the 6-opioid receptor from the G-protein with 
which it interacts using an IgG fraction derived from antiserum AS7. In addition, it 
may be noted that other G-protein specific antisera were without effect. It is 
therefore possible to conclude that the 5-opioid receptor functions exclusively 
through the activation of GI2 in the NG108-15 cell line and that the true "Gj" of the 
adenylate cyclase cascade is the product of the Gi2 gene.
The ability to modify each of receptor-agonist binding affinity (herein), 
receptor-stimulation of high affinity GTPase activity (McKenzie and Milligan,
1990) and receptor-regulation of effector function (McKenzie and Milligan, 1990; 
McFadzean et al., 1989) using antisera which identify the C-terminus of various G- 
proteins implies that such tools are likely to be of widespread use in assessements of 
the specificity/selectivity of receptor-G-protein interactions. For example, it is 
difficult to produce cell -free systems in which coupling of receptor to G-protein to 
phosphoinositidase C is adequately maintained, but the coupiing of such receptors to 
the relevant G-protein is often well maintained. As such, the use of antibody-induced 
production of low affinity interactions between receptor and [^Hjligand may well 
provide a suitable assay for identification of the G-protein of this system, (Gp). As 
stated earlier, many other G-protein linked receptors show a much greater 
alteration of affinity for agonist when uncoupled from G-protein and as such, may 
provide a more sensitive system for examining possible alterations in affinity state 
elicited by antisera which can specifically recognise members of the G-protein 
fam ily.
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Conclusions
The data presented in chapter 3 demonstrated that NG108-15 cells do not 
express detectable levels of G ita , but detectable levels of G!2a, Gi3a and Goa, as 
well as two forms of Gsa and the (3-subunits common to all G-proteins are • 
expressed. However, it is possible to resolve multiple charge variants of Gsa from 
S49 lymphoma ceils using two dimensional electrophoresis (Schieifer et ai., 
1980). In addition, two charge variants of Go have been identified in both brain 
(Goldsmith et ai., 1988) and NG108-15 cells (Muiianey and Milligan, 1990), 
which are not resolved under standard one dimensional polyacrylamide gel 
electrophoresis conditions. This raises the question, do NG108-15 ceils express 
more that one isoform of Gi2a and Gi3a. At present, isolation of cDNA's from a 
variety of different tissues have identified only one cDNA sequence corresponding 
to Gi2a and Gi3a (Strathmann et ai., 1989). in addition, screening of genomic 
libraries with rat cDNA clones has identified only one gene .encoding Gi2a and Gi3a 
(Kaziro, 1990). However it may be possible that alternate splicing or post- 
transiational modifications may produce variants of both Gi2 and GI3 which are 
not resolved under the electrophoresis conditions employed in chapter 3. Attempts 
to analyse both Gi2a and Gi3a expressed by NG108-15 ceils, using two- 
dimensional electrophoresis have met with little success (results not shown). The 
reason for this difficulty is unclear, however it may be a reflection of lipid 
modification of the G-protein a-subunit preventing entry into the first 
dimensional gel (results not shown). Two-dimensional analysis of Gi2a and Gi3a 
purified from bovine brain has revealed the presence of a single polypeptide 
corresponding to each of Gi2a and Gi3a (Goldsmith et ai., 1988). it is therefore 
likely that only one form of GI2a and Gi3a are expressed by NG108-15 cells.
G-proteins have been classically designated as belonging to one of two 
groups; pertussis toxin sensitive G-proteins and cholera toxin sensitive G- 
proteins. Tdl and Td2 are substrates for both toxins. Cholera toxin, which was 
originally thought to catalyse the ADP-ribosylation of only Gs, has been 
demonstrated to catalyse the ADP-ribosylation of 'Gi' in NG108-15 cell
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membranes, when the experiments were performed in the absence of guanine 
nucleotides. The cholera toxin catalysed incorporation of radioactivity from 
[22p]NAD+ into Gi was attenuated by pretreatment of the ceils with pertussis 
toxin and stimulated by the addition of the 5-opioid agonist, DADLE, suggesting that 
interaction of the 5-opioid receptor with a pertussis toxin sensitive G-protein 
enables the G-protein to become a substrate for cholera toxin catalysed ADP- 
ribosylation. This provides a means of identifying the G-protein(s) which 
interacts with the 5-opioid receptor. However, after cholera toxin catalysed ADP- 
ribosylation of 'Gi', it was not possible to obtain adequate resolution of ’Gi" under 
resolving polyacrylamide/SDS electrophoresis conditions (section 2.10) to be 
able to unequivocally identify this G-protein (results not shown). It would be 
possible to circumvent this problem by specifically immunoprecipitating the G- 
protein in question, however this was not performed.
The C-terminal region of the G-protein a-subunit has been identified as the 
site of functional interaction with receptor. The antisera described in Table 2.1 
were generated against synthetic peptides which were either homologous to, or 
corresponded to the C-terminal decapeptide of a-subunits of Gi2, Gi3, Go and Gs. 
The specificity of both primary antisera and IgG fractions derived from each 
antiserum was assessed, and it was hoped that these antisera would be useful as 
selective tools to prevent interaction of the corresponding G-protein with 
receptor. Antiserum AST was generated against a synthetic decapeptide homologous 
to the C-terminus of Tdl (KENLKECGLF). This region has one amino-acid 
difference from the last ten C-terminal amino-acids in the a-subunit of both G il 
and Gi2, which are identical (KNNLKDCGLF). As such it was thought that AST 
would be able to specifically identify the a-subunits of Td, G il and Gi2. Tdl and 
Td2 share an extremely restricted distribution, being expressed only in 
photoreceptor containing cells (Milligan, 1990). Fortuitously, NG108-15 cells 
do not express G il (McKenzie and Milligan, 1990), which allows AST to be used 
as a specific probe for Gi2 in this cell line. Preincubation of NG108-15 cell 
membranes with an IgG fraction isolated from antiserum AST prevented 
productive coupling between the 5-opioid receptor and G-protein, as assessed by 
the attenuation of the ability of DADLE to both stimulate GTPase activity and
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inhibit adenylyl cyclase.
As an additional means of detecting the uncoupling of receptor from G- 
protein, the binding of [^HjDADLE was assessed in NG108-15 cell membranes in 
a variety of conditions. In membranes which have been either pretreated with 
pertussis toxin, or in the presence of non-hydrolysabie analogues of GTP such as 
Gpp(NH)p, the 5-opioid receptor was uncoupled from the G-protein with which it 
interacts and adopted a lowered affinity for agonist (Kurose et al., 1982). 
Unfortunately this does not allow identification of the G-protein involved since 
pertussis toxin can catalyse the ADP-ribosylation of Gi2a, Gi3a andGoa in this 
cell line. When NG108-15 cell membranes were preincubated with an IgG 
fraction isolated from antiserum AST, the 5-opioid receptor adopted a state with 
lowered affinity for agonist. The reduction in affinity produced by this 
preincubation was similar in magnitude to the alteration in affinity produced by 
either pertussis toxin pretreatment or the presence of Gpp(NH)p, suggesting that 
the 5-opioid receptor was no longer capable of interacting with a G-protein to 
form a ternary complex with high affinity for agonist.
In the data described above, IgG fractions generated from either antiserum 
specific for Gi3, Go and Gs, or igG isolated from pre-immune serum, were 
ineffective in attenuating coupling between G-protein and the 5-opioid receptor. It 
may be suggested that each IgG fraction was inactive, however this is unlikely 
since antiserum 0C1 has previously been demonstrated to attenuate the ability of 
a 2 adrenergic receptors to inhibit voltage operated calcium channeis in 
differentiated NG108-15 cells (McFadzean et ai., 1989). In addition, antibodies 
affinity purified from an anti-Gs antiserum which was raised in an identical 
manner to the Gs specific antiserum, CS1 (Table 2.1) have been demonstrated to 
attenuate p-adrenergic receptor mediated stimulation of adenylyl cyclase in 
human platelet membranes (Simonds et al., 1989b). Antiserum CS1 has been 
demonstrated to attenuate isoproterenol stimulation of adenylyl cyclase in cardiac 
membranes (Milligan, personal communication).
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Although there is no evidence to suggest that pertussis toxin sensitive G- 
proteins other than Gi2, Gi3 and Go are expressed by NG108-15 cells, it is 
conceivable that the 8-opioid receptor is capable of interacting with a G-protein 
other than Gi2, without stimulating the GTPase activity of the G-protein to a 
measurable level (see section 1.6ii). In such a stimulation, it would not be 
possible to assess the specificity of interaction of the 8-opioid receptor with the 
G-protein family. In addition if this were correct, then it would have to be 
assumed that the 8-opioid receptor was only capable of forming a ternary complex 
with Gi2, since pretreatment of NG108-15 cell membranes with an IgG fraction 
from AS7 produced a reduction in affinity for agonist which was of the same 
magnitude as agents which are known to uncouple G-proteins from receptors, such 
as Gpp(NH)p and pertussis toxin catalysed ADP-ribosylation (Hsia et al., 1984). 
It should be noted that the effects of Gpp(NH)p and IgG from AST were not additive, 
each reagent produced the maximal effect in isolation.
The most likely explanation for the results described herein is that the 8- 
opioid receptor interacts exclusively with Gi2 and that GI2 must therefore 
represent the G-protein which mediates inhibition of adenylyl cyclase in NG108- 
15 ceil membranes.
It may be suggested that the ability to uncouple receptor from G-proteins 
using G-protein specific antisera could be widely applicable to a variety of other 
G-protein mediated signalling systems.
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